European Society for Medical Oncology (ESMO) 2010

  1. Polymorphisms in drug metabolising enzymes and drug transporters: Influence on drug pharmacokinetics and patient response to treatment
  2. A historical view and perspectives on angiongenesis inhibition and in particular anti-VEGF therapy in cancer
  3. Detection, clinical relevance and specific biological properties of disseminated cancer cells
  4. MicroRNA identification in plasma and serum: A new tool to diagnose and monitor diseases
  5. Micromanagers of malignancy: The role of microRNAs in regulating metastasis
  6. miRNA in lymphomas, profile expression/prognosis
  7. Cancerous microRNAs and regulatory RNA binding proteins
  8. Introduction
  9. Conclusions
  10. Preservation of fertility in young patients
  11. Optimizing endocrine treatment of pre-menopausal women
  12. Should bone targeted treatment be used in the adjuvant setting?
  13. Evolving issues in inflammatory breast cancer
  14. Introduction
  15. Conclusions
  16. Gefitinib – the resurrection
  17. Erlotinib – the adult
  18. Bevacizumab – the adolescent; bevcizumab achievements in non-small-cell lung cancer (NSCLC)
  19. Cetuximab - the newborn
  20. New molecular targets – the next generation of drugs
  21. Introduction
  22. Conclusions
  23. From platinum to PARP (Introduction)
  24. Targeting the Achilles heel: Synthetic lethality
  25. Encouraging first experiences with PARP inhibitors
  26. Early tales: PARP and BRCA
  27. Later tales: Phase II and beyond
  28. Conclusions
  29. Introduction
  30. Aggressive versus non-aggressive initial treatment
  31. Intermittent or continuous therapy
  32. Personalizing treatment based on biomarkers
  33. The combination of targeted agents: A look to the future
  34. Conclusions
  35. Introduction
  36. Improved inhibition of the androgen receptor
  37. Angiogenesis in castrate resistant prostate cancer
  38. Bone targeting in prostate cancer
  39. Results from molecular biology that translate to treatment
  40. Conclusions
  41. Introduction
  42. Introduction
  43. Molecular subtypes of ovarian cancer: Insights into the drivers of high-grade ovarian serous and clear cell tumours
  44. The molecular classification of ovarian carcinoma: implications for treatment
  45. Pathway driven treatments of ovarian cancer: Beyond chemotherapy
  46. Functional imaging of ovarian cancer
  47. What can the pathologist offer for optimal treatment choice?
  48. Conclusions
  49. Treatment of triple negative breast cancer
  50. Treatment of Her2-overexpressing breast cancer
  51. New hormonal agents in the treatment of advanced prostate cancer
  52. New agents for bladder cancer
  53. How to select targeted therapy in renal cancer
  54. Lung neuroendocrine
  55. Gastrointestinal neuroendocrine tumors
  56. Merkel tumors
  57. The epithelial-mesenchymal transition (EMT) phenomenon
  58. Cancer stem cells
  59. Circulating cancer cells
  60. Multigene predictors to assess risk of relapse
  61. Benefits and adverse effects of endocrine therapy
  62. Chemotherapy with or without trastuzumab
  63. Introduction
  64. Biomarkers in molecular classification and diagnostics of head and neck squamous cell carcinoma
  65. What can the molecular pathologist offer for optimal decision-making?
  66. New signalling pathway inhibitors and EGFR resistance
  67. Chemotherapy: Which drugs and when?
  68. How to integrate molecular targeted agents in the continuum of care
  69. Multiple myeloma
  70. Follicular lymphoma
  71. Therapeutic implications of HPV positive tumors
  72. Chronic lymphocytic leukemia
  73. Molecularly-targeted therapies in thyroid cancer
  74. Conclusions
  75. Anemia
  76. Cardiotoxicity
  77. Introduction
  78. Bone loss
  79. Chronic lymphocytic leukemia The use of biomarkers to guide treatment in hematological malignancies
  80. Multiple myeloma
  81. Evidence-based staging
  82. Mantle cell lymphoma
  83. Chronic myelogeneous leukemia
  84. Conclusions
  85. Adjuvant chemotherapy: Where is it going?
  86. Do we have markers to select patients for adjuvant therapies?
  87. How can proteomic profiling guide us in selecting therapy?
  88. The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer
  89. Optimal treatment for relapsing ovarian cancer
  90. Should we continue to use the term non-small cell lung cancer?
  91. How to integrate current knowledge in selecting first-line therapy
  92. Consequences of targeted treatments for second-line therapy
  93. The role of papilloma virus infection
  94. Introduction
  95. Integrating systemic agents into multimodality treatment of locally advanced diseases
  96. Differences in cancer survival in Europe
  97. Social inequalities and cancer
  98. Optimal treatment for relapsing or metastatic disease
  99. Cancer control plans in Europe
  100. Moving forward with cancer control
  101. Pathologic diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies
  102. Conclusions
  103. Histology-driven chemotherapy of soft tissue sarcoma
  104. Targeted therapies in soft tissue sarcoma
  105. Is there any role for surgery in the multidisciplinary treatment of esophageal cancer?
  106. Multimodality treatment for localized gastroesophageal cancer
  107. New trends for staging and therapy for localized gastroesophageal cancer: The role of PET scan
  108. Introduction
  109. Skin toxicity
  110. Gastrointestinal toxicity
  111. Renovascular and cardiac toxicity
  112. Conclusions
  113. Introduction
  114. Angiogenesis inhibitors: Are they useful for all sarcomas?
  115. mTOR inhibitors: From lymphangioleiomyomatosis to where?
  116. Is the indication of IGFR antibodies in advanced refractory sarcomas expanding?
  117. At the crossroads of molecular pathways and sarcoma subtypes
  118. Conclusions
  119. Pharmogenomic and SNP in diverse ethnicity
  120. Progression of systemic chemotherapy for advanced HCC in China
  121. Personalized management of lung cancer: EGFR mutation and beyond
  122. Colorectal cancer
  123. Conclusions
  124. Treatment of triple negative breast cancer
  125. Treatment of Her2-overexpressing breast cancer
  126. Lung neuroendocrine
  127. Gastrointestinal neuroendocrine tumors
  128. Image guided therapy of metastases from colorectal cancer
  129. Merkel tumors
  130. The epithelial-mesenchymal transition (EMT) phenomenon
  131. It’s resectable, but is it curable?
  132. Radiotherapy: From palliation to cure and prophylaxis?
  133. Locoregional delivery of chemotherapy for metastatic CRC - what's the evidence?
  134. Conclusions
  135. Cancer stem cells
  136. Circulating cancer cells
  137. What is the optimum screening method for cervical cancer in developing countries?
  138. Chemotherapy: Which drugs and when?
  139. HPV vaccination: What practical experience tells us to date
  140. How to integrate molecular targeted agents in the continuum of care
  141. New hormonal agents in the treatment of advanced prostate cancer
  142. New agents for bladder cancer
  143. How to select targeted therapy in renal cancer
  144. Cervical cancer control: A global strategy
  145. Multigene predictors to assess risk of relapse
  146. Benefits and adverse effects of endocrine therapy
  147. The Health Minister’s response to managing cervical cancer in low-income countries
  148. Chemotherapy with or without trastuzumab
  149. Conclusions
  150. Multiple myeloma
  151. Follicular lymphoma
  152. Chronic lymphocytic leukemia
  153. Evidence-based staging
  154. Adjuvant chemotherapy: Where is it going?
  155. Benefit
  156. Do we have markers to select patients for adjuvant therapies?
  157. Peril
  158. Conclusions
  159. Anemia
  160. Cardiotoxicity
  161. Bone loss
  162. How can proteomic profiling guide us in selecting therapy?
  163. The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer
  164. Optimal treatment for relapsing ovarian cancer
  165. Pathologic diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies
  166. Histology-driven chemotherapy of soft tissue sarcoma
  167. Targeted therapies in soft tissue sarcoma
  168. The role of papilloma virus infection
  169. Integrating systemic agents into multimodality treatment of locally advanced diseases
  170. Necessity
  171. Optimal treatment for relapsing or metastatic disease
  172. Should we continue to use the term non-small cell lung cancer?
  173. How to integrate current knowledge in selecting first-line therapy
  174. Utopia
  175. Consequences of targeted treatments for second-line therapy
  176. Conclusions
  177. Is there any role for surgery in the multidisciplinary treatment of esophageal cancer?
  178. Multimodality treatment for localized gastroesophageal cancer
  179. New trends for staging and therapy for localized gastroesophageal cancer: The role of PET scan
  180. Introduction
  181. Introduction
  182. Introduction
  183. Pro speaker
  184. Contra speaker
  185. Conclusions
  186. Introduction
  187. Pro Speaker
  188. Contra Speaker
  189. Conclusions
  190. Introduction
  191. Pro Speaker
  192. Contra Speaker
  193. Conclusions
  194. The risk of stage and the risk of tumor biology: microscopic nodal tumor
  195. Triple negative small tumors
  196. Discussion
  197. An intermediate case of HCC
  198. An early stage HCC
  199. Discussion
  200. Discussion
  201. Treatment options in early stage seminoma
  202. Relapsed and/or refractory non-seminoma
  203. Discussion
  204. Chemotherapy
  205. Radiotherapy
  206. Discussion
  207. Site-related co-morbidities in decision making
  208. Supportive care measures to improve patient outcome
  209. Discussion
  210. Richter's syndrome
  211. Transformed follicular lymphoma
  212. Discussion
  213. What nurses contribute
  214. What doctors contribute
  215. Discussion
  216. Tailoring the drug
  217. Cancer of Unknown Primary site: 20 questions to be answered
  218. Cancer of Unknown Primary site: 20 questions to be answered
  219. Nasopharyngeal cancer
  220. Tailoring the scalpel
  221. Nasopharyngeal cancer
  222. Discussion
  223. Multiple myeloma
  224. Multiple myeloma
  225. Osteosarcoma
  226. Osteosarcoma
  227. Mesothelioma
  228. Mesothelioma
  229. Genetic counselling for hereditary predisposition to ovarian and breast cancer
  230. Genetic counselling for hereditary predisposition to ovarian and breast cancer
  231. Advances in systemic treatment of metastatic melanoma
  232. Advances in systemic treatment of metastatic melanoma
  233. Statistical issues and how to use biomarkers as surrogates in the 21st century
  234. Advances in the treatment of metastatic or unresectable biliary tract cancer
  235. Advances in the treatment of metastatic or unresectable biliary tract cancer
  236. Biobanking in clinical trials: what, when and how should I collect samples?
  237. Stopping a cancer trial early: is it really for the benefit of patients? What about the quality of data
  238. How to write an outstanding manuscript
  239. How to conduct effective public speaking and slide presentations
  240. Medical information: Where to find it, what to trust
  241. Locally advanced rectal cancer (Surgery)
  242. Locally advanced rectal cancer (Medical Oncology)
  243. Discussion
  244. Optimal integration of chemotherapy and radiotherapy in small cell lung cancer (Radiotherapy)
  245. Optimal integration of chemotherapy and radiotherapy in small cell lung cancer (Medical Oncology)
  246. Discussion
  247. Discussion
  248. Localised prostate cancer (Medical Oncology)
  249. Localised prostate cancer (Radiotherapy)
  250. Discussion
  251. Locally advanced laryngeal cancer
  252. Locally advanced laryngeal cancer (Radiotherapy)
  253. Discussion
  254. Locally advanced pancreatic cancer
  255. Locally advanced pancreatic cancer
  256. Discussion
  257. Statistical issues and how to use biomarkers as surrogates in the 21st century
  258. Biobanking in clinical trials: What, when and how should I collect samples?
  259. Stopping a cancer trial early: is it really for the benefit of patients? What about the quality of data?
  260. Session shooter
  261. Session shooter
  262. Session shooter
  263. CST in oncology: Results from a consensus meeting among European experts in 2009
  264. A reaction to the proposition of the European consensus on CST in oncology
  265. Mandatory training, minimal requirements and implementation of CST in oncology: The European perspective
  266. The future of CST in oncology
  267. Introduction
  268. Conclusions
  269. Introduction
  270. The biology of antiangiogenic therapy in the adjuvant setting
  271. Re-appraising the biological basis of antiangiogenic drugs for adjuvant therapy
  272. An analysis of currently available adjuvant colorectal data
  273. COX-2 inhibition in the adjuvant setting for colorectal cancer
  274. The status of cancer in Europe now
  275. What the European Union can do for patients
  276. What cancer advocacy groups can do for patients
  277. Introduction: My life with targeted therapy
  278. Targeted therapy: A general overview
  279. My life with targeted therapy
  280. Targeted therapy: Hope or hype
  281. Participation in phase I studies
  282. General discussion
  283. Early Rehabilitation-where does it lead?
  284. The importance of psycho-oncology
  285. Common paths in the European Union
  286. The long term and late effects of cancer: Implications for research and public policy
  287. Psychological and social consequences
  288. Poster presentation and discussion
  289. General principles in treatment of frail and elderly patients
  290. What is co-morbidity and how is it evaluated?
  291. When not to operate
  292. General discussion
  293. Overview & Presentation: Latest developments in breast cancer
  294. General discussion: Latest developments in breast cancer
  295. Overview & Presentation: Latest developments in gastrointestinal tumors
  296. General discussion: Latest developments in gastrointestinal tumors
  297. Overview & Presentation: Latest developments in prostate cancer
  298. General discussion: Latest developments in prostate cancer
  299. Overview & Presentation: Latest developments in haematological malignancies
  300. General discussion: Latest developments in haematological malignancies
  301. General discussion
  302. General discussion
  303. General discussion
  304. Short review of major points emerging from the breakout sessions
  305. General discussion
  306. Introduction
  307. ESMO CR Questionnaire
  308. Breast cancer (triple negative)
  309. Discussant
  310. GIST
  311. Pancreatic cancer
  312. Discussant
  313. Conclusions
  314. Discussant
  315. Introduction
  316. Presenting bad news to the patient
  317. The risk of burn out: Are young oncologists at higher risk?
  318. Presenting a completed research project as an oral presentation
  319. Presenting the data of a project in a manuscript
  320. Invited Discussant
  321. Q&A
  322. Introduction
  323. Management of cancer pain
  324. Systemic therapeutic options for bone metastases
  325. Management of fatigue / cachexia
  326. Palliative chemotherapy versus best palliative care – evidence based decision
  327. Conclusions
  328. Session "Shooters"
  329. Session "Shooters"
  330. Session "Shooters"
  331. Session "Shooters"
  332. Introduction
  333. Global recognition of Medical Oncology
  334. ESMO/ASCO updated Global Core Curriculum for training in medical oncology and log book opportunities
  335. How you and your institution can benefit from being a home or host mentor within the ESMO fellowship program
  336. How to check the status of your trainees knowledge and readiness for the license exam: ESMO examination opportunities
  337. Teaching medical oncology to medical students
  338. Q&A
  339. Evaluation of Pattern and Natural History of pulmonary metastasis in breast cancer patients between years 1996-2006 in Mashhad- Omid hospital
  340. The predictive value of pre-operative body composition and histopathology on survival post-pancreaticoduodenectomy in pancreatic cancer
  341. Changes in daily activities of cancer patients after diagnosis: How do Canadian and Iranian patients perceive the change?
  342. Management of hematologic toxicity in patients with advanced or metastatic gastric cancer treated with Docetaxel, Cisplatin an Fluorouracil (DCF): results of monocentric experience.
  343. Is capecitabine efficacious in triple negative metastatic breast cancer?
  344. Study of ifosfamide “day by day” dosing as a second-line chemotherapy for recurrent adult Ewing sarcoma family tumor patients - single center study
  345. Silibinin inhibits invasive properties of human glioblastoma U87MG cells through suppression of cathepsin B and nuclear factor kappa B-mediated induction of matrix metalloproteinase 9
  346. The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan-cetuximab
  347. Perineural invasion is a strong independent prognostic factor following pre-operative chemo/radiotherapy for locally advanced rectal cancer
  348. Phase I study to assess the safety, tolerability, and pharmacokinetics of the specific Eg5 inhibitor AZD4877 in Japanese patients with solid tumours
  349. A phase II study with Capecitabine and Cisplatin as first-line therapy in advanced gastric cancer
  350. BCR- ABL Kinase Mutations to Imatinib Resistance in Chronic Myeloid Leukemia
  351. What have we accomplished with targeted chemotherapy for incurable solid cancers?
  352. What can the pathologist offer for optimal treatment choice?
  353. Adjuvant effect of IV clodronate on delay of bone metastasis in high-risk prostate cancer patients: A prospective study
  354. Prognostic significance of free peritoneal tumor cells (FPTCs) in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric carcinoma undergoing a potentially curative resection
  355. p38alphaMAPK in the prognosis after neoadjuvant chemotherapy in locally advanced non-small cell lung cancer (NSCLC)
  356. Expression of survivin in adenoid cystic carcinoma of the head and neck and its clinicopathological relationship
  357. Oxycodone/acetaminophen combination tablet in patients with metastatic bone pain: a randomized, double-blinded, placebo-controlled trial
  358. Correlation of BRAF status with clinical response to cetuximab in KRAS wild type (KRAS wt) metastatic colorectal (mCRC) patients - a single institution experience
  359. Paradigm in systemic treatment of advanced gastric cancer in Slovak Republic
  360. A phase II study of paclitaxel, ifosphamide and nedaplatin as a second-line treatment in patients with cisplatin-refractory metastatic urothelial cancer
  361. 5-fluorouracil/leucovorin (5FU/LV) combined with irinotecan and oxaliplatin (FOLFIRINOX) as second line chemotherapy in patients with metastatic pancreatic adenocarcinoma
  362. Public-Private Partnership in Cancer Drug Development: A Policy Analysis
  363. Expression of the gastrin-releasing peptide receptor in hepatocellular carcinomas and its role as a prognostic biomarker
  364. Neuroendocrine tumors: 20-years Rare Hormonal Tumors Group experience
  365. Selective cytotoxicity of BIBR 1532 on acute promyelocytic leukemia cells through induction of P21 and suppression of C-Myc-dependent transcription of hTERT
  366. Neoadjuvant therapy in esophageal carcinoma followed by a long interval until resection: a high incidence of complete pathological response
  367. Breast invasive lobular carcinoma. Is it worth doing any complementary study?
  368. Prospective study about depression in oncology and assessment of the medical decision making strategy.
  369. Chemotherapy with or without Bevacizumab in advanced colorectal cancer: A Phase III trial
  370. Criteria of prognosis for radiation-associated myelofibrosis with myeloid metaplasia following the Chernobyl accident
  371. Nature and subjectivity of Dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugs
  372. Possible involvement of CXCL14 in anchorage-independent growth and bone metastasis from lung cancer
  373. Paclitaxel /Carboplatin versus Single agent Carboplatin in Patients with Epithelial Ovarian Cancer and correlation to serum marker VEGF
  374. Classical Kaposi’s Sarcoma in Morocco: clinocopathologic and therapeutic study of 51 cases
  375. Phase II study of 5-florouracil/leucovorin in combination with paclitaxel and oxaliplatin (POF) in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma
  376. Health resource utilization (HRU) associated with skeletal-related events (SREs) in patients (pts) with bone metastases (BM) – US interim analysis (IA) results from a multinational observational study
  377. mFOLFOX-4 followed by mFOLFIRI or the Reverse Sequence in Metastatic Gastric Cancer
  378. Gastric cancer (GC) adjuvant (A) chemotherapy (CT): a literature based meta-analysis (MA)
  379. Detection and functional analysis of miRNAs in peripheral blood exosomes from cancer patients.
  380. Pharmacoepidemiological platform for post-marketing evaluation of targeted therapies in oncology
  381. A phase I study of ridaforolimus, the oral mTOR inhibitor, as a single agent in Japanese patients with advanced solid tumors.
  382. Plasma levels of Heparanase as a marker of tumor progression and aggressiveness in patients with colorectal and breast cancer
  383. Radiotherapy response of brain metastases in patients with non-small cell lung cancer (NSCLC) and methylation status of O6-methyl guanine methyl transferase (MGMT) promoter region
  384. Encouraging data from a Phase I study of the first oral PARP inhibitor olaparib in Japanese patients with solid tumours
  385. Sequential Therapy in Metastatic Renal Cell Carcinoma – Simulation and Comparison of Progression-Free-Survival Outcomes
  386. Efficacy and safety of second-line bevacizumab (BV) plus FOLFIRI / FOLFOX in patients with metastatic colorectal cancer (mCRC) who failed prior-combination chemotherapy without BV: Multicenter retrospective 2nd-BV study in Tsukuba Cancer Clinical Trial Group (TCTG)
  387. Does the type of EGFR activating mutation impact outcomes with erlotinib treatment?
  388. Role and significance of circular suturing devices in surgical treatment of rectal cancer
  389. The role of religiosity in care of lung cancer patients
  390. A Phase I study of AZD1152, an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia
  391. Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel
  392. Digestive cancers in an elderly population: which treatment for the intermediate Balducci group?
  393. Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: A multicenter AGEO study
  394. Phase II study of weekly paclitaxel, cisplatin, and 5-fluorouracil (PCF) for advanced gastric cancer.
  395. Construct validity of the Quality of Life in Life-Threatening Illness-Patient questionnaire (QOLLTI-P) in cancer patients
  396. Diagnostic pitfalls in primary splenic non-Hodgkin’s lymphomas
  397. Couple types and coping strategies: difficulties of cooperation in conjoint drawing
  398. Burden of care. Positive and negative effects of caregiving
  399. Phase I Study of Concurrent Pemetrexed, Cetuximab and Radiation Therapy with or without Cisplatin in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  400. High dose brachytherapy in patients with recurrent oesophageal cancer as a palliative intervention
  401. Predictive factors for Adjuvant therapy in patients with localized Gastric & Gastro-esophageal junction (G/GEJ) Cancer: A Population based study
  402. Validation study of epidermal growth factor receptor (EGFR) mutation tests using DNA from control admixture samples and formalin-fixed paraffin-embedded (FFPE) samples in non-small cell lung cancer (NSCLC) in the diagnostic setting
  403. Alcohol, Tobacco, and Risk of Gastrointestinal (GI) Cancers
  404. Early evaluation of efficacy in molecularly targeted therapy of gastrointestinal stromal tumor
  405. Capecitabine (X) alone and X-based combinations in treatment of anthracycline- and taxane-resistant metastatic breast cancer (MBC)
  406. Multicenter Phase II study of second-line FOLFIRI+Cetuximab with KRAS wild type gene in metastatic CRC (FLIER)
  407. Transition from 2D conventional to 3D conformal radiation therapy in patients with brain gliomas: clinical outcome (MANSOURA UNIVERSITY experience)
  408. Management of oral mucositis (OM) with a muco-adhesive oral rinse: European clinical experience
  409. Quality of life survivors of non Hodgkin lymphoma
  410. Relations of breast cancer patients and their doctors
  411. Sleep disruption in colorectal cancer patients
  412. A phase III, randomized double-blind placebo-controlled study of epoetin beta in lung and gynecological cancer receiving platinum-based chemotherapy: Japan Erythropoietin Study Group
  413. Phase II Study of Neoadjuvant Chemotherapy with CPT-11 and Nedaplatin ( CPT-11/NDP ) for Stage Ib2/II Carcinoma of the Cervix ( Japanese Gynecologic Oncology Group 1065 Study)
  414. Does external ultrasonography of the neck add diagnostic value to integrated PET-CT scanning in the diagnosis of cervical metastases in patients with esophageal carcinoma?
  415. Multicenter Phase II Study of an Opioid-based Pain Control Program for Patients with Head and Neck Cancer Treated by Chemoradiotherapy
  416. Capecitabine plus Oxaliplatin combination Chemotherapy for patients with inoperable Gall Bladder Cancer - Results of a Single Institution Phase II Study
  417. Our experience in the use of trastuzumab in patients with advanced stomach cancer
  418. EGFR mutations and max SUV 18F-FDG-PET values in lung adenocarcinoma patients
  419. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a Japanese phase II study in patients with cytokine-refractory metastatic renal cell cancer (mRCC)
  420. Job Stress in health care professionals. A psycho-oncological analysis of the Oncology Division
  421. The evaluation of the Breast Cancer Screening Programme in the Khanty-Mansiysky Autonomous Okrug - Ugra, Western Siberia.
  422. Randomized cross-over AIO phase III trial comparing gemcitabine plus erlotinib followed by capecitabine vs. capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer
  423. The insulin-like growth factor system in endometrial cancer patients with metabolic syndrome
  424. Effects of exemestane or tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis
  425. The interim analysis of an open nonrandomized prospective study comparing laparoscopic surgery with XELOX chemotherapy and open surgery with mFOLFOX6 chemotherapy for resectable colorectal cancer
  426. Impact of diagnosis of melanoma on solar protection
  427. Psychiatric disorders and psychosocial concerns in patients with newly diagnosed colorectal cancer
  428. Risk factors for bacteremia in febrile neutropenic episodes in patients with colorectal cancer
  429. Initial attitudes of patients with lung cancer related to psychosocial rehabilitation
  430. Psychological characteristics of lung cancer patients
  431. The influence of Israeli oncology nurses' attitudes and health beliefs on their usage of self-protective measures while handling cytotoxic drugs
  432. The role of age in medical and psychosocial outcomes in colorectal cancer patients
  433. Early detection program focusing on primary and secondary health care providers achieved major and sustainable reduction of late stage diagnosis of breast cancer
  434. Cytotoxicity of curcumin combined with docetaxel in MCF7 breast tumor cells implicates the glutathione cycle and an antioxidant response: a metabolomics investigation
  435. Occurrence of a B large-cell lymphoma in the vertebras and ribs at the margin of the irradiation field for a laryngeal epithelioma
  436. Granulocyte colony-stimulating factors (G-CSF) patterns of use effect on neutropenia-related outcomes and response rate in patients with solid tumours undergoing chemotherapy (CT)
  437. The potential of molecular-targeted therapy with EGFR and VEGFR signaling inhibitors against biliary tract cancer
  438. Pulmonary Artery Sarcomas Presenting as Pulmonary Hypertension: A review and discussion of further treatment
  439. Usefulness of noninvasive biomarkers to predict prognosis in bladder cancer
  440. Predictive significance of preoperative peripheral blood values for stage T4 gastric cancer
  441. A phase II trial of weekly docetaxel combined with carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer
  442. Is a pathological complete response a surrogate marker of recurrence-free survival after preoperative chemoradiotherapy for local advanced rectal cancer?
  443. Trans-Arterial Chemoembolization of metastatic Colorectal Carcinoma (MCRC) to the liver adopting Polyvinyl Alcohol Microspheres (PAM) loaded with Irinotecan compared with FOLFIRI (CT): evaluation at two years of a phase III clinical trial.
  444. Updated results from a large, multicentre study of 1st-line bevacizumab (Bev) combined with paclitaxel (Pac) for HER2-negative metastatic breast cancer (mBC) in routine oncology practice
  445. Efficacy and Necessity of Nasojejunal Tube after Gastrectomy
  446. Trial participation in a multicentre phase III trial (CAIRO) in advanced colorectal cancer (ACC) patients (pts) in The Netherlands, and a comparison of outcome between trial and non-trial pts.
  447. Prognostic and predictive impact of obesity in HER2 positive breast cancer
  448. Bleomycin induced Lung Toxicity in patients with Germ Cell Tumors treated with Bleomycin containing regimens
  449. Sexual dysfunctions and cancer, or cancer and sexual dysfunctions?
  450. Final safety data from patients (pts) who received maintenance (mnt) bevacizumab (Bv) in the MO19390 (SAiL) trial: first-line Bv plus chemotherapy (CT) in advanced or recurrent non-small cell lung cancer (NSCLC)
  451. Fatal outcome of temozolomide-induced bone marrow aplasia in two patients treated with concurrent chemoradiation for high grade glioma.
  452. Combination Study of Navitoclax (ABT-263) with (gemcitabine [G]) in Patients (pts) with Solid Tumors
  453. Local use of carboplatin in complex treatment of retinoblastoma
  454. Influence of age on the pharmacokinetic of i.v. vinflunine: results of a phase I trial in elderly cancer patients
  455. The location of lymphangiogenesis is an independent prognostic factor in rectal cancers with or without preoperative radiotherapy
  456. Clinicopathologic correlation of cancer susceptibility loci from Genome-wide Association (GWAS) Studies of Colorectal Cancer (CRC).
  457. A Phase I-II Study of Dasatinib (D) In Combination With Weekly (w) Paclitaxel (P) For Patients (Pts) With Metastatic Breast Carcinoma (MBC)
  458. A Dendritic Cell Vaccine Transduced With Ad5-f35-dLMP1-I-LMP2 For Patients With Metastatic Nasopharyngeal Carcinoma – A Phase II Clinical Trial
  459. Downregulation of Med19 gene expression inhibited the growth of breast cancer cells
  460. Predictive factors in locally advanced squamous cell carcinoma (SCC) of the oesophagus treated with preoperative radiochemotherapy (RCT) and surgery
  461. Expert nurse consensus on the follow-up and management of patients receiving erlotinib for the treatment of non-small-cell lung cancer
  462. Study on the prevalence of post-treatment chronic pain in breast cancer patients and interference of pain with life functions
  463. Dose-escalation study of Pemetrexed/Carboplatin combination therapy for chemo-naïve NSCLC patients
  464. Early Osteoporosis Risk In Premenapousal Women With Breast Cancer After Ovarian Ablation
  465. Prognostic factors of lung cancer patients with carcinomatous meningitis
  466. Cancer in an Italian nursing home
  467. Rare cancers in Europe
  468. Impact of neoadjuvant chemoradiation in localised oesophageal cancer: results of a randomised controlled phase III trial FFCD 9901
  469. Does the mutation of Wnt occur On Osteosarcomas?
  470. Aberrant Methylation of p16 Tumor Suppressor Gene and Death-Associated Protein Kinase in Malignant Pleural Effusion
  471. Supportive care in relapsed head and neck cancer: Transdermal Buprenorphine Formulation
  472. Alcohol Drinking and Risk of Lung Cancer
  473. Management Of Advanced Gastric Cancer Using Capecitabine In Korle Bu Teaching Hospital, Ghana: An Experience From A Resource Limited Setting
  474. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models
  475. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma – data from the Czech registry
  476. Prognostic significance of the maximum standardized uptake value on positron emission tomography according to histological subtypes for non-small cell lung cancer
  477. Assessment of quality of life (QoL) in phase III trials in advanced non-small cell lung cancer (NSCLC)
  478. A randomized, pilot, stratified trial regarding the perception and satisfaction of patients with complementary therapies in a dedicated room.
  479. Cytogenetic changes in lymphocytes of peripheral blood in patients with osteogenous tubular sarcoma
  480. Cytogenetic studies in skin cancer
  481. Third CECOG Consensus on the Systemic Treatment of Non Small Cell Lung Cancer
  482. Molecular genetic profile of osteogen tubular sarcoma in children and teenagers
  483. Description and prevalence of palliative care inpatients: a prospective study in 14 Blgian hospitals
  484. The mTOR signaling pathway as potential therapeutic target in meningiomas
  485. Fulvestrant (F) plus oral metronomic Cyclophosphamide (CTX) and Methotrexate (MTX) (mCM) in advanced breast cancer (ABC) patients (pts): a monoinstitutional case-cohort report.
  486. Current phase 1 trials: Dose-levels and first signs of efficacy.
  487. The ZOTECT study: Effect of intravenous zoledronic acid on bone metabolism in patients with metastatic bone disease in breast cancer and prostate cancer
  488. Panitumumab (pmab) Regimen In Second-line Monotherapy (PRISM) in Patients (pts) with Recurrent (R) or Metastatic (M) Squamous Cell Carcinoma of the Head and Neck (SCCHN): Interim Safety Analysis
  489. Final Results of the Hellenic Cooperative Oncology Group Phase III trial (HE10/00) exploring the efficacy of postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in high risk breast cancer patients.
  490. A multicenter study of image-guided radiofrequency ablation of small breast carcinomas
  491. Therapeutic synergism of Lapatinib and NVP-AEW541 against human pancreatic tumour cells
  492. Phantom breast syndrome and psychological distress among breast cancer patient.
  493. Gemcitabine plus oxaliplatin (GEMOX) regimen in radioactive iodine resistant metastatic thyroid cancer: activity and safety study.
  494. Diagnosis and management of metastatic malignant disease of unknown primary origin(MUP) - Large cancer centre experience.
  495. Trabectedin has a low cardiac risk profile: a comprehensive safety analysis
  496. Treatment and outcomes in primary cardiac sarcoma : the IGR experience
  497. The impression we give to patients when breaking bad news: A multicenter study in a Turkish cancer population
  498. Obesity and Overweight as a Risk factor for breast cancer in a Mexican population
  499. Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab in Patients with Metastatic Colorectal Cancer
  500. Duration of paclitaxel (PTX)-induced peripheral neuropathy (PN)
  501. Cognitive Symptoms in Cancer Patients attending Medical Oncology Clinics
  502. Potentiation of Gemcitabine effects with a Cetuximab and Trastuzumab combination in a novel human pancreatic orthotopic model
  503. Breastfeeding in breast cancer survivors: pattern, behaviour and effect on breast cancer outcome
  504. Non-Hodgkin lymphoma: increased survival in case of adherence to quality indicators
  505. Trends in the treatment of locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) in Europe between 2006 and 2009
  506. Clinical value of circulating VEGFR2+pAKT+ cells as a functional surrogate biomarker in metastatic colorectal cancer treated with bevacizumab and chemotherapy.
  507. A phase Ib pharmacological study of sorafenib in combination with gemcitabine / cisplatin in patients with refractory solid tumors including non-small cell lung cancer
  508. Recent progress in JSMO and society activities
  509. EGFR-TKI for EGFR mutated NSCLC: New evidence
  510. Anti-HER2 and angiogenesis inhibitors for gastric cancer: Updated results
  511. Predictive biomarkers in the treatment of advanced colorectal cancer
  512. The immediate future of customized treatment in lung cancer
  513. Clinical outcome of patients with cancer submitted to hemodialysis (HD) at the BRAZILIAN NATIONAL CANCER INSTITUTE (INCA)
  514. Conclusions
  515. Introduction
  516. Fyn-HnRNPA2B1/Sam68 Signaling Pathway Modulates Bcl-x Alternative Splicing in Pancreatic Cancer
  517. An Exploratory Study to Confirm or Refute The Novel Hypothesis that Iatrogenic Hypercortisolism Causes Osteoporosis In Breast Cancer Survivors On Aromastase Inhibitors
  518. Neoadjuvant chemotherapy with GM- or G-CSF: differential effects on dendritic cell subsets in patients with locally advanced breast cancer
  519. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin (PLD) formulations in preclinical models: Is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of PLD products?
  520. HPV infection in epithelial ovarian cells of women at high risk of developing ovarian cancer
  521. Outcomes of phase II clinical trials in advanced/metastatic non-small-cell lung cancer published within the last decade
  522. Bevacizumab/ Trastuzumab-combination induces rapid tumor control and long-lasting remission in patients with metastatic HER2-positive breast-cancer and high tumor burden
  523. The single nucleotide polymorphim C>G rs420549 in TGFBR1 and microRNA 511 (miR-511) as a new biomarkers in advanced colorectal cancer.
  524. The Role of Multislice CT-angiography to Assess Giant Cranio-facial Meningiomas Vascular Supply Mode.
  525. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations
  526. A Double-Blind, Randomized, Placebo-Controlled Phase III Study Of Gefitinib (G) versus placebo (P) In Patients (Pts) With Advanced NSCLC, Non-Progressing After First-Line Platinum-Based Chemotherapy (EORTC 08021- ILCP )
  527. Opioid-induced constipation prevalence and correlation with the therapy: an Italian prospective, multicentric analysis of 1210 oncologic patients.
  528. Relationship between markers of systemic inflammation and clinical symptoms and survival in patients with malignant mesothelioma (MM)
  529. The study of pathogenetic mechanisms of thrombosis in patients with polycythemia vera syndrome
  530. Modeling the Pharmacokinetic/Pharmacodynamic Platelet Response of Inotuzumab Ozogamicin, a Novel Antibody Drug Conjugate, Administered Alone or in Combination with Rituximab in Patients With Non-Hodgkin’s Lymphoma
  531. Elevated serum levels of the HER2 extracellular domain (ECD) in primary breast cancer (PBC) with HER2 overexpression predict early failure of adjuvant trastuzumab
  532. Framework and statistical issues in MONITOR-GCSF, a pharmacoepidemiological study of febrile neutropenia prophylaxis with biosimilar filgrastim
  533. Efficacy and safety of induction chemotherapy with cisplatin plus paclitaxel followed by chemoradiotherapy for locally advanced head and neck cancer – An interim analysis of safety and response rate
  534. HER-2 status correlation between primary breast cancer and corresponding distant metastatic sites
  535. The value of KRAS mutational status as a predictive biomarker in metastatic colorectal cancer
  536. Preliminary Pharmacokinetics (PK) and Safety comparison of Child-Pugh A (CPA) vs. Child-Pugh B (CPB) patients (pts) enrolled in a phase 2 study in Hepatocellular Carcinoma (HCC)
  537. Serum tumor markers CEA, CYFRA and Ca125 are associated with worse prognosis in advanced non- small cell lung cancer (NSCLC).
  538. A Randomized trial of 1st line Docetaxel and Cisplatin at 75/60 vs 60/60 mg/m2 for patients with stage IIIB or IV Non-Small Cell Lung Cancer
  539. A Randomized Controlled Trial of Antimicrobial Prophylaxis Infusion after Gastric Cancer Surgery (OGSG0501)
  540. Evaluation of effective factors for lymphedema after primary treatment of invasive breast carcinoma
  541. Improvement of physical activity as an alternative objective variable to measure treatment effects of anti cachexia therapy in cancer patients.
  542. Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS)
  543. Amphiregulin nuclear translocation might reduce chemosensitivity in gastric cancer.
  544. Cardioprotective effect of telmisartan in cancer patients treated with epirubicin.
  545. Comparison of CFF (cisplatin, 5-fluorouracil, folinic acid) and modified DCF (docetaxel, cisplatin, 5-fluorouracil) regimens in the first line treatment of metastatic gastric cancer
  546. The Outcomes of the Specialized Genetic Program Provided for the Carriers of the Genetic Alterations Predisposing to the Breast Cancer.
  547. Oral vinorelbine (NVBo) + cisplatin (CDDP) as chemoradiotherapy (CT-RT) treatment (Trt) after induction in locally advanced non small cell lung cancer (NSCLC): results of a Phase II Study.
  548. Oral vinorelbine (NVBo) and cisplatin (P) with concomitant radiotherapy (RT) followed by either consolidation therapy with NVBo and P plus best supportive care (BSC) or BSC alone in stage (st) III non small cell lung cancer (NSCLC): preliminary results of a phase III study.
  549. Radiotherapy after hyperbaric oxygen concurrent with superselective intra-arterial carboplatin chemotherapy enhances survival of patients with oral cancer
  550. Thrombovascular Events (TVEs) and Predisposing TVE Risk Factors in Cancer Patients Receiving Chemotherapy and Epoetin Alfa QW or TIW for Anemia
  551. The Risk of Lifelong DNA damage caused by Lung Cancer Among Rural Male Smokers who begin at Teenage
  552. Breast cancer treatment and sexuality. Moroccan Women's perception?
  553. A Randomized clinical trial of Paclitaxel loaded Polymeric micelle and Cisplatin versus Paclitaxel and Cisplatin in advanced non-small cell lung cancer (NSCLC)
  554. Adjuvant chemotherapy prescription according to multidisciplinary team decision or the MINDACT protocol (microarray in node-negative and 1 to 3 positive lymph node disease may avoid chemotherapy) (EORTC10041 BIG 3-04)
  555. Extramedullary Myeloid Leukemia: single institution experience
  556. Value of bone resorption marker N-telopeptide crosslinks in predicting skeletal related events and response to Zoledronic acid in bone metastases
  557. R-CHOP 14 in the treatment of Diffuse Large-B-Cell Lymphoma: retrospective study of efficacy and toxicity
  558. Prediction of response to chemotherapy in NSCLC patients
  559. Implementation of PCR -Array Technique in evaluation of oral mucosa among patients undergoing chemotherapy
  560. QOL Analysis from NEJ 002 Study Comparing Gefitinib to Chemotherapy for Non-Small Cell Lung Cancer with Mutated EGFR
  561. Phase 2 study of irinotecan as the third line treatment for advanced non-small cell lung cancer (NJLCG0703)
  562. Phase II Study of Combination Chemotherapy with Biweekly Cetuximab and Irinotecan for Wild-type KRAS Metastatic Colorectal Cancer Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines
  563. Results of neoadjuvant chemoradiotherapy with Docetaxel and 5-FU followed by esophagectomy for locally advanced esophageal cancer
  564. Clinical Outcomes in Metastatic Colorectal Cancer patients treated with Bevacizumab and K-ras Mutation Status
  565. Pharmacological interventions for fertility preservation during chemotherapy – a systematic review and meta-analysis
  566. Correlation of a cancer stem cell marker (aldehyde dehydrogenase 1) to neoadjuvant chemotherapy response in breast cancer
  567. Circulating endothelial cells (CECs) and their apoptotic fraction (APO-CECs): mutually independent biomarkers during Bevacizumab-based treatment for advanced colorectal cancer patients
  568. Optimal administration duration of uracil-tegafur on adjuvant chemotherapy for completely resected stage I lung adenocarcinoma: retrospective analysis from JLCRG phase III study
  569. ultrasonographic and mammographic findings of basal phenotype( CK5 or 6) breast cancer
  570. Evaluation of epidemiologic factors in gastroesophageal cancer in northeastern Iran
  571. mRNA expression of BRCA1, RAP80 and SUMO ligases (PIAS1 and PIAS4) and survival in gastric cancer patients (p) receiving second-line docetaxel (doc)
  572. Treatment for recurrence after hepatectomy in patients with colorectal liver metastasis
  573. p53 in renal cell carcinoma: its role in angiogenesis and metabolic pathways
  574. Induction Docetaxel and S-1 followed by Concomitant Radiotherapy with Low-dose Daily Cisplatin in Locally Advanced Head and Neck Carcinoma
  575. A Phase II study of cediranib in combination with mFOLFOX6 in Japanese patients (pts) with metastatic colorectal cancer (CRC)
  576. Increased Circulating Vitamin D and Testosterone Levels in Patients with Cancer
  577. A population based analysis of changes in therapy and survival of metastatic renal cell carcinoma (mRCC)
  578. Darbepoetin alfa dosing weekly and every three weeks in cancer patients with chemotherapy-induced anaemia – efficacy data from the CHOICE study
  579. Low serum cholesterol as a risk factor for fistula formation and a prognostic factor in T4 esophageal cancer patients with definitive chemoradiotherapy.
  580. A biopsy-driven and biomarker discovery clinical trial in metastatic colorectal cancer led by a new Quebec-wide translational research network, to identify signatures of clinical resistance
  581. Results of a phase 1, dose escalation study to assess the safety, efficacy and pharmacokinetics of siltuximab, an anti-IL-6 antibody in patients with solid tumors
  582. Onset of body weight loss during concurrent chemo-radiation is independent of treatment-induced esophagitis in patients with locally advanced non-small cell lung cancer
  583. Axitinib Pharmacokinetics and Blood Pressure Changes in Front-line Metastatic Renal Cell Carcinoma (RCC) Patients
  584. RESULTS OF THE FIRST RANDOMIZED PHASE II STUDY OF CATIONIC LIPOSOMAL PACLITAXEL (ENDOTAGTM-1) TARGETING TUMOR ENDOTHELIAL CELLS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER (TNBC)
  585. What Do German Office-Based Community Oncologists Expect from ESMO? Results from a 2010 Survey among Members of the Professional Association of Haematologists and Oncologists in Germany (BNHO)
  586. Bevacizumab (BV) Treatment (Tx) to Progression (BTP): Outcomes from a US Community Practice Network
  587. A phase II multicenter trial of neoadjuvant chemotherapy with bevacizumab plus mFOLFOX6 for resectable cases of synchronous liver metastasis from colorectal cancer: the first interim analysis
  588. Surgical resection of metachronous solitary metastasis from non-small cell lung cancer
  589. Oral Aprepitant in combination with 5-HT3 antagonists could prevent vomiting after TACE in Hepatocellular Carcinoma
  590. Phase I dose escalation trial of selective c-MET inhibitor ARQ 197 in Japanese patients with metastatic solid tumors
  591. Phase II Trial of First-line Capecitabine Plus Oxaliplatin in Patients with Metastatic Nasopharyngeal Carcinoma
  592. Malnutrtion, depression, anxiety : a comorbid condition
  593. Randomized phase II trial of uracil/tegafur (UFT) and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer : NJLCG 0601
  594. Analysis of Time-To-Progression (TTP) and Progression-Free-Survival (PFS): possible implications for optimizing the development, approval, costs and consequences of cancer therapies.
  595. Impact of KRAS and BRAF gene mutation status on outcomes from the Phase III AGITG MAX trial of capecitabine (C) alone or in combination with bevacizumab (B) +/- mitomycin C (M) in advanced colorectal cancer (CRC)
  596. Prognostic impact of insulin-like growth factor gene polymorphisms on survival of patients with colorectal cancer.
  597. Validation study of epidermal growth factor receptor (EGFR) mutation tests using bronchofiberscopic brushing cytology samples and pleural effusion from non-small-cell lung cancer (NSCLC) patients in the diagnostic setting
  598. Antitumor Immunity, Efficacy and Safety of CGTG-102 (Ad5/3-D24-GMCSF), an Infectivity Enhanced Oncolytic Adenovirus, in Treatment of Chemotherapy Refractory Solid Tumors
  599. First Randomized Trial Comparing Balloon Kyphoplasty (BKP) to Non-Surgical Management among Cancer Patients with Vertebral Compression Fractures
  600. N-terminal pro-brain natriuretic peptide (NT-proBNP) as a marker of outcome in elderly cancer patients receiving chemotherapy
  601. Carboplatin plus weekly Docetaxel as salvage chemotherapy in Docetaxel-resistant and Castration-resistant Prostate Cancer (DRPC).
  602. Antiangiogenic therapy of metastatic colorectal carcinoma – results from two centres
  603. Is Advenced Parental Age a Risk Factor for Colorectal Cancer? Turkish Oncology Group Study
  604. Darbepoetin alfa in the treatment of chemotherapy-induced anaemia; effects of target haemoglobin label change: data from the APRIORI study
  605. Patterns of Gastric Cancer Recurrence after Adjuvant Chemoradiation
  606. Neo-adjuvant chemotherapy treatment and response in different breast cancer subtypes: pooled multi-layer analysis of the German trials
  607. The activity of MRP1 membrane transporter confers resistance to anticancer drugs in glioblastoma multiforme cells
  608. Randomized pharmacokinetic evaluation of subcutaneous versus intravenous palonosetron in cancer patients treated with platinum-based chemotherapy.
  609. Molecular Profiling as a Strategy to Prospectively Identify Primary Solid Tumours in Metastatic Cancer Patients
  610. Molecular mechanisms involved in the response to combined antiangiogenic-antihormonal therapy in breast cancer
  611. Phase II study of everolimus in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
  612. Immunogenicity and safety of two doses of AS03A-adjuvanted Influenza A H1N1v 2009 Vaccine in Cancer patients on chemotherapy - VACANCE study
  613. Chemotherapy Significantly Improves Overall Survival In Cholangiocarcinoma patients; Single Center Experience
  614. Conatumumab (CON) or AMG 479 or placebo (pbo) + gemcitabine (gem) in patients (pts) with metastatic pancreatic cancer (mPC): a placebo-controlled, randomized, phase 2 study
  615. Influence of income and education on anticancer drug purchasing decisions in Hong Kong Chinese cancer patients
  616. Phase 2 study of telatinib in combination with capecitabine and cisplatin as first-line treatment in patients with advanced cancer of the stomach or gastro-esophageal junction (GEJ)
  617. Efficacy of erlotinib for CNS relapse after gefitinib treatment in non small cell lung cancer patients
  618. Oxaliplatin Stop-and-Go Strategy with Oral S-1 Maintenance Therapy in Advanced Colorectal Cancer; CCOG-0704 Study
  619. Proteomic analysis of large cell neuroendocrine carcinoma, small cell lung carcinoma and large cell carcinoma from formalin-fixed paraffin embedded samples and validation by immunohistochemical staining
  620. Use of subcutaneous NGcGM3/VSSP vaccine in the treatment of advanced melanoma patients. A phse I/II clinical trial.
  621. Loss of Immunolabeling of Kruppel Like Factor 10 is Associated with Advanced Stage and Rapid Progression of Pancreatic Cancer
  622. Prognostic significance of apoptosis-related proteins in diffuse large B-cell lymphoma (DLBL) patients (pts) treated with CHOP-based chemotherapy
  623. Genetic testing of cancer predisposition and progression: analysis of gene variations in tumor is required
  624. Efficacy of zoledronic acid in patients with colorectal cancer metastatic to bone
  625. BRCA1 germline mutations are associated with gynecologic sarcomas
  626. Relationship between performance status, nutritional status and chemotherapy dose-intensity in patients with solid tumors
  627. Breast Cancer in the Kingdom of Saudi Arabia (KSA). A review of all Male Breast Cancer (MBC) cases from the Saudi Cancer Registry (SCR) from 1994-2004
  628. Expression of CYP27B1 and CYP24 in renal cell carcinoma,and effect of 1α,25-dihydroxyvitamin D3 treatment on these enzyme expression in renal cell carcinoma cells
  629. Survival update of a randomized Phase 2 study (IMA901-202) investigating therapeutic vaccination with multiple tumor-associated peptides (TUMAP) in renal cell carcinoma (RCC) patients after failure of previous therapy with cytokines or kinase inhibitors
  630. Prospective phase II trial of a combination of gemcitabine and UFT as first-line treatment in elderly patients with advanced non-small cell lung cancer
  631. Capecitabine-based therapy for patients with brain metastases from breast cancer.
  632. Reducing mortality rates related to Capecitabine induced diarrhoea: Importance of Clinical Audit
  633. Circulating Tumor Cells in Colorectal Cancer. A prospective study.
  634. Identification and validation of gene expression models that predict outcome in patients with early stage laryngeal cancer.
  635. Influence of AKT1, AKT2 and FRAP1 Polymorphisms on Response and Survival in Head and Neck Cancer (SCCHN) Patients Treated with Docetaxel and Cetuximab
  636. Interactions with anticancer agents in clinical practice: more frequent than we imagine
  637. Induction chemotherapy (CT) with docetaxel, cisplatin, and fluorouracil (TPF) followed by concomitant cisplatin plus radiotherapy in locally advanced nasopharyngeal cancer (NPC)
  638. Cost-effectiveness of adjuvant imatinib in patients with surgically resected localized gastrointestinal stromal tumors (GIST): Canadian societal perspective
  639. The ENDORAD trial: RAD001 (everolimus) monotherapy as second line or third line treatment of advanced endometrial carcinoma: a phase II trial of GINECO group.
  640. Differential effect of oxaliplatin and irinotecanin KRAS mutant colon carcinoma in vitro
  641. Safety and pharmacokinetics of First-Line AMG 479 in Combination with Paclitaxel and Carboplatin (PC) for Advanced, Squamous Non-Small Cell Lung Cancer (NSCLC)
  642. Development of a multi-centric assessment tool for measuring and improving standardised organisation and provision of care in cancer structures.
  643. Clinical predictive factors of increased overall survival with bevacizumab/irinotecan for primary recurrent glioblastoma (GBM).
  644. Neoadjuvant platinum containing regimen for locally advanced triple negative breast cancer.
  645. Phase I study of sunitinib (SU) plus S-1 and cisplatin (P) in patients (pts) with advanced or metastatic gastric cancer (GC)
  646. Vinorelbine and Docetaxel combination as first line treatment in patients with metastatic breast cancer – Results of a multicentric phase II trial in Iran
  647. Clinical outcome of patients treated with hepatic arterial infusion of oxaliplatin and L-folinic acid modulated 5-fluorouracil for inoperable colorectal cancer liver metastases, a single center experience
  648. HER2 status in 100 patients with gastric adenocarcinoma
  649. Nurse-led Sunitinib Clinic for Aggressive Management of Toxicities - results and outcomes
  650. Heat shock proteins 27, 105 expressions in oral tongue squamous cell carcinoma and their correlations with clinicopathological characteristics by immunohistochemistry
  651. Targeting CD70 in Non-Hodgkin Lymphoma and Renal Cell Carcinoma: A Phase 1 Study of the Antibody-Drug Conjugate SGN-75
  652. What direct costs are assosiated with evaluation of Upper gastrointestinal cancers? Results of a 32 month audit.
  653. A novel, simple and cost-effective KRAS mutation detection method, Luminex® assay: results from a multicenter, prospective clinical trial.
  654. Effects of denosumab vs zoledronic acid (ZA) on pain in patients (pts) with advanced cancer and bone metastases: An integrated analysis of 3 pivotal trials
  655. Treatment of castration refractory prostate cancer patients with 2 different immunotherapeutic approaches against EGFR.
  656. The development of the novel photodynamic therapy with glycoconjugated chlorine for stomach and colon cancer.
  657. Sorafenib mediates apoptosis in hepatocellular carcinoma cells through kinase-independent inhibition of signal transducers and activators of transcription 3
  658. An Interim analysis of a phase II, open-lable, multi-center, prospective study of paclitaxel plus capecitabine with subsequent capecitabine maintenance as first-line treatment in advanced gastric cancer
  659. A phase II study of erlotinib plus capecitabine (XEL) as first line treatment for Asian elderly patients (pts) with advanced adenocarcinoma of lung (ML 22206 study)
  660. Analysis of neurosensory adverse events (NSAEs) induced by FOLFOX4 treatment in advanced/recurrent or adjuvant colorectal cancer in Asian and Western patients (Pts)
  661. CARMA3: a novel target for cancer therapy
  662. Correlation between skeletal related events and reducing osteolysis level in patients with breast cancer bone metastases: Role of Ibandronate.
  663. Impact of Adjuvant Chemotherapy on survival of patients with stage II Colon Cancer: Retrospective Study
  664. Biomarker profiles are not of predictive value for response and outcome in patients with locally advanced rectal cancer undergoing cetuximab-based preoperative chemoradiotherapy
  665. The role of personality variables in the formation of colorectal cancer patients’ psychological distress and health-related quality of life
  666. Serum M30 AND M65 values in patients with advanced stage non-small cell lung cancer compared with healthy control group
  667. Pain management in critically ill patients: what is important? The results from Italian ECAD_O survey
  668. What Greek women with breast cancer want to know about their illness and how much do they want to participate in treatment decision making?
  669. Cost comparison: capecitabine + oxaliplatin (XELOX) vs 5-FU/LV + oxaliplatin (FOLFOX4) in the adjuvant treatment of patients with colon cancer (aCC)
  670. Prospective study of host cell reactivation assay (HCRA) in non-small-cell lung cancer (NSCLC) patients (p)
  671. S-nitrosothiol homeostasis and nitrosative stress modulate proliferation of breast cancer cells
  672. Multicenter phase II study of S-1 (S) plus cisplatin (P) with concurrent thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (LA-NSCLC): West Japan Oncology Group (WJOG) 3706 trial
  673. A Let-7 microRNA complementary site polymorphism in the KRAS 3’-UTR region as a genetic regulator in advanced colorectal cancer
  674. The multi-targeted kinase inhibitor AEE788 exerts anti-proliferative effects in BRAF mutated colorectal cancer cells
  675. First report of the safety, pharmacokinetics (PK), and preliminary activity of PF299804 in Japanese patients (pts) with advanced solid tumors
  676. Immunohistochemistry (IHC) with EGFR mutation-specific monoclonal antibodies (mAbs) for screening EGFR mutations in non-small-cell lung cancer (NSCLC) patients (p)
  677. Accelerated MVAC chemotherapy in patients with advanced bladder cancer pretreated with platin-gemcitabine regimens
  678. Nilotinib enhances the cytotoxic effect of doxorubicin through selectively inhibiting the activity and cellular expression of the multidrug resistance protein P-glycoprotein in soft tissue sarcomas
  679. Stem cell marker nestin expression correlates with proliferation and cell cycle in non-small cell lung cancer
  680. TRAP1 and Sorcin cooperate in a survival pathway responsible for inducing drug-resistance in human colorectal carcinoma (CRC)
  681. Ixabepilone (Ixa)-associated peripheral neuropathy (PN): retrospective review of data from phase 2 and 3 clinical trials
  682. Active specific immunotherapy with anti-idiotype (Racotumomab) vaccine in the treatment of patients with advanced non-small cell lung cancer: Preliminary report.
  683. Phase I study to assess the safety and tolerability of saracatinib (AZD0530) plus carboplatin (C) and/or paclitaxel (P) in patients with solid tumours
  684. Treatment of lymphedema in patients with cervical cancer at localized stages
  685. Cancer of Unknown Primary patients with Midline nodal distribution: midway between poor and favourable prognosis?
  686. Microbubble ultrasound compared to dynamic contrast MRI and CT for the assessment of vascular response to sunitinib in renal cell carcinoma
  687. Platinum and capecitabine for the treatment of penile carcinoma: a retrospective case series
  688. Esophageal cancer in northeast of Iran
  689. Circulating tumour cells in Cancer of Unknown Primary site: Correlation with clinico pathologic characteristics and prognosis.
  690. Safety and pharmacokinetics of first-line AMG 479 (MAb to IGF1R) or AMG 102 (MAb to HGF/SF) with platinum-based chemotherapy in extensive-stage small cell lung cancer (SCLC)
  691. CRAB trial: Updated results from a prospective phase II study evaluating neoadjuvant Capecitabine, RAdiotherapy (RT) and Bevacizumab in locally advanced rectal cancer
  692. Epirubicin cardiotoxicity on breast cancer adjuvant setting
  693. Health related quality of life (HRQL) outcomes of ipilimumab treatment in patients with previously treated unresectable stage III or IV melanoma (USIII/IV Mel)
  694. Ipilimumab produces durable objective responses in patients with previously treated, advanced melanoma: results from a phase III trial
  695. Extensive characterization of EGFR pathways may help in integrating the use of EGFR-targeted therapies in patients with squamous cell anal cancer
  696. A first-in-human phase I study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin’s lymphoma (NHL)
  697. Prostate cancer, relationship between suffering religiosity anxiety and depression
  698. Exposure-Response Relationships of AMG 386 in Combination With Weekly Paclitaxel in Advanced Ovarian Cancer: Facilitation of Phase 3 Dose Selection By Population Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling
  699. Clinical outcomes (COs) by sex in non-small cell lung cancer (NSCLC) patients (pts): Preliminary results from ARIES, a bevacizumab (BV) observational cohort study (OCS)
  700. High prevalence and poor prognosis of triple negative tumors in Hispanic patients with breast cancer
  701. A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin (FMP therapy) for advanced hepatocellular carcinoma
  702. Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TFOX) for advanced gastric and oesophageal adenocarcinoma (AGEC): tolerance and response in 38 patients: preliminary report.
  703. A multicenter feasibility study with S-1, oxaliplatin and oral leucovorin (SOL) for the patients with untreated metastatic colorectal cancer : the result of interim analysis.
  704. Oxaliplatin + 5-fluorouracil/leucovorin (FOLFOX4) in advanced HCC: updated efficacy results of the EACH trial
  705. Cost-effectiveness and budget impact analyses of gefitinib in 2nd-line treatment for advanced NSCLC from Thai payer perspective
  706. Survival Benefit of Gastrectomy ± Metastasectomy in Metastatic Gastric Cancer Patients Receiving Chemotherapy
  707. Access of high-risk breast cancer patients to adjuvant clinical research programs in French comprehensive cancer centres: a survey by the REMAGUS group
  708. Preoperative treatment for Colorectal liver metastases: Impact on Hepatic Histology and Postoperative Outcome
  709. Randomized Phase II Trial (NCT00637975) Evaluating Activity and Toxicity of Fixed Dose of Oxycodone and Increasing Dose of Pregabalin Versus Increasing Dose of Oxycodone and Fixed Dose of Pregabalin for the Treatment of Oncological Neuropathic Pain (NEUROPAIN-01)
  710. Circulating Tumor Cells (CTCs) in locally advanced rectal cancer (LARC) patients undergoing neoadjuvant treatment.
  711. Neo-adjuvant chemotherapy (NACT) in Hormonal Receptor positive (HR+) or Triple Negative (TN) operable breast cancer (BC): a randomized study comparing standard to response–adapted sequence.
  712. OPTIMAL TREATMENT OF THE AXILLA AFTER POSITIVE SENTINEL LYMPH NODE BIOPSY IN PRIMARY INVASIVE BREAST CANCER PATIENTS (SURGERY VERSUS RADIOTHERAPY). EARLY RESULTS OF A RANDOMIZED CLINICAL TRIAL
  713. Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer patients treated with adjuvant chemotherapy after curative resection
  714. Expression of Bax Predicts Outcome in Advanced Gastric Cancer Patients Treated With 5-fluorouracil and Platinum Palliative Chemotherapy
  715. AXL mRNA overexpression correlates with lung metastases in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations
  716. Isotretinoin plus clindamycin association for symptomatic erlotinib-induced cutaneous rash in advanced non-small cell lung cancer: a new therapeutic option.
  717. Long term survival of high risk melanoma patients immunized with an allogeneic whole cell genetically modified vaccine (AGI-101) after complete resection
  718. Validation of PRO_10, a multigene prognostic signature, in patients (pts) with early, estrogen receptor positive (ER+) postmenopausal breast cancer (BC)
  719. A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study
  720. kras mutations differing for aminoacid substitution confer different drug sensitivity and resistance in NSCLC
  721. A Phase II Prospective Study of Ketoconazole in Castration-Resistant Prostate Cancer Patients (CRPC)
  722. Long-term follow-up of a phase II feasibility study of regional hyperthermia added to chemoradiotherapy in advanced cervical cancer
  723. Safety subgroup analyses from the CECOG phase III TURANDOT trial: first-line bevacizumab (Bev) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC)
  724. Correlation between anthracycline-induced delayed emesis and the use of H2-blockers
  725. Effect of Arsenic Trioxide on Nucleostemin Gene Expression in Acute Promyelocytic Leukemia Patients
  726. A retrospective analysis of trabectedin activity in pre-treated advanced Ewing sarcoma (ES): experience in 31 patients
  727. Hot flushes (HF) during androgen deprivation therapy: Direct comparison of monthly degarelix and leuprolide in a Phase 3 trial
  728. Methylnaltrexone for opioid-induced constipation in patients with advanced cancer: results of a retrospective study.
  729. Enumeration circulating tumor cells (CTCs) is a prognostic and predictive factor for progression-free survival (PFS) and overall survival (OS) in colon cancer patients receiving first-line chemotherapy plus bevacizumab. A TTD Spanish Group Cooperative Study.
  730. The continuing role of platinum-based chemotherapy in the era of targeted drugs in advanced nasopharyngeal carcinoma (NPC): A systematic review
  731. Clinical activity of gemcitabine-based chemotherapy in frail and/or heavily pre-treated patients with bone sarcomas.
  732. Neutral endopeptidase (NEP) and endothelin 1 (ET-1) are inversely expressed in hormone-naïve prostate cancer and are predictors of biochemical failure from radical prostatectomy
  733. No Improvement of Outcome with Reduced vs. Conventional High Intensity Conditioning for Allogeneic Stem Cell Transplants in Ewing Tumor Patients
  734. HB-EGF-CTF nuclear translocation induces gastric cancer invasion.
  735. Clinical response to ipilimumab: effect of systemic corticosteroids used to manage immune-related adverse events (irAEs)
  736. Indirect comparison and UK cost-effectiveness analysis of paclitaxel albumin vs docetaxel for pretreated metastatic breast cancer
  737. Different primary tumours and their mediastinal lymph nodes metastases
  738. Capecitabine and cisplatin plus concomitant radiation therapy in patients with locally advanced squamous cell carcinoma of the esophagus (LA-SCCE)
  739. Ipilimumab improves overall survival in patients with previously treated, advanced melanoma: long-term survival results from a phase III trial
  740. Is There a Role for Induction Chemotherapy (iCT) in Locally Advanced Head and Neck Squamous Cell Carcinoma (LAHNSCC)? A Single Institution Experience
  741. Promoter hypermethylation of tumor suppressor genes in urine sediment from prostate cancer patients
  742. Sunitinib (SU) with cisplatin (P) and capecitabine (X) or oxaliplatin (O) and X (XELOX) in advanced gastric cancer (GC) – a phase I, dose-finding study
  743. Bevacizumab (BV) in combination with FOLFOXIRI compared with BV plus FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC): preliminary safety results of the TRIBE study by the Gruppo Oncologico Nord-Ovest (GONO).
  744. Clinical Significance and Functional Relevance of MAGED-4B in Breast Cancer
  745. Increased Dicer expression levels are associated with higher grades of leiomyosarcomas
  746. Plasma M30 and M65 Levels in Patients with Advanced Gastric Cancer: IS There an Impact on Survival of Patients?
  747. Ipilimumab improves survival in previously treated, advanced melanoma patients with poor prognostic factors: subgroup analyses from a phase III trial
  748. An artificial neural network for predicting recurrence in patients with distal gastric adenocarcinoma underwent gastrectomy
  749. Impact of cancer on spousal communication in couples coping with cancer: result of exploratory study in a Moroccan context
  750. Optimal schedule of concomitant chemoradiotherapy (CRT) with S-1
  751. Targeted therapy in first-line therapy of metastatic renal cell cancer (mRCC): systematic review with meta-analysis (SRMA).
  752. Long term follow-up for EBUS-TBNA negative mediastinal lesions
  753. Relationship between mRNA expression levels and clinical efficacy of oral uracil and tegafur/leucovorin chemotherapy in patients with colorectal cancer
  754. Multicenter Phase II study of FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan; ROOF study
  755. Evaluation of adrenal suppression after dexamethasone therapy as an antiemetic in cancer patients
  756. Efficacy and safety of intrapericardial bleomycin for malignant pericardial effusion.
  757. Interim analysis of the German non-interventional post marketing surveillance study (NIS) on Quality of Life (QoL) of capecitabine in patients with metastatic breast cancer (MBC)
  758. Weekly regimen of paclitaxel-carboplatin-cetuximab as first-line chemotherapy in patients with platinum-resistant recurrent or metastatic squamous cell carcinoma of head and neck (sschn): results of a phase II study.
  759. TEMOCAR: carboplatin in addition to radiotherapy and temozolomide in newly diagnosed unresectable glioblastoma
  760. Prognosis of elderly breast cancer patients with intermediate or high risk who received suboptimal adjuvant therapy.
  761. Safety and tolerability of lapatinib in combination with vinorelbine (N) and capecitabine (C) as second line treatment in patients with Her2 positive metastatic breast cancer (MBC).
  762. Cancer pain management in oncological settings. The role of oxycodone: a new option as starting strategy therapy?
  763. Venous thromboembolism (vte) as predictor of neoplasia
  764. Retrospective study regarding the efficacy of 2nd or higher line chemotherapy of patients in advanced or recurrent gastric cancer (ARGC) after the failure of S-1 or S-1 combination chemotherapy (S+α)
  765. Natural history of malignant bone disease in colorectal cancer: final results of a large Italian "bone metastases" survey
  766. A pilot trial of preoperative chemoradiotherapy using capecitabine, external beam radiation and cetuximab followed by definitive surgery in patients with localized (non-metastatic) rectal cancer
  767. The italian cross-sectional survey on the management of bone health in oncology: The ZETA STUDY
  768. Activity of sunitinib in advanced soft tissue sarcoma and its correlation with potential predictive biomarkers.
  769. HER2 status as predictor of Mammographic Screening detection: Comparison of Interval- and Screen-Detected Breast Cancers
  770. Results of a Randomized, Phase II Study of Bevacizumab and Bortezomib vs. Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: AMBER Study
  771. Activity and safety of Dose-Adjusted Infusional CHOP chemotherapy with Rituximab (DA-POCH-R) in very elderly patients with poor-prognostic untreated Diffuse Large B-Cell Non-Hodgkin’s Lymphoma
  772. Phase I trial of a fusion heat shock protein (gp96-Ig) in advanced non-small cell lung cancer (NSCLC) patients who have failed palliative chemotherapy and erlotinib
  773. Novel chemotherapy combinations in advanced gastric cancer: An updated meta-analysis
  774. Sorafenib does not improve the results of chemotherapy in advanced pancreatic cancer: A GISCAD randomised phase II trial.
  775. Evaluation of Hepatocyte Growth Factor (HGF) as a Prognostic Indicator in Acute Myeloid Leukemia
  776. Mitoxantrone as second-line chemotherapy in patients with castrate-resistant prostate cancer (CRPC).
  777. Medical ozone (O3) heals Osteonecrosis of the jaw (ONJ) in patients treated with bisphosphonates (BPs). Preliminary results
  778. A multi-institutional phase II study of single agent ABI-007 in platinum refractory urothelial carcinoma
  779. PSA doubling time is the strongest predictor for metastases, castration resistance, and death in patients with prostate cancer treated with intermittent androgen deprivation for isolated biochemical relapse.
  780. Randomized Phase II Study of Hepatic Arterial Infusion with or without Antineoplastons as Adjuvant Therapy after Hepatectomy for Liver Metastases from Colorectal Cancer
  781. A final results of a phase II study of first-line gefitinib for elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations; NEJ 003 study.
  782. Genetic epidemiology of Gastrointestinal Stromal Tumors (GISTs): North American and Argentina patient population profile
  783. Assessment of supportive care for Hand-Foot syndrome and stomatitis in relapsed ovarian cancer patients receiving Pegylated liposomal doxorubicin
  784. Quantitative high-dimensional monitoring of proteins in response to anti-cancer agents
  785. Serum Albumin levels as a surrogate marker for Docetaxel induced toxicity in nonmetastatic Breast Cancer Patients.
  786. Prognostic implication of Gemcitabine-based chemotherapy and intraoperative radiation therapy in unresectable pancreatic cancer
  787. A retrospective survey of systemic anticancer therapy in women with metastatic breast cancer (MBC) in Belgium
  788. Phase I study of S-1 plus trastuzumab combination therapy in human epidermal-growth receptor 2-positive metastatic breast cancer
  789. Phase I/II Trial of Zoledronic Acid plus Interleukin-2 in Patients with solid and hematological malignancies
  790. Randomized phase II study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer (GOIRC 02/2006): preliminary results
  791. Surgery + Radiotherapy VS. Exclusive Chemo-Radiation Therapy in Oral and Oropharyngeal Cancer: Long Term Functional and Psychological Impact
  792. Impact of KRAS status on survival in patients (pts.) with metastatic colorectal cancer (mCRC) undergoing bevacizumab (bev) containing chemotherapy regimen– Analysis of the AIO Colorectal Cancer Study Group
  793. Comparison between two schemes of induction chemotherapy (ICT) concomitant chemoradiation (CRT) in locally advanced nasopharyngeal cancer (NPC)
  794. Neoadjuvant chemotherapy (NAC) with docetaxel and liposome-encapsulated doxorubicin in locally advanced HER2- breast cancer (LABC)
  795. Efficacy of continuous infused 5-fluorouracil, doxorubicin, and mitomycin (iFAM) in the treatment of gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in salvage setting
  796. Meta-analysis of published randomized clinical trials (RCTs) comparing platinum/etoposide (PE) versus platinum/topoisomerase 1 inhibitors (PTIs) regimens for extensive-disease small-cell lung cancer (ED-SCLC)
  797. Prospective transGEICAM study of Oncotype DX® in clinical decision making in estrogen receptor-positive node-negative breast cancer women
  798. Psychological adjustment in patients with prostate cancer
  799. "Determina KRAS" Project: what´s new after twenty months?
  800. The importance of family on quality of life of palliative cancer patients
  801. Smoking-induced p16 methylation in young women
  802. KRAS mutational status in Japanese patients with colorectal cancer: Results from a multicenter, cross-sectional, large observational study conducted by the Japan Study Group of KRAS Mutation in Colorectal Cancer
  803. Phase I and pharmacologic study of docetaxel (D), oxaliplatin(O), capecitabine ( C) for untreated patients (pts) affected by advanced gastric cancer (AGC).
  804. Phase II study of docetaxel and 5-Fluorouracil (5-FU) with concurrent radiotherapy in patients with advanced esophageal cancer
  805. Topoisomerase IIα in colorectal carcinoma: expression and prognostic role
  806. Evidence provided by non-randomised trials is not conclusive on the efficacy of 2nd line treatments in patients with metastatic hormone refractory prostate cancer (mHRPC)
  807. Management of febrile neutropenia at an outpatient clinic: Risk self-assessment by a simplified scoring system
  808. A Phase II Study of Pemetrexed, Carboplatin and Thoracic Radiation with or without Cetuximab in Patients with Locally Advanced Unresectable Non-Small Cell Lung Cancer: UPDATED RESULTS OF CALGB 30407
  809. Efficacy, safety and pattern of relapse of Bevacizumab (BEV) versus chemotherapy for recurrent glioblastoma multiforme (GBM): A McGill University study
  810. Implications of expression markers of apoptosis in colorectal cancer with metastasis in liver
  811. Epigenetic, genetic and clinical predictive factors of severe toxicity to 5-FU-based chemotherapy in gastrointestinal cancer
  812. The role of perioperative Bevacizumab in the management of patients with colorectal cancer and liver metastases treated with liver metastasectomy
  813. Influence of the family of oncological patients: An ethical problem?
  814. Integrative omics based next-generation molecular markers and targets in colorectal cancer
  815. Functional magnetic resonance imaging with food stimuli in lung cancer patients with and without anorexia
  816. Long-term outcomes in Early favourable Hodgkin´s lymphoma treated with single modality ABVD: A single centre experience.
  817. Non-randomized phase II study comparing metronomic regimens of chemotherapy in patients (pts) with refractory metastatic colorectal cancer (mCRC)
  818. Small cell Lung cancer in women: the Spanish female-specific database WORLD07
  819. Treatment of Lymphoma in the Elderly - Toxicities and Outcomes
  820. Importance of religion and spirituality in cancer patients cared for in oncological, supportive care, psychological and rehabilitation ambulatory settings
  821. Is obesity changes the expression profile of genes coding IGF in the colorectal cancer patients?
  822. Japanese current perceptions of lung cancer-Analysis from international survey by global lung cancer coalition (GLCC)
  823. Preliminary results from the South Australian (SA) Clinical Registry for Advanced Colorectal Cancer (CRC) assessing the impact of age and choice of chemotherapy on outcome
  824. Perfusion Computed Tomography as prognostic and predictive factor in patients with colorectal cancer liver metastases treated with bevacizumab
  825. Dynamics of Circulating Endothelial Cells and Endothelial Progenitor Cells in Breast Cancer Patients Receiving Cytotoxic Chemotherapy
  826. Pilot Study of Pathological Complete Response (pCR) in LABC patients treated with dose dense AC x 4 followed by weekly paclitaxel x 12 with capecitabine.
  827. Maintenance chemotherapy in advanced non-small cell lung cancer: cost utility of pemetrexed and gemcitabine
  828. microRNA-196b and microRNA-363 were identified as gastric cancer specific microRNAs in human gastric cancer tissue using microarray experiment
  829. Comparison of the Efficacy and Tolerability of Raltitrexed-based Chemotherapy Versus 5-Flurouracil-based Chemotherapy in Asian Colorectal Cancer Patients
  830. A phase II trial of paclitaxel plus doxorubicin plus carboplatin in patients with intermediate risk, high risk, or recurrent endometrial cancer : A Japan Endometrial Cancer Study Group trial
  831. Survival Benefit Associated with Fluoropyrimidines, Platinum Agents, Taxanes, and Irinotecan During All Lines of Treatment in Patients with Advanced Gastric Cancer
  832. FOLFOX-induced steroid-refractory interstitial lung disease responding to cyclophosphamide: a case report
  833. MGMT -535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy
  834. Attitude and knowledge about end-of-life support: a Bavarian survey
  835. A phase II study of Tumor Treating Fields (TTFields) in combination with pemetrexed for advanced non small cell lung cancer (NSCLC)
  836. P3H collagen prolyl hydroxylases are tissue selective tumour suppressors
  837. Vinflunine after failure of a first-line vinorelbine based chemotherapy in advanced breast cancer: results of a phase II multicentre study.
  838. Management and cancer outcomes of secondary malignancies following liver transplantation.
  839. Hypomagnesemia related to anti-EGFR monoclonal antibody therapies: a pooled analysis of randomised trials.
  840. The analgesic therapy of patients with hematologic or solid tumours: results from Italian ECAD_O survey
  841. The Relation between Endoglin (CD105), Thrombospondin-1 and VEGFR-3 and Treatment Results in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combination Therapy
  842. Evaluation of completeness and quality of the information process during genetic counselling for cancer predisposition. Preliminary results of the Genetic Counselling Service (GCS) of Southern Switzerland
  843. Evaluation of 18F-Flurodeoxyglucose PET/CT compared to contrast-enhanced full-dose PET/CT in the management of patients with lymphoma
  844. Triplet combination of capecitabine plus oxaliplatin and irinotecan in the treatment of patients with previously untreated advanced gastric cancer (AGC)
  845. mTOR Inhibition and Renal Cell Carcinoma; a comparison between Sirolimus and Temsirolimus
  846. Phase I clinical and pharmacokinetic study of Dasatinib in once daily schedule in Japanese patients with advanced solid tumors: study CA180058
  847. circulating tumor cells in breast cancer: are currently available detection methods enough?
  848. Pharmacokinetic (PK) evaluation of erlotinib with or without sunitinib to treat metastatic non-small cell lung cancer (NSCLC) in a phase II trial
  849. Capecitabine (X) in advanced breast cancer in the real life setting - First 12-month results from the ELIXIR cohort
  850. Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan(200 mg/m2) and Autologous Transplantation (MEL200) in Newly Diagnosed Myeloma Patients: A Phase III Trial
  851. ICON7: A PHASE III RANDOMISED GYNAECOLOGIC CANCER INTERGROUP TRIAL OF CONCURRENT BEVACIZUMAB AND CHEMOTHERAPY FOLLOWED BY MAINTENANCE BEVACIZUMAB, VERSUS CHEMOTHERAPY ALONE IN WOMEN WITH NEWLY DIAGNOSED EPITHELIAL OVARIAN (EOC), PRIMARY PERITONEAL (PPC) OR FALLOPIAN TUBE CANCER (FTC)
  852. Breast cancer is a more aggressive disease in Palestinian Arab women than in Jewish women in Israel
  853. Phase II study of irinotecan plus S-1 combination for previously untreated advanced non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial 0601
  854. Relationship between Lymphopenia and Circulating Tumor Cells as Prognostic Factors for Overall Survival in Metastatic Breast Cancer
  855. Dexamethasone (DEX)-sparing regimen for prevention of emesis following moderately emetogenic chemotherapy (MEC): analysis of prognostic factors affecting anti-emetic outcome. An I.T.M.O. study
  856. Phase I dose-escalation study of imatinib mesylate (IM) associated with fixed dose of oral metronomic cyclophosphamide (MC) in selected tumors which may benefit from IM.
  857. Serum LDH level as a prognostic factor for the patients with advanced gastric cancer
  858. Samital in prophylaxis of chemo-radiotherapy (CT-RT) induced mucositis in head and neck squamocellular cancer (HNSCC) patients (PTS): results of a prospective monoinstitutional phase II trial.
  859. Is mucinous carcinoma an independent histologic type in colon cancer? : a significance of mucin in histologic classification.
  860. Carboplatin and gemcitabine in elderly and/or frail patients (pts) with advanced transitional cell carcinoma (TCC): a phase II study
  861. Combined chemo-radiotherapy with gemcitabine in patients with locally advanced inoperable transitional cell carcinoma (TCC) of the urinary bladder and/or in patients ineligible for surgery: Results of a phase I trial
  862. Outcome in Young Women with Breast Cancer: Moroccan experience
  863. Detection of BCR ABL Fusion Protein in CML and ALL by Flowcytometric Bead Assay:An Indian Experience
  864. Are Primary Tumour Standardized Uptake Value (PT SUVmax), Total Lesion Glycolysis (TLG) and Metabolic Volume (MV) measured on FDG PET(CT) predictors of survival in Non-Small Cell Lung Cancer (NSCLC) ?
  865. A randomized Phase II clinical trial of the Src inhibitor saracatinib (AZD0530) and carboplatin + paclitaxel (C+P) versus C+P in patients (pts) with advanced platinum-sensitive epithelial ovarian cancer (EOC)
  866. Olfactory Neuroblastoma: Impact of Induction Chemotherapy and Proton Beam Therapy
  867. Paclitaxel (P) and bevacizumab (Bev), as first-line chemotherapy, in patients with HER2-negative metastatic breast cancer (MBC). The Hellenic Cooperative Oncology Group experience with biomarker evaluation.
  868. Incidence of HER-2/neu Positivity in Series of Breast Cancer Cases and Its Significance in Prognostication in Five Year Follow-Up in Eastern India
  869. Duration of Trastuzumab Therapy May Improve Survival in HER2(+) Metastatic Breast Carcinoma Patients in the Absence of Adjuvant Trastuzumab
  870. Comparison of two modalities of induction chemotherapy in head and neck cancer with unresectable bulky nodal disease; an intent-to-treat analysis
  871. An awareness and screening programme of cervical cancer in rural West Bengal
  872. Phase II study of the oral PARP inhibitor olaparib (AZD2281) versus liposomal doxorubicin in ovarian cancer patients with BRCA1 and/or BRCA2 mutations
  873. Identification of predictive biomarkers for individual response to mFOLFOX6 in colorectal cancer patients
  874. Results of a multicenter phase II trial with the deacetylase inhibitor (DACi) panobinostat in relapsed Small Cell Lung Cancer (SCLC) patients.
  875. Compliance to Vitamin Supplementation and Toxicity during 2nd Line Treatment with Pemetrexed in Patients with Stage III/IV Non Small Cell Lung Cancer (NSCLC) in Daily Practice
  876. Toward the characterization of a genetic profile with prognostic value at CDKN2A locus in melanoma patients
  877. Introduction chemotherapy with docetaxel, cisplatin and S-1（TPS）followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma.
  878. Sorafenib activity in NSCLC cell lines seems related to a different type of K-RAS mutations
  879. Morphological alterations in rats and rabbits after infection with Bovine Leukemia Virus. In vivo laboratory model of a human viral T-lymphocytic leukemogenesis
  880. RIPK1 polymorphism as prognostic marker for survival in patients with colorectal cancer after complete resection
  881. Bone metastasis in clear cell renal cell carcinoma: a predictive factor for outcome on sunitinib in retrospective analysis
  882. Five-Year Survival (OS) and Patterns of Failure for Human Papillomavirus (HPV) Positive and Negative Oropharynx Cancer (OPC) in the TAX 324 Clinical Trial: Results of Sequential Therapy
  883. Non-Random Integration of Epstein-Barr Virus (EBV) into Chromosomes of Burkitt’s Lymphomas Cell Lines
  884. Adjuvant chemotherapy for early breast cancer in Italy: What has changed today versus the early 2000’s. A comparison between two observational national studies − NORA and NEMESI.
  885. Breast Cancer Treatment in Men
  886. A phase I, dose-finding study of sunitinib (SU) in combination with cisplatin (P) and 5-fluorouracil (5-FU) in patients (pts) with advanced gastric cancer (GC)
  887. Effectiveness of taxane monotherapy (TM) and taxane combination (TC) treatment in patients with advanced breast cancer
  888. Prognostic value of early complete metabolic response by FDG-PET during neo-adjuvant chemotherapy in advanced ovarian cancer patients
  889. Phase II study of belotecan and cisplatin as first-line chemotherapy for extensive disease of small cell lung cancer: Preliminary results
  890. Meta-analysis of randomized phase II/III trials adding bevacizumab to platin-based chemotherapy as 1st-line treatment in patients with advanced non-small cell lung cancer (NSCLC)
  891. Taxane-based treatment options for patients with HER2-positive advanced breast cancer: results of an observational study
  892. Cutaneous infections in the emergency unit of a cancer research centre.
  893. To detect the expression of cytokeratin 19 in peripheral blood of patients with breast cancer and its clinical significance
  894. Cetuximab in combination with docetaxel in patients (pts) with metastatic castration resistant (mCRPC) and docetaxel-refractory prostate cancer: final analysis of the multicenter phase II trial SAKK 08/07
  895. Preclinical evaluation of Trabectedin in patient derived tumor xenografts in vitro and in vivo, and identification of a predictive gene signature
  896. Single-centre experience of quality assurance (QA) measures in a phase 2 trial of radiotherapy (RT) + panitumumab vs chemo-RT (CRT) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)
  897. Patients with metastastic soft tissue sarcoma (STS) benefit from reexposition to anthracyclines with comedication of dexrazoxane
  898. Tolerability of Trabectedin (Tr) plus pegylated liposomal doxorubicin (PLD) in platinum sensitive (P-S) vs. platinum resistant (P-R) patients (pts) with relapsed ovarian cancer
  899. Retrospective analysis of 470 metastatic uveal melanoma (MUM) patients managed at Institut Curie between 2000 and 2008.
  900. Randomized phase 2 study of PF299804, an irreversible human epidermal growth factor receptor (EGFR) inhibitor, versus (v) erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) after chemotherapy (CT) failure: quantitative and qualitative benefits
  901. Testin downregulation and survivin overexpression in early-stage breast cancer
  902. Assessment of pharmacokinetic interaction between ipilimumab and chemotherapy in a randomized study
  903. Docetaxel, cisplatin and capecitabine (DCX) as perioperative chemotherapy in gastro-esophageal adenocarcinoma. (A phase II study of the Arbeitsgemeinschaft Internistische Onkologie AIO).
  904. A new organizational model in the city of Milan has improved the best setting of care for terminal patients
  905. Granulocyte colony stimulating factor (G-CSF) prophylaxis and febrile neutropenia (FN) incidence in patients with solid tumours receiving myelotoxic chemotherapy who are assessed as high risk for FN: IMPACT SOLID study
  906. Determination of Molecular markers for BRCA1/2 heterozygosity using gene expression profiling
  907. Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells
  908. Influence of ABCB1, ABCG2 and MGMT promoter methylation and gene polymorphisms on clinico-pathological characteristics of glioma patients
  909. Phase II Study of First-line Sunitinib (SU) in Combination with Irinotecan, Leucovorin, and 5-Fluorouracil (5-FU) (FOLFIRI) in Japanese Patients (pts) with Unresectable/Metastatic Colorectal Cancer (mCRC)
  910. Factors Affecting Survival In Patients Given Multiple Lines Of Chemotherapy (CT) For Metastatic Breast Cancer (MBC): What Do We Gain Beyond The Third Line ?
  911. A single institution experience of bimonthly gemcitabine plus vinorelbine in metastatic breast cancer patients
  912. Pemetrexed (P) plus carboplatin (Cb) as up-front treatment for patients with brain metastases of lung adenocarcinoma
  913. Lace-Bio: Results of pooled analysis of prognostic and predictive values of histology and lymphocytic infiltration
  914. Sorafenib Safety Over Time in >4600 Patients with Renal Cell Carcinoma (RCC): Insights from an Integrated Database of 8 Company-Sponsored Trials
  915. Characterisation of the hepatic safety profile of trabectedin: pooled analysis of 19 phase II clinical trials (CTs) in 1132 patients with solid tumours
  916. The usefulness of measuring circulating tumor cells in patients with small-cell lung cancer
  917. A blinded placebo (P) controlled phase 1/2 dose escalation study (DES) of brivanib (B), an oral selective dual inhibitor of FGF and VEGF signaling, in combination with cetuximab (C) and irinotecan (I) in patients (pts) with KRAS wild type (KWT) advanced or metastatic colorectal cancer (amCRC): safety, tolerability and pharmacokinetics (PK) findings
  918. Patients’ ratings of the effect of toxicities on likely adherence to gastrointestinal stromal tumor (GIST) treatments
  919. Teratoma with malignant differentiation in male germ-cell tumors (GCT): updated results from a single Institution series and future perspectives.
  920. Multidisciplinarity in the management of prostate cancer (PCa): results of a prospective observational study in Switzerland
  921. Expression of XIAP and miRNA-21 as predictor factors for lymph node invasion in rectum cancer.
  922. Impact of Circumferential Margin (CRM) Size on Overall Survival (OS) in Oesophageal Cancer (OC)
  923. Meta-analysis of the validity of progression-free survival as a surrogate endpoint for overall survival in metastatic colorectal cancer trials
  924. Cancer research is leading the way – A Study of Cancer Publications in Pivotal Medical Journals over the last two decades
  925. Phase III study of pemetrexed in combination with cisplatin (PEM/CIS) versus placebo plus cisplatin (CIS) in patients with recurrent or metastatic squamous cell head and neck cancer (HNC)
  926. Bevacizumab in combination with chemotherapy in metastatic colorectal cancer - The McGill experience
  927. Evaluation of different polymorphisms as markers of sunitinib efficacy and toxicity in first line treatment of renal clear cell carcinoma: a prospective study of the Spanish Oncologic GenitoUrinary Group .
  928. Prognostic Factors Influencing Outcome of Patients with Recurrent or Metastatic Carcinoma (R&M ) of the Head and Neck: Results of an Italian Monoinstitutional Study.
  929. A prospective multicenter GETUG phase II trial of gemcitabine, cisplatin, and ifosfamide (GIP) in patients with relapsed metastatic germ-cell tumors (GCT).
  930. Impact of different prognostic factors on the development of Brain Metastasis In adjuvant Breast Cancer Patients
  931. Comparison of denosumab versus zoledronic acid (ZA) for treatment of bone metastases in advanced cancer patients: An integrated analysis of 3 pivotal trials
  932. Final results from ARQ 197-209: a global randomized placebo-controlled phase 2 clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR-inhibitor naïve patients with advanced non-small cell lung cancer (NSCLC)
  933. Psychosocial care of Italian adult cancer patients: a large collaborative, hospital-based quality improvement project (HUCARE)
  934. A phase 1 dose escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients with advanced solid tumors
  935. Pre-treatment platelet count as a prognostic marker in patients with Glioblastoma (GBM) treated with Radiotherapy and Concurrent and Adjuvant Temozolomide (RCAT).
  936. Trabectedin: still active beyond progression in advanced soft tissue sarcomas
  937. SORAFENIB (S) + GEMCITABINE/CISPLATIN (GC) VS GC ALONE IN THE FIRST-LINE TREATMENT OF ADVANCED NON–SMALL CELL LUNG CANCER (NSCLC): PHASE III NSCLC RESEARCH EXPERIENCE UTILIZING SORAFENIB (NEXUS) TRIAL
  938. Sorafenib (S) with FOLFIRI as first line therapy for metastatic colorectal cancer (mCRC): a phase I study
  939. Treatment of B-non Hodgkin lymphoma in children with and without monoclonal antibodies
  940. Merkel Cell Polyomavirus (MCPyV) DNA Present in Non Small Cell Lung Cancer (NSCLC)
  941. A phase II study of weekly Gemcitabine- Topotecan in pretreated small cell lung cancer (SCLC) patients (pts).
  942. A first-in-human Phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors
  943. Circulating Amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (mCRC) patients (pts).
  944. Long Term Persistent Alopecia and Suboptimal Hair Regrowth after Adjuvant Chemotherapy for Breast Cancer: Alert for an Emerging Side Effect: French ALOPERS Observatory
  945. Breaking bad news in a Greek regional hospital
  946. Colorectal (CR) resectable liver metastases: long-term patient survival after preoperative transarterial chemoembolization (TACE) with oxaliplatin following hepatic resection (HR)
  947. Attitudes of Health Professionals to Patients who receive Chemotherapy Information from the Internet and their Discussion of Internet Information with Patients
  948. Fertility and sexuality concerns of cancer survivors.
  949. Effect of PF299804 on CYP2D6 activity in healthy volunteers (HVs) who are extensive metabolizers (EM)
  950. RANDOMIZED PHASE 2B STUDY OF PRALATREXATE VS ERLOTINIB IN PATIENTS WITH STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC) AFTER FAILURE OF PRIOR PLATINUM-BASED THERAPY
  951. Final results of a randomized phase III trial comparing folfirinox (F: 5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). The Prodige 4 / ACCORD 11 trial.
  952. Chemotherapy using Gemcitabine (G) & Cisplatin (C) in recurrent and metastatic Squamous Cell Carcinoma of the Cervix.
  953. Cytokine interleukin-16 is an important growth-promoting factor for multiple myeloma
  954. Predictive value of molecular markers expression in locally advanced rectal cancer (LARC) treated with neoadjuvant bevacizumab (BEV) and capecitabine (CAPE) + standard radiotherapy (RT).
  955. Feasibility of Removal of Huber Needle by Patients or Their Family Members during Chemotherapy for Colorectal Cancer
  956. Response and Survival in Oesophageal Cancer patients following neoadjuvant chemotherapy assessed by FDG-PETCT imaging and correlation to pathologic response
  957. Characteristics associated with health-related quality of life of patients with neuroendocrine tumor (NET)
  958. Comparison of Medical Expenditure according to Types of Hospice care
  959. Preclinical Development of an Intracranial Triple Negative Breast Cancer (TNBC) Tumor Model: A Pilot Study
  960. Impact of different patient management approaches on the control of capecitabine-related adverse events: a prospective cohort analysis from SAEDA II
  961. Lung Cancer in Never-Smokers
  962. Some PPARγ ligands sensitize human non-small lung cancer cells to ionizing radiation-induced apoptosis through up-regulation of ROS generation
  963. A large, multicenter, retrospective epidemiological survey: The incidence and treatment of bone metastatic disease in Chinese cancer patients.
  964. Expression of Matrix Metalloproteinase 1 (MMP1), Dickkopf-1 (Dkk1) and Colony-Stimulating Factor Receptor 1 (CSF1R) in bone metastatic tissue (BMT) and in serum of patients with bone metastases (BM) from different solid tumors
  965. LACE-Bio Pooled Analysis of the Prognostic and Predictive Value of p53 Mutations and Expression by Immunohistochemistry (IHC) in Patients with Resected Non-Small Cell Lung Cancer (NSCLC)
  966. The result of percutaneous cryoablation for resectable primary lung cancer
  967. Larynx preservation (LP) in selected stage III and IV patients (PTS)with squamous cell carcinoma (LC) using concurrent chemotherapy (CT) and hyperfractionated radiotherapy (RT).
  968. FIRST BIOMARKER ANALYSES FROM A PHASE III, RANDOMISED, OPEN-LABEL, FIRST-LINE STUDY OF ERLOTINIB VERSUS CARBOPLATIN (CBDCA) PLUS GEMCITABINE (GEM) IN CHINESE PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITH EGFR ACTIVATING MUTATIONS (OPTIMAL, CTONG 0802)
  969. Updated results of adjuvant carboplatin (carbo AUC 7 and 7.7) in stage I seminoma (sem) of the testis from the BOC Oncology Centre
  970. Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC) in metastatic renal cell cancer (mRCC): results and evaluation of circulating t-regulatory cells (TREG) and other cytokines. A GOIRC study.
  971. Initial treatment dose and reasons for dose adjustment during oral capecitabine chemotherapy
  972. ERCC1, flk-1, clusterin, and Her2/neu overexpression and risk of recurrence in patients (pts) treated with cystectomy for muscle-invasive urothelial carcinoma of the bladder (UC)
  973. The effect of acquisition of cisplatin-resistance on sensitivity to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer cells
  974. Treatment of leptomeningeal metastasis from non-small cell lung cancer with epidermal growth factor receptor tyrosine kinase inhibitors
  975. Meta-analysis of Randomized Clinical Trials (RCTs) exploring Single Agent Chemotherapy (SACH) versus Multi-Agent Chemotherapy (MACH) in addition to Trastuzumab (T) for HER-2-Overexpressing Advanced Breast Cancer (ABC): What is the Most Appropriate Comparator?
  976. Mutations and beyond: Identification of predictors of outcome in randomized clinical trials (RCT) of 1st-line Gefinitib (G) in Advanced Non Small Cell Lung Cancer (NSCLC) with Sensitizing Epidermal Growth Factor Receptor Mutations (EGFR-M).
  977. Clinical outcome and incidence of renal failure (RF) after concurrent chemo-radiation with 3-weekly (3WC) versus weekly (1WC) cisplatin for locally advanced squamocellular head and neck cancer (SCHNC)
  978. A combination of cisplatin and 5-fluorouracil plus a taxane for advanced squamous-cell carcinoma (SCC) of the penis. A single Institution series.
  979. Updated results of the combination of paclitaxel, cisplatin and gemcitabine (TPG) followed by surgery as third-line therapy for male germ cell tumors.
  980. Diagnostic approach in patients with unknown primary cancer
  981. Safety and pharmacokinetics of intrathecal administrateration of pemetrexed in the rat
  982. Nodal metastases of penile squamous-cell carcinoma (SCC): prognostic parameters of a recent series of patients undergoing lymph-node dissection (LND) ± chemotherapy.
  983. Phase I trial with NGR-hTNF: Predictive potential of cytokines and angiogenic factors (CAFs)
  984. Radiation injures in patients with prostate cancer after interstitial radiation therapy with sealed I-125-sources and concurrent radiation therapy
  985. Peculiarities and results of surgical treatment of Lung Cancer Stage T3N0-2
  986. Five-year results of the randomized phase III trial comparing S-1 monotherapy versus surgery alone for stage II/III gastric cancer patients after curative D2 gastrectomy (ACTS-GC study)
  987. Clinical development of Namitecan (ST1968) a novel camptothecin derivative: phase I clinical data D1 Q3WK schedule
  988. Routine Detection of BRAF and NRAS mutations in FFPE tissue by Pyrosequencing
  989. Bevacizumab and Irinotecan in Recurrent Malignant Glioma : Results of a French Retrospective Cohort Study OMIT of 264 patients in Real Practice!
  990. Mitomycin-C, 5-fluororacil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma
  991. Eficacy and Safety of FOLFIRI-Bevacizumab for the Second-line Treatment of Metastatic Colorectal Carcinoma
  992. Cancer registry integration in the Umbria Regional Cancer Network: breast cancer as a model to build a supportive information system
  993. Results of a randomized phase III study of single-agent amrubicin (AMR) versus carboplatin and etoposide (CE) in elderly patients with extensive-disease small cell lung cancer (ED-SCLC)
  994. High-dose chemotherapy and autologous hematopoietic stem cell transplantation as adjuvant treatment in early stage and operable breast cancer: retrospective long-term analysis of the European experience
  995. FOLFIRI vs FOLFIRI + bevacizumab in first-line therapy of metastatic colorectal cancer: retrospective analysis of 81 patients in our institution
  996. NGR-hTNF in combination with doxorubicin in relapsed small-cell lung cancer (SCLC)
  997. A Phase II study of S-1 for Previously Untreated Elderly Patients with Advanced Non-Small Cell Lung Cancer
  998. The significance of DNA methylation of Estrogen Receptor alpha (ERa) expression in primary Breast Cancer (BC)
  999. Early complete cytogenetic remissions in acute promylocytic leukemia patients treated with Arsenic trioxide as a first line therapy
  1000. Sunitinib efficacy and tolerability in patients with neuroendocrine tumors out of a trial: a Spanish Multicenter Cohort.
  1001. RNA expression of XPG, ERCC1 and BRCA1 in myxoid liposarcoma patients treated neoadjuvant with trabectedin
  1002. Novel Gold Speckled Silica Nanoparticles as Mediators of Tumor Imaging and Photothermal Ablation Therapy for Breast Cancer
  1003. NGR-hTNF in combination with doxorubicin in progressive or recurrent ovarian cancer
  1004. Encouraging overall survival (OS) with bevacizumab (Bev) in patients with recurrent high-grade glioma (HGG) treated outside clinical trials.
  1005. Integrative evaluation of EGFR downstream signalling functionality to predict response to anti-EGFR monoclonal antibodies in KRAS wild-type mCRC
  1006. A Prognostic Model to Identify Patients with Advanced Pancreas Adenocarcinoma Who could Benefit from second line chemotherapy
  1007. Efficacy and safety of second-line treatment with panitumumab plus irinotecan, both given every three weeks (Q3W), in patients (pts) with wild-type (WT) K-RAS metastatic colorectal cancer (mCRC): A study from the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD)
  1008. Experience with the monoclonal antibody bevacizumab (Bev) combined with chemotherapy in children with poorly differentiated glial CNS tumours
  1009. Reduction in Surgical and Non-Surgical Interventions for Prostate Cancer With Dutasteride Treatment in the REduction by DUtasteride of prostate Cancer Events (REDUCE) Study
  1010. A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia
  1011. A Phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941
  1012. Medical treatment choices of patients affected by advanced NSCLC in routine clinical practice: results from the Italian observational “SUN” (Survey on the lUng cancer maNagement) study.
  1013. Does adjuvant chemotherapy benefit patients with node-positive, hormone-receptor positive, and HER2 negative breast cancer?
  1014. An EZH2 polymorphism predicts progression-free survival (PFS) in metastatic colorectal cancer (CRC) patients treated with first-line FOLFIRI plus bevacizumab (BV)
  1015. High-level resistance to antimicrobials in febrile neutropenia: experience from a tertiary care cancer center in India
  1016. SUNITINIB (SU) IN COMBINATION WITH ERLOTINIB (E) FOR THE TREATMENT OF ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE III STUDY
  1017. Treatment outcome of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of Oxaliplatin (FOLFOX) and Irinotecan (FOLFIRI) based sequential chemotherapy
  1018. FINAL OVERALL SURVIVAL (OS) RESULTS FROM A PHASE III, RANDOMISED, OPEN-LABEL, FIRST-LINE STUDY OF GEFITINIB (G) V CARBOPLATIN/PACLITAXEL (C/P) IN CLINICALLY SELECTED PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ASIA (IPASS)
  1019. RELEVANT: Prospective evaluation of efficacy and safety of bevacizumab therapy in metastatic colorectal carcinoma; interim analysis of resecatability rate
  1020. Histone deacetylase inhibitor vorinostat reduces expression of platelet-derived growth factor receptor A (PDGFRA) and matrix metalloproteinase-2 (MMP2) genes in glioblastoma cell lines
  1021. Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy of skin moisturizers and limecicline. A phase II study.
  1022. Surgical approaches for NSCLC in elderly patients.
  1023. Pemetrexed in comparison to gemcitabine as maintenance chemotherapy (MCT) in advanced non-small cell lung cancer (NSCLC): A systematic review and meta-analysis
  1024. Differences in clinicopathological features, DNA copy number profiles and outcome of metastatic colorectal cancer (CRC) patients with hepatic versus extrahepatic disease.
  1025. Quantification of incident and prevalent cases of prostate cancer in Italy using local epidemiological data
  1026. Intrathecal chemotherapy (ITCT) improves prognosis in leptomeningeal carcinomatosis (LC) from breast cancer (BC): a single institution experience
  1027. FISH-evaluated HER2 expression level but not p53 status predicts response to docetaxel-based first-line chemotherapy in advanced breast cancer patients.
  1028. Salvage chemotherapy (CT) of patients (pts) with late-relapse metastatic germ cell tumor (mGCT): single institute experience
  1029. Association of the influx transporter organic anion transporting polypeptides polymorphism on the pharmacokinetics of imatinib
  1030. The diagnosis of lung infection with Pneumocystis jirovecii must be considered in cases of dyspnea in solid tumours
  1031. Vandetanib in locally advanced or metastatic medullary thyroid cancer (MTC): a randomized, double-blind Phase III trial (ZETA)
  1032. Radiotherapy may Potentiate Immunotherapy through Presentation of Novel Tumor Antigens.
  1033. Clinical validation of a 26-gene signature predicting response to Cetuximab in wild type K-ras metastatic colorectal cancer.
  1034. Male breast cancer: About 127 cases collected at the National Institute of Oncology from 1985 to 2007
  1035. Impact of age on prognosis of locally advanced head and neck cancer (LAHNC) treated with chemoradiation (CRT). A single institutional experience
  1036. Australian Breast Cancer Patients Enrolled in the Lapatinib Expanded Access Program (LEAP)
  1037. Phase II study of induction treatment (IT) of cetuximab (Cet) with chemotherapy (docetaxel, cisplatin, 5FU –DCF-) followed by Cet with concurrent chemoradiotherapy (cisplatin) in patients (p) with locoregional oesophageal cancer (LROC). The TTD-06-02/GICOR Spanish Cooperative Groups trial
  1038. Gemcitabine or Erlotinib in combination with Sorafenib in elderly patients with advanced non small cell lung Tumor (GEST): a randomized phase II study.
  1039. Impact of adverse drug reactions (ADR) on systemic therapy in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC)
  1040. Clinical Activity of Crizotinib (PF-02341066), in ALK-Positive Patients with Non-Small Cell Lung Cancer (NSCLC)
  1041. Comparitive Analysis of two Radiotherapy techniques for Post Mastectomy Chestwall Irradiation in an Indian center
  1042. Management and prognosis of patients with non small cell lung cancer (NSCLC) metastatic to the brain: a single institution series
  1043. Carboxyl Terminus of Hsc70-interacting Protein (CHIP) mediates degradation of C-MET receptor
  1044. CEDIRANIB + FOLFOX/XELOX VERSUS PLACEBO + FOLFOX/XELOX IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC): A RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY (HORIZON II)
  1045. Predictive relevance of thyroid transcription factor-1 (TTF-1) expression in advanced non-small cell lung cancer (NSCLC) of elderly patients (pts) treated with gemcitabine and carboplatin
  1046. Are breast cancer (BC) prognostic factors different in young patients?
  1047. RAD001 as second line treatment in advanced Biliary Tract Cancer (BTC) patients (pts): an I.T.M.O. monoinstitutional experience
  1048. Use of herbal therapy among cancer patients: Consideration of its use and users
  1049. A natural history of a series of radioactive iodine (131I-RAI)-resistant advanced differentiated thyroid cancer (DTC)
  1050. Oncologic and functional outcomes after preoperative chemoradiotherapy followed by intersphincteric resection for very low rectal cancer
  1051. Salvage chemotherapy (CT) with Pemetrexed (PEM) for non small cell lung cancer (NSCLC): an implementation study.
  1052. Targeted agents reshape cancer clinical trials
  1053. Colorectal Cancer Patients Profile and Benefit to Bevacizumab Treatment Based Regimens: The Results of a Romanian Local Observational Study (PEPSACO)
  1054. Correlation of serum TGF Beta 1 and VEGF 165 levels to clinico-pathological response, ER and PR status in locally advanced breast cancer: a pilot study
  1055. Sunitinib-related psoriasis remission in patients affected by advanced clear cell renal cell carcinoma (RCC)
  1056. Distant recurrences at median of 5-years among 9.779 postmenopausal women with hormone receptor-positive early breast cancer treated on the TEAM trial of adjuvant endocrine therapy
  1057. Liver resection plus local destruction of liver metastases for patients with metastatic colorectal cancer
  1058. Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Bortezomib-Thalidomide maintenance for Initial Therapy of Multiple Myeloma: A prospective randomized trial
  1059. Low expression level of nucleostemin (GNL3), stimulator of cancer stem cell feather, is a promising biomarker to predict pathologic complete response (pCR) in neoadjuvant treatment with breast cancer.
  1060. Usefulness of Staging Laparoscopy and Induction Chemotherapy with S-1 plus Docetaxel for Advanced Gastric Cancer
  1061. clinical and economic burden of toxicities associated with monoclonal antibodies for metastatic colorectal cancer (mcrc)
  1062. Patients Not Receiving Systemic Therapy For Metastatic Colorectal Cancer – What Are The Drivers And What Are The Outcomes?
  1063. Bone marrow involvement and 7q gain in diffuse large B-cell lymphoma: a combination of clinical and molecular data
  1064. Hepatic resection for hepatocellular carcinoma.
  1065. Neo-adjuvant chemotherapy with regional hyperthermia (RHT)for localized high-risk soft-tissue sarcoma (HR-STS) with abdominal/retroperitoneal location
  1066. Hypomagnesaemia after induction TPF chemotherapy followed by concomitant cisplatin/cetuximab/radiotherapy (ccRT) in locally advanced head and neck cancer (LAHNC)
  1067. Long term survival in advanced rectal cancer and the effects of treatment method
  1068. A randomized phase II trial of adjuvant chemotherapy with docetaxel (DOC) plus cisplatin (CIS) versus paclitaxel (PAC) plus carboplatin (CAR) in patients with completely resected non-small cell lung cancer (NSCLC) (TORG0503)
  1069. Safety and Efficacy Results from a Phase 1/2 Study of the Anti-IGF-IR Antibody Figitumumab in Patients with Refractory Ewing’s and Other Sarcomas
  1070. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 (Multicentre Italian Trials in Ovarian cancer) randomized phase III trial.
  1071. A multicenter phase II trial to evaluate the combination of cetuximab (C) plus TPF (docetaxel, cisplatin and fluorouracil) as induction chemotherapy (IC) followed by cetuximab plus accelerated radiotherapy (RT) with concomitant boost in patients (pts) with unresectable locally advanced squamous cell carcinoma of head and neck (SCCHN)
  1072. PHASE IIB/III DOUBLE-BLIND RANDOMIZED TRIAL OF AFATINIB (BIBW 2992, AN IRREVERSIBLE INHIBITOR OF EGFR/HER1 AND HER2) + BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO + BSC IN PATIENTS WITH NSCLC FAILING 1–2 LINES OF CHEMOTHERAPY AND ERLOTINIB OR GEFITINIB (LUX-LUNG 1)
  1073. Maintenance bevacizumab (Bv) with or without pemetrexed (pem) following first-line Bv-cisplatin (cis)-pem in patients (pts) with advanced non-squamous non-small cell lung cancer (NSCLC): preliminary safety data from AVAPERL1 (MO22089)
  1074. Phase I and pharmacodynamic study of NGR-hTNF administered at high doses in refractory patients with solid tumors
  1075. A PHASE III RANDOMIZED STUDY COMPARING THE EFFICACY OF CEDIRANIB AS MONOTHERAPY, AND IN COMBINATION WITH LOMUSTINE, WITH LOMUSTINE ALONE IN RECURRENT GLIOBLASTOMA PATIENTS
  1076. A retrospective analysis of 41 primary localized rectal/pararectal gastrointestinal stromal tumors (GISTs) from the French Sarcoma Group (FSG).
  1077. Positive airway stenting for symptomatic tracheobronchial strictures in metastatic non-lung cancer patients
  1078. Updated Results of a Phase 1b/2 Study using a 30 min infusion of Carfilzomib (CFZ) in Patients (Pts) with Relapsed Malignancies
  1079. Psychiatric assessment in cancer patients: preliminary results of cross sectional study
  1080. A Phase II Study of Two Dose Levels of Vorinostat (V) in Combination with Fluorouracil (5-FU) and Leucovorin (LV) in Fluoropyrimidine-Refractory Colorectal Cancer (CRC) Patients (pts)
  1081. Epirubicin (E) in combination with cisplatin (CDDP) and capecitabine (C) versus docetaxel (D) combined with 5-fluorouracil (5-FU) by continuous infusion (C.I.) as front-line therapy in patients with advanced gastric cancer (AGC): preliminary results of a randomised phase II trial of the Gruppo Oncologico dell'Italia Meridionale
  1082. Decoding of Colon cancer and Breast cancer association
  1083. Randomized phase II study of sunitinib (SU) plus erlotinib (E) vs. placebo (P) plus E for the treatment of metastatic non-small cell lung cancer (NSCLC)
  1084. Dynamic tumor growth evaluation could predict overall survival for patients included in phase 1 clinical trials
  1085. Sorafenib in Older Patients with Advanced Renal Cell Carcinoma: Subanalysis by Age of an Integrated Database of 8 Company-Sponsored Clinical Trials
  1086. Bevacizumab (B) with irinotecan (I) in recurrent glioblastoma (GBM): a national retrospective cohort of the ANOCEF (Association des Neuro-oncologues d’Expression Française) Group.
  1087. Aprepitant palonosetron and dexamethasone to prevent nausea and vomiting during multiple cycles of cisplatin-based chemotherapy
  1088. Clinical response of triple negative breast cancer to taxanes
  1089. Correlation of Epidermal Growth Factor Receptor Status with Treatment Outcome in Postoperative Glioblastoma Multiforme Patients Treated with Chemoradiotherapy
  1090. Impact of epoetin beta on executive functions in anaemic patients with breast cancer receiving chemotherapy: results of a prospective cohort study
  1091. Integrated Care Pathways (ICPs) For Non-Small Cell Lung Cancer (NSCLC) Patients (Pts): A Multidisciplinary Quality Improvement Project
  1092. Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both in a phase III study of previously-treated patients with advanced melanoma: update of clinical characteristics of patients
  1093. A Phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR/HER1 mutations (LUX-Lung 2)
  1094. Immunohistochemical expression of HER2 in Linitis Plastica–type Gastric Carcinoma
  1095. Fatigue, Quality of Life and Cognitive Functions in Metastatic Kidney cancer Patients with Anti-Angiogenic treatment
  1096. SOCS-1,-3 gene delivery in gastric cancer cells induces a potent anti-proliferative effect via the suppression of JAK/STAT and P38 MAPK signaling pathways.
  1097. Vandetanib in locally advanced or metastatic differentiated thyroid cancer (papillary or follicular; DTC): a randomized, double-blind Phase II trial
  1098. Multiple tumors in elderly patients: epidemiology and survival in a single center experience
  1099. Oral Chemotherapeutic Agent Followed by Aggressive Chemotherapy Improves Overall Outcome in Adult Acute Myeloid Leukemia (AML): A Study From Developing Country
  1100. Internet Usage by Patients receiving Chemotherapy Information - Is the Internet Beneficial or Deleterious to Patients?
  1101. Effect of low-molecular-weight heparin (LMWH) nadroparin on hemostatic variables in ambulatory cancer patients enrolled in the PROTECHT trial
  1102. High incidence of severe sorafenib-induced diarrhea in patients with hyperbilirubinemia and/or hypoalbuminemia.
  1103. Antitumor activity of Toll-like Receptor 9 agonist IMO overcomes K-Ras mutation and cooperates with cetuximab in colon and pancreatic cancers
  1104. Determination of a new RECIST threshold using everolimus treatment in metastatic renal cell carcinoma: Evaluation from the RECORD-1 study
  1105. Baseline cardiovascular risk factors predict cardiovascular (CV) events during androgen deprivation therapy (ADT) with degarelix
  1106. Activity of BIBW 2992, an irreversible EGFR/HER1 and HER2 TKI, in lung adenocarcinoma patients harboring less common EGFR mutations
  1107. Molecular cytogenetic characterization of chromosome 1 abnormalities in human multiple myeloma cell lines
  1108. Population pharmacokinetic-pharmacodynamic (PK/PD) analysis of safety and efficacy of eribulin in metastatic or locally advanced breast cancer patients
  1109. Should CA 125 still be part of tumour evaluation criteria in ovarian cancer trials? Experience of the GCIG CALYPSO trial.
  1110. Evaluation of a hospital-home medical program (HHMP) for the management of chemotherapy-related toxicities in the outpatient setting.
  1111. EFFICACY AND SAFETY OF PF299804 AS FIRST-LINE TREATMENT (TX) OF PATIENTS (PTS) WITH ADVANCED (ADV) NSCLC SELECTED FOR ACTIVATING MUTATION (MU) OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)
  1112. mFOLFOX6 + cediranib vs mFOLFOX6 + bevacizumab in previously untreated metastatic colorectal cancer (mCRC): a randomized, double-blind, Phase II/III study (HORIZON III)
  1113. mRNAs overexpression in glioblastomas versus low-grade gliomas
  1114. Lapatinib (L) Plus Capecitabine (C) in HER2-positive Metastatic Breast Cancer (MBC): An Exploratory Analysis of Overall Survival (OS) Based on Poststudy Therapy
  1115. Efficacy and Safety of Cetuximab plus Irinotecan in Irinotecan-Refractory Elderly Patients (>65 years) with Metastatic Colorectal Cancer (mCRC)
  1116. Clinical significance of incidental focal colorectal uptake detected in 18F-FDG PET-CT studies
  1117. RANDOMIZED PHASE III STUDY OF 5-FLUOROURACIL/FOLINATE/OXALIPLATIN GIVEN CONTINUOUSLY OR INTERMITTENTLY WITH OR WITHOUT CETUXIMAB, AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER: THE NORDIC VII STUDY (NCT00145314), BY THE NORDIC COLORECTAL CANCER BIOMODULATION GROUP
  1118. Trastuzumab-based therapy after disease progression following lapatinib and capecitabine in HER2-positive (HER2+) metastatic breast cancer (MBC)
  1119. The mTOR inhibitor everolimus cooperates with the TLR9 agonist IMO in renal cell carcinoma by interfering with both tumor cells and microenvironment
  1120. Association between mdr1 expression levels and chemotherapy response in non small cell lung cancer (NSCLC) patients
  1121. Clinical Outcome of Patients with Metastatic Melanoma Undergoing Phase I Clinical Trials
  1122. are TKIs still active in patients treated with TKI and everolimus? Experience from 36 patients treated in France in the RECORD 1 trial.
  1123. The Effects of Patient and Tumor Charecteristics and Treatment Modalities on Prognosis of Patients With Uveal Melanoma
  1124. Prognostic value of serum carcinoembryonic antigen (CEA) in first line treatment of advanced colorectal cancer (ACRC)
  1125. Association of epigenetic inactivation of the ESR1 gene by aberrant methylation promoter with prognostic factors in breast cancer patients
  1126. Integrated safety results from 4 randomized, double-blind, placebo-controlled studies of sipuleucel-T
  1127. Healthcare Costs of Second-line (2L) Metastatic Colorectal Cancer (mCRC) Patients Treated with Bevacizumab (BV) Versus Cetuximab (CX)
  1128. Ixabepilone (Ixa) and capecitabine (C) in patients (pts) with triple-negative breast cancer (TNBC): A retrospective analysis of phase 2 and phase 3 clinical studies
  1129. Bevacizumab improves pathologic response in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases: Report from a retrospective study.
  1130. The role of del(13q14.3) in diffuse large B-cell lymphomas
  1131. Preliminary results of a Phase 1 study of intravenous administration of GL-ONC1 Vaccinia virus in patients with advanced solid cancer with real time imaging.
  1132. A phase II study of intrapleural paclitaxel against malignant pleural effusion (MPE): effectiveness, safety and pharmacokinetic.
  1133. Health-related quality of life in patients with metastatic sarcoma -- the Sarcoma treatment and Burden of Illness study in North America and Europe (SABINE) study
  1134. Concomitant Temozolamide Plus Radiotherapy Followed by Adjuvant Temozolamide in Malignant Gliomas
  1135. Refractory vs sensitive relapsed SCLC: Validation of standard definition and assesment of alternative classification
  1136. A pooled analysis of the final results of the two randomized phase II studies comparing Gemcitabine (G) vs Gemcitabine + Docetaxel (G+D) in patients (pts) with metastatic/relapsed leiomyosarcoma (LMS)
  1137. A Phase 2 Pharmacodynamic Study of Pre-operative Figitumumab (F) in Patients (pts) with Localized Prostate Cancer (PCa)
  1138. Aggressive fibromatosis treated with combination of CVP and tamoxifen: a case series update analysis
  1139. A phase I/II study of TKI258 (dovitinib), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer (mRCC): Preliminary phase II results.
  1140. Incidence of cancer treatment-induced bone loss (CTIBL) in non-osteoporotic men with prostate cancer (PC) receiving androgen deprivation therapy (ADT) and efficacy of treatment with zoledronic acid (ZOL): results from the ROBUST bone mineral density (BMD) sub-study.
  1141. Value of educational campaign to raise awareness of Gastrointestinal stromal tumours (GIST) and its impact on the referral patterns in a tertiary referral cancer centre.
  1142. Predictive factors for complete pathological response after neoadjuvant chemotherapy in breast cancer. Results from a single institution.
  1143. Phase II study with docetaxel, oxaliplatin and S-1 combination chemotherapy for patients with metastatic gastric cancer
  1144. Fibroblast Growth Factor Receptor 2 (FGFR2) Polymorphism Status of Turkish Breast Cancer Patients
  1145. LACE-Bio Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation in Completely Resected Non-Small Cell Lung Cancer (NSCLC)
  1146. Palmar-plantar erythrodysesthesia (PPE) in patients (pts) with ovarian cancer (OC) or metastatic breast cancer (MBC) treated with pegylated liposomal doxorubicin (PLD): an observational study
  1147. New preoperative chemotherapy with lyposomal anthracyline, cisplatin and metronomic capecitabine for operable and locally advanced breast cancer: data of efficacy and safety
  1148. Neoadjuvant trastuzumab, docetaxel, and carboplatin (TCH) for Human Epidermal Growth Factor Receptor -2 (HER-2) positive breast cancer: Pathological tumour response rates in an Irish teaching Hospital
  1149. Randomised phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968): impact of age on disease-free survival (DFS) or overall survival (OS)
  1150. Continuous and intermittent Vorinostat (V) in combination with FOLFIRI in advanced upper gastrointestinal cancer (AUGC): Preliminary results of a phase I pharmacokinetic (PK) study
  1151. Patient preferences for reducing toxicities of treatments for gastrointestinal stromal tumor (GIST): A conjoint analysis study
  1152. Relationship between performance status improvement and pain relief in patients with Bone Metastatic Pain. BMP study
  1153. A Phase 2 Trial of Linifanib Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
  1154. Second line Chemotherapy with Capecitabine (CAP) and Oxaliplatin (OX) in Patients (PT) with Pancreatic or Biliary Tree Adenocarcinoma (ADC).
  1155. Safety and Efficacy of Maintenance Bevacizumab in HER2-negative metastatic breast cancer
  1156. The expression of toll-like receptor pathway molecules in peripheral blood mononuclear cells and its use as a potential biomarker for tumor behavior in laryngeal carcinoma.
  1157. Incidence, time and mode of detection of testis cancer (TC) relapses: retrospective analysis of a single-institution cohort on a uniform follow-up program.
  1158. Psychological Assessment and Support to children and young adults with cancer in New Delhi
  1159. Efficacy findings from the X-ACT trial of capecitabine vs. 5-FU/LV as adjuvant therapy for patients with stage III colon cancer: no impact of age on disease-free survival or overall survival
  1160. CAPECITABINE and LAPATINIB: which of the two is working on the brain?
  1161. Randomized phase 2/3 trial of a tumor vascular disrupting agent, fosbretabulin tromethamine (CA4P), with carboplatin (C), and paclitaxel (P) in anaplastic thyroid cancer (ATC): Interim safety and efficacy results of the FACT trial
  1162. A Phase 1 study of IPI-926, an inhibitor of the Hedgehog pathway, in patients (pts) with advanced or metastatic solid tumors
  1163. Clinical outcome of Asian vs. non-Asian patients with metastatic renal cell carcinoma (mRCC) with continuous once-daily dosing of sunitinib as first-line therapy
  1164. Can chemotherapy treatment be an aggravating factor of the underlying psychiatric illness at the cancer patients?
  1165. Bi-weekly Paclitaxel – Gemcitabine in Small Cell Lung Cancer Patients Preteated with Platinum-Etoposide Chemotherapy.
  1166. Randomized, double-blind, placebo-controlled, multicentre phase III study of capecitabine / cisplatin + bevacizumab (bev) or placebo (pl) as 1st-line therapy in patients (pts) with advanced gastric cancer (AGC) (AVAGAST update)
  1167. Misplacement and early malfunction of port-a-cath central venous catheters in outpatient chemotherapy
  1168. Radium-223 chloride, a novel, highly targeted alpha-pharmaceutical for treatment of bone metastases from castration-resistant prostate cancer (CRPC): hematologic and safety profile with repeated dosing
  1169. Socio-economic status and education level influence Breslow thickness, disease free and overall survival in clinical stage I-II AJCC skin melanoma
  1170. Novel Kras mutation detected amongst Gallbladder cancer patients from Eastern India.
  1171. Rapid progression of extrahepatic disease in selected patients with colorectal cancer liver metastases after Yttrium-90 radioembolization
  1172. Population Pharmacokinetics of Temsirolimus in Pediatric Patients with Relapsed/Refractory Solid Tumors
  1173. Intraarterial chemotherapy in treatment of advanced primary cervix cancer
  1174. Clinical Outcome of Female Genital Tract Lymphomas (FGTL) treated at the BRAZILIAN NATIONAL CANCER INSTITUTE (INCA)
  1175. Evaluation of the possibility of outpatient management of febrile neutropenia patients with an intermediary risk of complications and impact on cost
  1176. Anthracycline and concurrent radiotherapy significantly reduced breast cancer relapse rate
  1177. Results from Two Phase 1 Trials of Her2/Neu-Directed Active Cellular Immunotherapy in Patients with Advanced Malignancies
  1178. High inconsistencies among lists of cautioned & prohibited drugs in oncology phase 1 and phase 2 trials.
  1179. Local recurrence of rectal cancer in a developing country: how to manage?
  1180. Association Between False Beliefs And The Use Of Complementary And Alternative Medicine In 844 Cancer Patients: A French AERIO Survey
  1181. Patient (Pt) Reported Symptoms of Chemotherapy (Chemo) and VEGFR/EGFR Antibody Therapies for the Treatment of Metastatic Colorectal Cancer (MCRC) in a US Community-Based Oncology Practice Network
  1182. ABIRATERONE ACETATE (AA) PLUS LOW DOSE PREDNISONE (P) IMPROVES OVERALL SURVIVAL (OS) IN PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHO HAVE PROGRESSED AFTER DOCETAXEL-BASED CHEMOTHERAPY (CHEMO): RESULTS OF COU-AA-301, A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE III STUDY
  1183. Prevalence of Fasting among Cancer Patients during Ramadan 2009: Egyptian Experience
  1184. Analysis of plasma biomarkers, DCE-MRI, and KRAS mutations in patients (pts) with advanced colorectal carcinoma (CRC) treated with the multikinase inhibitor regorafenib
  1185. Survival Results of the IMPACT Trial of Sipuleucel-T for Advanced Prostate Cancer
  1186. Bowel Obstruction in Ovarian and Peritoneal Malignancy: The Christie Hospital Experience
  1187. Prognostic factors for survival in third-line chemotherapy in patients with recurrent and metastatic breast cancer.
  1188. Salvage chemotherapy with high dose chemotherapy and peripheral blood stem cell transplant in patients with germ cell tumors
  1189. Prevalence of mutation of a 657del5 gene of NBN among children with acute leukemia
  1190. A Galician Lung Cancer Group phase II study of bevacizumab (B), cisplatin and vinorelbine in chemo-naive patients (p) with non squamous non small cell lung cancer (NSCLC).
  1191. p53 responsive PIG3 gene polymorphism seems not associated with cerebral, colorectal and lung cancer
  1192. Long term survival of early and locally advanced breast cancer patients treated outside of clinical trials
  1193. Increasing Role of Metastasectomy in Metastatic Breast Cancer Patients: Who Benefits More ?
  1194. Accuracy of Pulmonary Function Tests in patients treated in phase I trials
  1195. An analysis of the risk of toxicity associated with participation in Phase 1 oncology trials of novel molecularly targeted agents (MTA) at the Drug Development Unit, Royal Marsden Hospital
  1196. Pulmonary embolism: Unsuspected finding in cancer patients
  1197. Inflammatory breast cancer in Egypt:is it really a separate entity?
  1198. A systematic review and consensus recommendations on the use of biomarkers in the treatment of Non-Small Cell Lung Carcinoma (NSCLC)
  1199. Meta-analysis of patients (pts) previously treated with taxanes from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for metastatic breast cancer (MBC).
  1200. Circulating endothelial cells and their clinical manifestation in pancreatic cancer patients treated with gemcitabine based chemotherapy
  1201. Clinical effectiveness of hyperbaric oxygen therapy in hemorrhagic cystitis after allogeneic bone marrow transplantation
  1202. Testing and Treatment Patterns in HER2+ Breast Cancer Patients in the Adjuvant Setting
  1203. Circulating tumor cells (CTC) and prostate-specific antigen (PSA) as response indicator biomarkers in chemotherapy-naive patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100
  1204. A randomised trial comparing peripherally inserted central venous catheters (PICC) vs subcutaneously implanted port-chamber catheters (PORT) for delivery of chemotherapy to patients with non-haematological malignancies
  1205. The treatment of metastatic rectal cancer (MRC): a review of the multidisciplinary approach at the Ottawa Hospital Cancer Centre (TOHCC)
  1206. Current Chemotherapy and Monoclonal Antibody Use Patterns in Metastatic Colorectal Cancer in Western Europe
  1207. Primary Bone Lymphoma
  1208. Phase 1b dose escalation trial evaluating c-Met inhibitor ARQ 197 and Gemcitabine in patients (pts) with advanced solid tumors on schedules refined by in vitro mechanistic studies.
  1209. Complete Phase IB study of TH-302 in combination with gemcitabine (G), docetaxel (D) or pemetrexed (P)
  1210. The impact of tumor histology on effectiveness in bevacizumab (BV) treated patients (pts) with advanced non-small cell lung cancer (NSCLC): Results from ARIES, a BV observational cohort study (OCS)
  1211. Patient-reported outcomes (PROs) in HER2+ Metastatic Breast Cancer (MBC) treated with T-DM1
  1212. A novel immunotherapy platform targeting paired cancer antigens through intra-lymph node immunization: final results of two Phase 1 clinical trials
  1213. Immuno-Positron Emission Tomography (PET) of Lewis Y (Ley) Expressing Xenografts Using 89Zr-Labelled Humanised Antibody hu3S193
  1214. FDG-PET/CT evaluation of early metabolic response after neoadjuvant chemotherapy in patients with esophageal and GEJ cancer – a pilot study
  1215. A phase II trial of induction chemotherapy with cisplatin, docetaxel and capecitabine followed by concurrent cisplatin- radiotherapy in advanced nasopharyngeal carcinoma
  1216. Evaluation of Neratinib (HKI-272) and Paclitaxel Pharmacokinetics (PK) in Asian and Caucasian Patients with ErbB2+ Breast Cancer: A Phase 1/2 Study of Neratinib in Combination with Paclitaxel
  1217. Metastasis suppressing/promoting microRNA expression in primary and metastatic colorectal cancer
  1218. Clinical significance of soluble vascular endothelial growth factor receptor-3 as a candidate biomarker for breast cancer patients
  1219. Clinical features and outcomes in epithelial ovarian cancer (EOC) associated with BRCA1 and BRCA2 mutations in Polish population – an observational study
  1220. Results of a phase 1/2 study of nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer with SPARC and CA19-9 correlatives
  1221. Improving the Quality of Abstracts for Cost-Effectiveness Analyses (CEA) in Oncology
  1222. S-1 plus carboplatin has become one of the standard regimens for　advanced non-small-cell lung cancer: Results of a randomized phase III study conducted by the West Japan Oncology Group (WJTOG 3605)
  1223. Quality of life assessment with combined EORTC QLQ-C30 and EORTC-HCC18 as a prognostic factor for patients with hepatocellular carcinoma: a prospective study
  1224. CNS prophylaxis and Rituximab based regimen may improve the outcome and decrease the incidence of CNS relapse in poor risk patients with DLBCL
  1225. Phase I study for KRN951 (AV-951), a selective VEGFR receptor 1, 2, 3 tyrosine kinase inhibitor in Japanese patients with metastatic solid tumors
  1226. Control of nausea with palonosetron versus granisetron both combined with dexamethasone in patients undergoing cisplatin (CDDP)- or anthracycline plus cyclophosphamide (AC/EC)-based regimens.
  1227. Clinicopathologic differences between lung cancer with EGFR gene major mutations (exon 19 deletions and exon 21 L858R) and other minor mutations
  1228. Serum IL-8 as a prognostic marker for triple negative advanced breast cancer
  1229. Title: Intermittent versus continuous erlotinib with concomitant modified ‘XELOX’ (q3W) in first-line treatment of metastatic colorectal cancer (mCRC)
  1230. CpG island methylator phenotype and microsatellite instability as a prognostic factor in colon cancer treated with adjuvant FOLFOX chemotherapy
  1231. Breast cancer stem cells involve in bone marrow metastasis
  1232. Features of recurrence of triple negative (TN) non-metastatic breast cancer (NMBC) patients: A single institution study
  1233. Complete Results from Phase I Dose Escalation Study of MetMAb, a Monovalent Antagonist Antibody to the Receptor Met, Dosed as Single Agent and in Combination with bevacizumab in Patients with Advanced Solid Malignancies
  1234. Retrospective analysis of effectiveness of angiotensin II receptor blockers (ARBs) in cancer chemotherapy–induced congestive heart failure
  1235. Differential expression patterns of MMPs and the role in invasion in epithelial premalignant tumors and invasive squamous cell carcinoma
  1236. Serum Chromogranin A - A marker for hormone-refractory carcinoma of prostate - and for prognosis
  1237. Circulating SPARC levels negatively impact chemotherapies in cancer models
  1238. Reaction of plasma hepatocyte growth factor by administration EGFR-TKIs in lung cancer patients
  1239. Final Safety and Efficacy Results of a phase II trial of Bevacizumab, Capecitabine, Oxaliplatin, Radiation Rectal Cancer Trial (A-CORRECT).
  1240. SPARC microenvironment signature (SMS) as a prognostic biomarker when combined with LDH and plasma SPARC
  1241. European reglementation for cetuximab still required the EGFR positive status : Results of a French Translational Study OMIT of 330 patients to define if this criteria is relevant.
  1242. A phase II trial of radioembolization and systemic chemotherapy in patients with liver metastases from primary cancer of the pancreas.
  1243. Her2 over-expression and gene amplification in gastric cancer
  1244. Antitumor activity of nab-paclitaxel and bevacizumab against a new triple negative breast cancer model
  1245. Stroma production within the primary tumor correlates with poor survival for stage I-II colon cancer patients.
  1246. Randomized phase II study of paclitaxel-carboplatin (PC) versus gemcitabine-carboplatin (GC) followed by paclitaxel-carboplatin (PC) in platinum-sensitive recurrent ovarian carcinoma (PSROC): a GEICO (Spanish Group for Investigation in Ovarian Cancer) study.
  1247. Late relapses in Hodgkin's disease
  1248. Clinical Practice of Ferric Carboxymaltose Use in Cancer Patients
  1249. Screening success and inclusion failure rates in a prospective trial of adjuvant chemotherapy for breast cancer in elderly women by the french geriatric oncology group GERICO
  1250. Psychological Distress, Fatigue, and Pain in Advanced Breast Cancer Patients: Relationships with Quality of Life Impairment
  1251. Results of combined chemo- and radiotherapy of osteosarcoma pulmonary metastases
  1252. Retrospective analysis of amrubicin in patients with gastrointestinal poorly differentiated neuroendocrine carcinoma (GI-PDNEC) refractory to chemotherapy
  1253. Tumor stage, humanpapilloma virus (HPV) and smocking status affect the survival of patients with oropharyngeal cancer: an Italian validation study
  1254. The p53 status affects the prognosis of patients with colorectal adenocarcinoma depending on the protein expression of NFY-C (Nuclear Factor Y, Subunit C).
  1255. Involvement of microRNAs in the invasion of esophageal cancer cells.
  1256. Evaluation of the predictive value of PIK3CA mutations and PTEN loss in the efficacy of trastuzumab therapy
  1257. Hypelipidemia in breast cancer chronic lymphedema
  1258. Desensitization to different chemotherapy agents: a successful collaboration between Oncology and Immunoallergology
  1259. Bone angiosarcoma: A retrospective analysis of 73 patients from two referral centres
  1260. The 70-gene expression profile for breast cancer patients in Italian hospitals
  1261. Incidence of second malignancies (SM) in the treatment field following pelvic radiotherapy (RT); a case-control study: from South East Wales (SEW)
  1262. Evaluation of KRAS mutation status in primary colorectal tumours and corresponding liver metastases
  1263. Considerations in the development and validation of genomic tests for cancer recurrence and treatment benefit
  1264. Do adult cancer survivors require psychotherapy? - An experience from Eastern India
  1265. Erlotinib maintenance therapy in patients with stable disease after first-line platinum-doublet chemotherapy for advanced NSCLC
  1266. Preparation of terminal care for outpatients with lung cancer receiving chemotherapy
  1267. Assessment and treatment of osteopenia/osteoporosis in elderly women receiving anastrazole for early breast cancer.
  1268. Clinical management patterns in non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study
  1269. Prognostic significance of gene expression profile in patients with Carcinomas of Unknown Primary (CaUP)
  1270. Identification of plasma biomarkers for the multikinase inhibitor regorafenib (BAY 73-4506) in patients (pts) with renal cell cancer (RCC)
  1271. Long-term economic burden of cancer patients
  1272. Should the primary tumor be resected in patients with unresectable synchronous metastasis of colorectal cancer ? Prognostic retrospective multicentric study of 128 patients
  1273. Sorafenib (So) in association with low-dose metronomic temozolomide (TMZ) in recurrent glioblastoma multiforme (GBM): preliminary results of a phase II study.
  1274. Surgical resection after down-staging chemotherapy for initially unresectable biliary tract cancer
  1275. Anemia and darbepoetin alfa administration in patients treated with CHOP+/-R chemotherapy: results from an observational study of patients with non-Hodgkin lymphoma
  1276. Prognostic significance of S100A4 expression in curatively resected stage IV stomach cancers
  1277. The cytoprotective effect of amifostine in concomitant chemoradiotherapy of locally advanced non-small cell lung cancer
  1278. Cabazitaxel plus prednisone /prednisolone significantly increases overall survival compared to mitoxantrone plus prednisone/prednisolone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results with updated overall survival of a multinational Phase III trial (TROPIC)
  1279. Transient isolated transaminase increases do not correlate with permanent clinical liver damage: Phase I experience with elisidepsin
  1280. EGFR mutation status and the efficacy of Gefitinib in combination with Paclitaxel and Carboplatin as neoadjuvant treatment in Locally advanced Cancer of Cervix : A study from Eastern India
  1281. Survival after surgical resection of hepatic metastases from colorectal cancer: a systematic review and meta-analysis
  1282. The influence of TYMS and MTHFR gene polymorphisms on toxicity and response in breast cancer patients treated with 5-fluorouracil-based chemotherapy
  1283. A Presurgical Trial Of Lapatinib Versus Placebo In Her-2 Positive Breast Cancer
  1284. Pro-senescence therapy for Neuroblastoma initiating stem cells
  1285. mTOR expression analysis in lung and gastroenteropancreatic poorly differentiated endocrine carcinoma (PDEC)
  1286. Administration of Granulocyte-Colony Stimulating Factors (G-CSF) in Solid Tumors. An Italian Observational Study by the OBSERVE Study Group
  1287. Multidisciplinary treatment of adult high grade gliomas. Institutional experience.
  1288. Phase II study of intrathecal long acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in HIV-related non-Hodgkin's lymphoma
  1289. Association of ABCC2 polymorphism with cisplatin disposition and efficacy
  1290. Abdominal obesity and weight gain as a consequence of taxane-based adjuvant chemotherapy for breast cancer
  1291. Germline polymorphisms of methylenetetrahydrofolate reductase (MTHFR C677T) and thymidylate syntase (TS VNTR) chemotherapy-related enzymes, in patients treated with Pemetrexed.
  1292. Biomarker results from ARQ 197-114: a phase 1b trial evaluating the cMET inhibitor ARQ 197 in cirrhotic patients (pts) with hepatocellular carcinoma (HCC)
  1293. Nadroparin for the prevention of thromboembolic events in ambulatory patients receiving chemotherapy with metastatic or locally advanced cancer: a post-hoc analysis of thromboembolic risk related to type chemotherapy in the PROTECHT study
  1294. Identification and Ranking of Side-effects in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin. A Multinational Collaborative Survey
  1295. Timing of subsequent surgery (S2) for positive margins (PM) and initiation of adjuvant systemic treatment (Tx) in early breast cancer (EBC)
  1296. Xeliri or Folfiri as salvage therapy in advanced pancreatic cancer
  1297. ABCSG-24: efficacy of anthracycline- and taxane-based neoadjuvant therapy ± capecitabine (C) in triple-negative early breast cancer (TNBC)
  1298. Radioembolization and systemic chemotherapy in patients with hepatic metastases from primary colorectal cancer
  1299. Influence of cytostatic agents on pH-regulating transporter in glioma cells
  1300. Biomarkers determination in non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung Study
  1301. The impact of educational material (EM) on compliance and persistence rates with adjuvant aromatase inhibitor (AI) treatment: first year data, presented on behalf of the CARIATIDE Study Investigators
  1302. Analysis of antibodies against Epstein-Barr virus and viral DNA quantification as early screening tools of nasopharyngeal carcinoma
  1303. Inter-observer reproducibility of evaluation of EGFR status in colorectal carcinoma
  1304. Baseline circulating tumour cell (CTC) counts enhance the performance of the Royal Marsden Hospital (RMH) prognostic score to optimise patient selection for Phase 1 clinical trials.
  1305. ProGRP levels in patients with lung cancer.
  1306. mTOR activation in advanced neuroendocrine tumors in treatment with somatostatin analogues - a single center study
  1307. Detection of tumor angiogenesis in solid tumours via the expression of αvβ3 Integrin using an RGD peptide, [18F]fluciclatide, and Positron Emission Tomography (PET) imaging.
  1308. Triple-negative (TN) treatment approach in Italy: an update of NEMESI, a multicenter observational study on early breast cancer (EBC) management
  1309. ERCC1, RRM1, TYMS and BRCA1 profiling for predicting response to chemotherapy in patients with non-small cell lung cancer (NSCLC).
  1310. Critical role of Bevacizumab schedule in combination with chemo-radiotherapy in neo-adjuvant treatment of rectal cancer: circulating endothelial cells and FDG-PET as markers for early prediction
  1311. A Phase II trial of neoadjuvant erlotinib followed by surgery for selected patients with stage IIIA, N2-positive Non-Small Cell Lung Cancer
  1312. Triple-negative breast cancer: experience at NCI-Cairo
  1313. 1st-cycle rash as a clinical marker of outcome in patients with advanced non-small cell lung cancer (NSCLC) receiving 1st-line chemotherapy (CT) plus cetuximab: analysis by histology
  1314. Integration of capecitabine (X) monotherapy with X combination therapy in patients with metastatic breast cancer (MBC): rationale and design of X maintenance study
  1315. Baseline Levels of Circulating Angiogenic Factors in Metastatic Colorectal Cancer pts (mCRC) Treated With Bevacizumab (BEV)
  1316. VEBEP regimen and highly active antiretroviral therapy (HAART) in patients (pts) with HD and HIV infection (HD-HIV): final results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study
  1317. Pharmacogenetics of endostatin gene (COL18A1) in three distinct Asian ethnic groups
  1318. The combination of exemestane and erlotinib in non small cell lung cancer
  1319. Efficacy of nadroparin in preventing thromboembolic events in ambulatory cancer patients receiving chemotherapy stratified according to Korana risk score: a post-hoc analysis of PROTECHT study
  1320. The influence of SLCO1B3 polymorphisms on docetaxel disposition in Asian nasopharyngeal carcinoma patients.
  1321. No conclusive evidence from Randomised Controlled Trials to inform second-line treatment options survival and clinical benefits, in patients with metastatic Hormone-Refractory Prostate Cancer (mHRPC) previously treated with docetaxel
  1322. Mouth Cancer Awareness Programme In Singapore
  1323. Incidence and prognostic value of BRAF mutation in metastatic colorectal cancer (CRC) with mismatch repair deficiency (dMMR)
  1324. Bevacizumab as a salvage treatment in heavily pretreated Non-Small-Cell Lung Cancer (NSCLC) patients.
  1325. Phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumours
  1326. Synergistic Cytotoxic and Apoptotic Effect by AT-101 and Cisplatin Combination through DNA Methyltransferase and Histone Deacetylase Enzymes in Human Ovarian Cancer Cell Lines
  1327. Environmental Contamination with Cytotoxic Drugs in the Home Setting in Outpatients on Cancer Chemotherapy
  1328. Evaluation of the Groningen Frailty Index (GFI) as a screening tool in elderly patients (pts): an interim analysis
  1329. Natural history and management of everolimus (E) induced oral ulcers (OU)
  1330. Long-term follow-up of rituximab and infusional cyclophosphamide, doxorubicin, and etoposide (CDE) in combination with HAART in HIV-related non-Hodgkin’s lymphomas (NHL)
  1331. Phase II multicenter study of erlotinib and radiation therapy (RT) for elderly patients (pts) with esophageal carcinoma (EC)- Final report
  1332. Body mass index (BMI) in prognosis of locoregionally advanced and metastatic squamocellular head and neck carcinomas (SCHNC)
  1333. Evaluating prevalence rate and prognosis of basaloid phenotype of breast carcinoma among Iranian - Khorasan patients
  1334. Comprehensive geriatric assessment-adapted chemotherapy in elderly patients (> 70 years) with diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL): final results and long term follow-up
  1335. Phase II study of docetaxel and carboplatin as first line chemotherapy in ovarian cancer
  1336. Nadroparin for the prevention of thromboembolic events in ambulatory patients with lung cancer receiving chemotherapy: a treatment-based sub-group analysis of the PROTECHT study
  1337. Thrombocytosis as a predictive and prognostic marker in advanced colorectal cancer (aCRC): Results of the MRC COIN trial explored.
  1338. Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402)
  1339. Genetic polymorphisms of the FcνRIIa-FcνRIIIa are not predictive of clinical outcomes after cetuximab based chemotherapy in patients with metastatic colorectal cancer
  1340. Importance of Perineural Invasion in Early Stage Colorectal Cancer
  1341. Master oncology: a multicenter, case-control, observational study on the epidemiology and risk factors for thromboembolic events in cancer patients
  1342. Hospitalized Febrile Neutropenia Patients: A Single Center Experience
  1343. Prognostic impact of immunohistochemical expression of Ki-67 in patient with advanced gastric cancer who underwent curative resection
  1344. SCOT registry: Small cell lung cancer treatment prospective registry: Interim data
  1345. Cardiovascular adverse events (CV-AEs) in a pooled analysis of 1090 patients (pt) from Phase 3 sunitinib (SU) trials
  1346. Evolution of chemotherapy options in HER2-negative metastatic breast cancer (MBC)
  1347. Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of the randomized trial of the German AIO CRC study group: KRK-0204
  1348. A phase 1 dose finding study of the class 1 selective Histone Deacetylase inhibitor (HDACi) CHR-3996 in patients with treatment refractory metastatic cancer
  1349. Prolonging chemotherapy until disease progression improves progression free and overall survival in metastatic breast cancer: results of a systematic review
  1350. Contribution of Low-Molecular Weight Heparin Addition to Concomitant Chemoradiotherapy in the Treatment of Glioblastome Multiforme
  1351. Phase II study of gemcitabine and oxaliplatin in unresectable gall bladder cancer
  1352. Photostent-02; Porfimer Sodium photodynamic therapy plus stenting versus stenting alone in patients (pts) with advanced or metastatic cholangiocarcinomas and other biliary tract tumours (BTC): A multicentre, randomised phase III trial
  1353. The role of contrast-enhanced ultrasound in detection of liver metastases from colorectal cancer: 2 years update results
  1354. Surgical Approach To Non-Colorectal Liver Metastases : Ege University Experience
  1355. Chemotherapy (CT) plus cetuximab as 1st-line treatment for advanced non-small cell lung cancer (NSCLC): meta-analysis of individual patient data
  1356. Safety, pharmacokinetics (PK), and efficacy of Imprime PGG plus cetuximab (cetux) with and without irinotecan (irino) in advanced metastatic colorectal cancer (mCRC) patients
  1357. Final results of the intergroup FFCD-GERCOR-FNCLCC 03-07 phase III study comparing two sequences of chemotherapy in advanced gastric cancers.
  1358. Enhancing detection of BRAF-mutated circulating melanoma cells by pre-PCR cleavage of wild-type sequences
  1359. A review of data collected on non-small cell lung cancer (NSCLC) patients in cancer registries, databases, retrospective and non-randomized prospective studies
  1360. Assessment Of General Features And Treatment Strategies Of Gastric Lymphoma Patients, Diagnosed And Followed In Doctor Abdurrahman Yurtaslan Oncology Education And Research Hospital
  1361. Increased age is associated with thromboembolic events in patients with germ cell tumors treated with chemotherapy
  1362. Sorafenib (SOR) plus capecitabine (CAP) in patients (pts) with triple-negative (TN) advanced breast cancer (BC): subgroup analysis of SOLTI-0701, a double-blind, randomised, placebo (PL)-controlled phase 2b study
  1363. Antitumor activity of sunitinib malate (SM) in solitary fibrous tumors (SFT)
  1364. Detection of circulating tumor cells in gastric cancer patients using telomerase-specific replication-selective adenoviral agent: prospective feasibility study
  1365. Comparison of a Sequential Treatment Versus a 5-FU/LV Regimen as Adjuvant Therapy for Resected Gastric Cancer. Tolerability and Feasibility Analysis of ITACA-S (Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach) Trial
  1366. Beyond CHAT: overall survival (OS) update from the CHAT study of first-line trastuzumab (H) plus docetaxel (T) with or without capecitabine (X) in HER2-positive metastatic breast cancer (MBC)
  1367. PREDICT Global Non-interventional Study: baseline characteristics of RCC patients treated with sorafenib
  1368. Predictive value of the simultaneous detection of somatic quantitative molecular alterations using the Quantitative Multiplex PCR of Short fluorescent Fragments method (QMPSF) in stage II-III colon cancer: a prospective study
  1369. A randomized, phase 2 study of paclitaxel (P) and carboplatin (C) ± conatumumab (CON) for first-line treatment of non-small cell lung cancer (NSCLC)
  1370. Efficacy and tolerance of neoadjuvant gemcitabine combined with a platinum salt in urothelial bladder carcinoma. Results of a French regional experience in Languedoc-Roussillon.
  1371. Palliative Cisplatin and Capecitabine Chemotherapy in Head and Neck Cancer
  1372. The Development of a Formulation of Trastuzumab for Subcutaneous Administration
  1373. Carcinoid & Neuroendocrine Tumor Society of Singapore (CNETS) Survey on Delay in Diagnosis of Neuroendocrine Tumors (NET)
  1374. The Influence of Family History of Breast and Prostate Cancer on Prostate Cancer Diagnoses in the REduction by DUtasteride of prostate Cancer Events (REDUCE) study
  1375. Gemcitabine in angiosarcoma
  1376. Treatment for patients with cytology positive and/or peritoneal dissemination from gastric cancer in our hospital
  1377. An Italian multicentre retrospective analysis of 189 advanced renal-cell carcinoma patients treated sequentially, either with Sorafenib followed by Sunitinib, or vice versa
  1378. The biological characteristics of early breast cancer (EBC), from NEMESI, an Italian retrospective observational study.
  1379. Optimization of microRNA (miRNA) extraction from formalin fixed paraffin embedded (FFPE) colorectal and lung cancer tissues, and validation of a microRNA internal control.
  1380. Oral prevalence and clearance of high-risk human papilloma virus (HR-HPV) in healthy people in San Patrignano, a rehabilitation community for substance abusers
  1381. Ability of FDG-PET/CT to detect residual disease on posttreatment follow-up of patients with head and neck squamous cell carcinoma treated with chemoradiotherapy compared with CT.
  1382. An assessment of annual lung cancer screening in Yokohama: The 27 years’ cumulative data.
  1383. How are Departments of Cancer Medicine organized in Europe? Results from a survey conducted in 7 countries.
  1384. The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression-free survival (PFS) in metastatic triple-negative breast cancer (TNBC): results of a randomized phase II study (BALI-1)
  1385. Phase II study of Irinotecan and Cisplatin with Concurrent Split-course Radiotherapy in Limited-Disease Small-Cell Lung Cancer
  1386. Evaluation of KRAS, BRAF and PI3KCA in synchronous and metachronous metastatic colorectal cancer (MCRC)
  1387. Early identification of left ventricular dysfunction with speckle tracking echocardiography in antineoplastic therapy-induced cardiotoxicity
  1388. Maintenance therapy of non-small cell lung cancer with erlotinib preserves quality of life
  1389. Informativity of serological oncoassociated marker СА 72-4 in early diagnostics of gastric cancer recurrence
  1390. Assessment of the the efficacy and safety of the lapatynib in combination with capecytabine in patients with metastatic HER-2 positive breast cancer treated in Centrum Onkologii Ziemi Lubelskiej (COZL)
  1391. Safety of first-line bevacizumab (Bv)-based therapy in the SAiL (MO19390) trial: central tumour location (CTL) and hypertension (HTN) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
  1392. Final safety outcomes by chemotherapy (CT) regimen for the MO19390 (SAiL) trial: first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC)
  1393. Although the AJCC new 7th edition’s number-based N- category improves over the 6th, Lymph Node Ratios are still a better prognostic indicator for overall survival.
  1394. Matrimonial risk factors in women with breast cancer
  1395. Small cell carcinoma of the bladder (SCCB): a single institution experience
  1396. Retrospective analysis of pancreatic (neuro)endocrine tumors at Fondazione IRCCS Istituto Nazionale Tumori of Milan
  1397. Cost minimisation analysis of first line poychemotherapy regimens in the treatment of advanced non-small cell lung cancer (NSCLC)
  1398. Sorafenib (Sor) Dosage Patterns in >4600 Patients (Pts) with Renal Cell Carcinoma (RCC), Including the Elderly and Pts Treated for >12 Months (mo): Results from an Integrated Database of 8 Company-Sponsored Trials
  1399. Long term follow up of new cases of Acute Promyelocytic Leukemia treated by Arsenic Trioxide as sole treatment without ATRA and/or chemotherapy
  1400. A Survey on Ethics Committees Reviewing Cancer Clinical Trials in India
  1401. Patterns of adjuvant endocrine therapy for early breast cancer in Ontario: a population-based study
  1402. Single-agent activity and safety of the investigational Aurora A kinase inhibitor MLN8237 in patients with platinum-treated epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
  1403. Factors influencing the time of sentinel node visualization in breast cancer patients using intradermal injection of the radiotracer.
  1404. Recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): changes in 1st-line treatment patterns in Europe 2008–2009
  1405. Clinicopathological Features of Double Primary Cancers in Patients with Gastric Cancer
  1406. Study BO21247: a phase I feasibility trial of concurrent chemoradiation (CCRT) and bevacizumab (Bv) in patients (pts) with locally advanced non-squamous non-small cell lung cancer (NSCLC)
  1407. Speckle tracking echocardiography identifies cardiac dysfunction induced by the anticancer Erb-B2 blocker lapatinib
  1408. Long term survival post curative intent gastrectomy in gastric cancer patients with positive peritoneal cytology (an independent indicator of poor prognosis)
  1409. Efficacy and Safety of Sorafenib (Sor) in Patients (Pts) with Advanced Hepatocellular Carcinoma (HCC): Subgroup Analyses of the SHARP and Asia-Pacific (AP) Trials by Baseline (BL) Transaminase (ALT/AST)/Alpha-Fetoprotein (AFP) and Bilirubin (Bil) Levels
  1410. Maintenance Temozolomide in Glioblastoma – 6 Versus 12 Cycles
  1411. A prospective, randomized, double-blind, placebo controlled, group sequential trial of Polyclonal Antibody Stimulator (PAS) for the treatment of advanced pancreatic cancer
  1412. Serum Thrombospondin-1 (TSP-1), Basic-Fibroblast Growth Factor (B-FGF), Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor-2 (VEGFR-2) as Predictive Factors for Sorafenib plus Interferon-α2A (IFN) In metastatic Renal Cell Carcinoma (mRCC): biologic results from the “RAPSODY” randomized phase II Trial.
  1413. Significant Impact of Her2/neu,Bcl-2 and P53 overexpression On Survival in Colorectal Cancer (Using Tissue Microarray)
  1414. A European Multi-Institutional Study of Prognostic Factors in Cancer Patients (pts) treated within Phase-I (Ph I) Oncology Trials
  1415. Tumor and blood plasma biomarker analyses in the AVAGAST phase III randomized study of first-line bevacizumab + capecitabine/cisplatin in patients with advanced gastric cancer
  1416. First Results of High-Intensity Focused Ultrasound for Localized and Locally Advanced Hormone-resistant Prostate Cancer
  1417. Prognostic and predictive role of PIK3CA mutations in non small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors (TKIs).
  1418. Effects of switching from leuprolide to degarelix on long-term prostate-specific antigen (PSA) and serum alkaline phosphatase (S-ALP) control
  1419. Rationale and design of the GASTRANOX trial on a low-molecular-weight heparin [LMWH], enoxaparin, with chemotherapy vs. chemotherapy alone in inoperable gastric and gastro-oesophageal cancer
  1420. Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small cell lung cancer: safety run-in results of an open-label, randomized, phase II (CERTO) study
  1421. A predictive model to estimate the true risk of severe neutropenia in cancer patients treated with chemaotherapy.
  1422. Evaluation of Rebound Ascites Following Discontinuation of Bevacizumab in Recurrent Ovarian Cancer
  1423. Expression of Annexin A4 at endometrial cancer and relation to carboplatin sensitivity
  1424. Open-label phase 1b study of AMG 386, a selective angiopoietin1/2-neutralizing peptibody, in combination with sorafenib or sunitinib in advanced renal cell carcinoma (RCC): interim results
  1425. The hypermutagenetic role of overexpressed DNA polymerase iota and its variant in bladder cancer
  1426. Impact of salivary composition changes on saliva quality & quality of life after radiotherapy of head and neck cancer: a prospective longitudinal study
  1427. Repercussions of cancer on Moroccan adolescent and young adult lives
  1428. Immune vs. clinical response monitoring in patients with metastatic hormone-refractory prostate cancer receiving combined Prostate GVAX and anti-CTLA4 immunotherapy
  1429. Circulating level of VEGF, E-selectin, TGF-α, EGF and 18F-FDG PET uptake in locally advanced rectal cancer (LARC) patients treated with chemoradiation (CTRT) and panitumumab (StarPan/STAR-02 Phase II Study)
  1430. Gene delivery of suppressor of cytokine signaling 3 (SOCS-3) induces a potent antitumor effect in malignant pleural mesothelioma
  1431. HER2 status in primary and paired distant metastatic sites of gastric carcinoma
  1432. Resection of colorectal cancer (CRC) metastases after bevacizumab (BV) treatment for 1st-line therapy: Results of the ETNA cohort study.
  1433. Pharmacogenomic prediction of tamoxifen (TMX) efficacy in women with estrogen receptor (ER) positive breast cancer based on CYP 2D6 and MDR-1 polymorphisms (pms).
  1434. Absolute PSA level and PSA response at 1 month as a surrogate predictor of durability of treatment response and in evaluation of other oestrogen preparations
  1435. An open-label phase II study of treatment with sunitinib in patients suffering from metastatic castrated refractory prostate cancer (CRPC) after progression with docetaxel-based regimen
  1436. Randomized phase II trial with an uPA inhibitor (WX-671) in patients with locally advanced non-metastatic pancreatic cancer
  1437. Early detection of colorectal cancer using mass spectrometry based serum protein profiling.
  1438. Literature search on End-of-life Aggressiveness of Care studies with respect to Anticancer treatments
  1439. Co-administration of pazopanib and simvastatin increases the incidence of transaminase elevations in patients with cancer
  1440. Phase II study of irinotecan (CPT-11) in patients (pts) with previously treated metastatic breast cancer (MBC): KMBOG0601
  1441. Randomized, Double-blind, Placebo-controlled Phase II Study of Vandetanib Maintenance for Advanced or Metastatic Non-small-cell lung cancer (NSCLC) following 1st-line Platinum-doublet Chemotherapy
  1442. First-line Treatment of Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST) with Nilotinib
  1443. Role of Epoetins in beta-thalassemia minor patients with solid tumors undergoing chemotherapy—Results of a retrospective analysis
  1444. The combination of DNA repair gene polymorphisms significantly affect the risk of bladder cancer in population of southwest china
  1445. Development of a comprehensive registry of gastrointestinal stromal tumor (GIST) patients (pts) in Eastern Ontario
  1446. Whole body 18F-FDG PET scanning is too early to be incorporated into staging system in multiple myeloma
  1447. Phase II Study with Panitumumab, Oxaliplatin, 5-Fluorouracil and concurrent Radiotherapy in high-risk Locally Advanced Rectal Cancer patients (STARPAN/STAR-02 Study)
  1448. Dose management and toxicities in 137 unselected patients with advanced kidney cancer treated with sunitinib
  1449. Thromboembolism in Patients with Advanced Gastric Cancer
  1450. 10-year follow-up of gastric submucosal tumors
  1451. Characteristics of inflammatory breast cancer patients who failed to show response to induction chemotherapy
  1452. Adherence to and persistence with an oral metronomic chemotherapy with capecitabine in heavily pretreated metastatic breast cancer (mbc) patients.
  1453. Persistent phosphorylated AKT associated with increased expression of Bcl-xl in a lapatinib resistant pancreatic cancer cell line.
  1454. Gemcitabine (G) fixed rate dose infusion (FDR) plus erlotinib (E) in patients with advanced pancreatic cancer (APC)
  1455. Trastuzumab (T) tolerability and activity in HER2+ metastatic breast cancer (MBC) patients (pts) aged ≥65 years old
  1456. Phase I study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors
  1457. Potential Therapeutic Properties of Plasmonically Heated Gold Nanoparticles in HeLa Cell Line
  1458. Correlation of microRNA profile with kinase genotype in gastrointestinal stromal tumours (GISTs)
  1459. Updated results of a randomized, open-label Phase II study exploring BIBW 2992 versus cetuximab in patients with platinum-refractory metastatic/recurrent head and neck cancer (SCCHN)
  1460. Final results from the IFCT-GFPC 0502 phase III study: maintenance therapy in advanced NSCLC with either gemcitabine (G) or erlotinib (E) versus observation (O) after cisplatin-gemcitabine induction chemotherapy (CT), with a predefined second-line treatment.
  1461. Nilotinib and sorafenib are more potent inhibitors for exon 11/17 c-Kit mutants than sunitinib: results of incorporating cell-based screening platform and virtual molecular modeling study
  1462. Adjuvant breast cancer chemotherapy based on sequential anthracyclin and taxane: retrospective analysis of hematological toxicity
  1463. Hedgehog Signalling is Active in Biliary Tract Cancer and Amenable to Pharmacological Inhibition
  1464. Thyroid-stimulating hormone (TSH) levels in patients with metastatic renal cell cancer treated with sunitinib
  1465. Successful Titration of Fentanyl Pectin Nasal Spray in a Broad Range of Patient Types for the Treatment of Breakthrough Cancer Pain
  1466. Evaluation of progression-free survival (PFS) by blinded independent central review (BICR) in patients (pts) with progressive, well-differentiated pancreatic neuroendocrine tumours (NET) treated with sunitinib (SU) or placebo
  1467. Lobular breast carcinoma: epidemiological, histological, therapeutic and evolutionary profiles in a series of 64 patients
  1468. Improving patients acceptance of totally implanted ports (tip); the experience of a single institution.
  1469. Early tumor shrinkage for the prediction of efficacy of cetuximab in metastatic colorectal cancer (MCRC): analysis from the CRYSTAL study
  1470. CpG island methylation in MGMT, cadherin E and H promoters, K-ras and B-raf mutations: determining progression and sequence in colorectal adenoma-carcinoma.
  1471. Phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of pancreatic neuroendocrine tumors (NET): Impact of somatostatin analogue (SSA) treatment on progression-free survival (PFS)
  1472. Review of patient-reported outcomes in phase II oncology clinical trials
  1473. Zoledronic acid (ZOL) reduces the incidence of skeletal-related event (SREs) and may improve survival in patients with bone metastases (mets) from renal cell carcinoma (RCC): A retrospective integrated analysis
  1474. NEMESI: A retrospective observational longitudinal study to investigate patient characteristics and treatment in the early breast cancer (EBC) in Italy.
  1475. Sorafenib and Bevacizumab combination targeted therapy in advanced neuroendocrine tumor: a phase II study of Spanish Neuroendocrine Tumor Group (GETNE-0801)
  1476. Comparative Outpatient Resource Utilization Study of Metastatic Renal Cell Carcinoma Patients receiving Oral vs. Intravenous mTOR Inhibitors.
  1477. Impact of epoetin beta treatment on haemoglobin levels in patients treated by chemotherapy for metastatic melanoma
  1478. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE III TRIAL OF EVEROLIMUS IN PATIENTS WITH ADVANCED PANCREATIC NEUROENDOCRINE TUMORS (PNET) (RADIANT-3)
  1479. Efficacy and tolerability of bevacizumab (B) and erlotinib (E) as first-line therapy in Asian patients (pts) with advanced hepatocellular carcinoma (HCC): a phase II trial
  1480. Her2 Status and Trastuzumab Use among Patients with Early Breast Cancer Receiving Care within the US Oncology Network
  1481. Adjuvant endocrine therapy, alone or in combination with zoledronic acid (ZOL), in premenopausal patients (pts) with endocrine-responsive early breast cancer (EBC): subgroup analyses of ABCSG-12
  1482. EFFICACY RESULTS FROM THE RANDOMISED PHASE III OPTIMAL (CTONG 0802) STUDY COMPARING FIRST-LINE ERLOTINIB VERSUS CARBOPLATIN (CBDCA) PLUS GEMCITABINE (GEM), IN CHINESE ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS (PTS) WITH EGFR ACTIVATING MUTATIONS
  1483. Extended adjuvant temozolomide after concomitant radio-chemotherapy with temozolomide in malignant gliomas
  1484. LDE225, a Smoothened (Smo) antagonist: Phase I safety and pharmacologic results in patients with advanced tumours
  1485. Metronomic cyclophosphamide and methotrexate chemotherapy combined with 1E10 anti-idiotype vaccine in metastatic breast cancer
  1486. Evaluation of ERCC1, BRCA1, thymidylate synthase (TS), class III beta tubulin (bTubIII), p53R2, RRM2 in stage I-III non-small cell lung cancer (NSCLC): a tissue microarray (TMA) study
  1487. Combined Modalities of Resistance in a Cisplatin-driven Human Betel-associated Oral Squamous Cell Carcinoma
  1488. Diagnostic markers in bronchial fluid of lung cancer patients; immunoassay development and validation
  1489. Correlation between triple negative breast cancer and brain metastases
  1490. Second-line treatment with pazopanib following first-line sunitinib or bevacizumab in advanced renal cell carcinoma: preliminary results of a phase II trial
  1491. High throughput somatic profiling of the Ras-Raf-MAP and PI3K-PTEN-Akt pathways in advanced colorectal cancer and correlations with response to cetuximab
  1492. Overall survival (OS) and progression free survival (PFS) results for a randomized phase 2 trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line Stage IIIb/IV non-small cell lung cancer (NSCLC)
  1493. Baseline quality of life as a prognostic tool of median survival in patients receiving sunitinib for metastatic renal cell carcinoma
  1494. Cytotoxic activity of engineered 5-fluorouracil-loaded poly(butylcyanoacrylate) nanoparticles
  1495. TSER and MTHFR gene Polymorphisms and Toxicity in Cancer Patients treated with fluoropyrimidine based chemotherapy.
  1496. CTC Biomarker Assessment To Aid Dosing Selection of E6201, A Potential MEK1 Inhibitor, For Treatment Of BRAF-Mutated Melanoma
  1497. pml expression in soft tissue sarcoma: prognostic value in alkylating agents/antraciclin based first line therapy
  1498. Retrospective analysis of triple-negative breast cancer in one Hungarian center
  1499. Human epidermal growth factor receptor 2 (HER2) positivity in Spanish patients (pts) with advanced gastric cancer (GC).
  1500. Safety and subgroup efficacy analyses in GOG218, a phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) or Fallopian tube cancer (FTC): a Gynecologic Oncology Group study
  1501. Development and measurement of guideline-based indicators for colorectal carcinoma.
  1502. Weekly paclitaxel and paraplatin as first line treatment in patients with recurrent or metastatic cervical carcinoma
  1503. In Vitro and In Vivo Synergistic Anticancer Effect of the HDAC Inhibitor Panobinostat (LBH589) Plus Zoledronic Acid (ZOL) in Human Prostate Cancer (PC) and Multiple Myeloma (MM) Models
  1504. Cilengitide in patients with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter: safety run-in results from a randomized, controlled, phase II study (CORE)
  1505. Is concurrent chemoradiotherapy with altered fractionation (C-AFRT) better than standard concurrent chemoradiotherapy (C-RT) in head and neck cancer? An exploratory network meta-analysis using individual patient data.
  1506. Breast cancer survival in Brazil related with the disparities in health services access.
  1507. Expression and clinic and prognostic significance of pten, p53, vegf and cerb-b2 in metastatic colorectal cancer treated with bevacizumab
  1508. RESULTS OF A RANDOMIZED, OPEN-LABEL, PHASE III TRIAL OF PATUPILONE (P) VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN TAXANE/PLATINUM REFRACTORY/RESISTANT PATIENTS WITH RECURRENT OVARIAN, FALLOPIAN, OR PERITONEAL CANCER
  1509. Vinorelbine (V) in pemetrexed-pretreated patients (PTS) with malignant pleural mesothelioma (MPM).
  1510. Breast cancer survivorship: a qualitative study from Iran
  1511. EFFICACY AND SAFETY OF TRASTUZUMAB-DM1 VERSUS TRASTUZUMAB PLUS DOCETAXEL IN HER2-POSITIVE METASTATIC BREAST CANCER PATIENTS WITH NO PRIOR CHEMOTHERAPY FOR METASTATIC DISEASE: PRELIMINARY RESULTS OF A RANDOMIZED, MULTICENTER, OPEN-LABEL PHASE 2 STUDY (TDM4450G)
  1512. The Oral MEK 1/2 Inhibitor GSK1120212 Demonstrates Early Efficacy Signals
  1513. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE III TRIAL OF EVEROLIMUS + OCTREOTIDE LAR VS PLACEBO + OCTREOTIDE LAR IN PATIENTS WITH ADVANCED NEUROENDOCRINE TUMORS (NET) (RADIANT-2)
  1514. Pharmacokinetics (PK) of sunitinib and its metabolite in patients with castrated refractory prostate cancer (CRPC) enrolled in the French multicenter PROSUT phase II study.
  1515. Influence of LIG4 1977 T/C polymorphism in Ovarian Cancer (OC) susceptibility
  1516. A randomized, double-blind, placebo-controlled phase 2 study of AMG 386 plus weekly paclitaxel in patients (pts) with advanced ovarian cancer
  1517. Zoledronic Acid (ZOL) Significantly Reduces Skeletal-Related Events (SREs) Versus Clodronate (CLO) in Patients (Pts) With Multiple Myeloma (MM): Results of the Medical Research Council (MRC) Myeloma IX Study
  1518. Economic Evaluation of Everolimus versus Sorafenib for the Treatment of Advanced Renal Cell Carcinoma after Failure on Treatment with Sunitinib
  1519. Kaposi's sarcoma treated continuously for about three years with weekly and biweekly vinblastine with good disease control: a case report.
  1520. The Effect of Psychological Support on Quality of Life in Breast Cancer Patients
  1521. early magnesium modifications as a surrogate markers of efficacy of cetuximab based anticancer treatment in advanced colorectal cancer patients.
  1522. Implication of breast cancer phenotype in patients with leptomeningeal carcinomatosis
  1523. PRIMARY EFFICACY AND SAFETY RESULTS OF SPECTRUM, A PHASE 3 TRIAL IN PATIENTS (PTS) WITH RECURRENT AND/OR METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) RECEIVING CHEMOTHERAPY WITH OR WITHOUT PANITUMUMAB (PMAB)
  1524. Sentinel Lump Node Mapping in Excisional Biopsy
  1525. Baseline presentation of Triple negative breast cancer (TNBC) and Her2+/neu breast cancer at a centre in South India
  1526. Long term cardiac safety of pegylated liposomal doxorubicin (PLD) in patients with breast cancer (BC) previously treated with conventional anthracyclines
  1527. Overexpression of mTOR a novel marker for poor survival in early stage NSCLC: a validation study.
  1528. Meta-analysis of patients (pts) ≥65 years from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for metastatic breast cancer (MBC).
  1529. Assessment of Neuropathy-Inducing Effects of Eribulin Mesylate versus Paclixatel and Ixabepilone in Mice
  1530. SUVmax of F-18 FDG-PET/CT in advanced gastric cancer with tubular adenocarcinoma: Correlation with pathologic findings including immunohistochemical staining.
  1531. Novel insights for therapeutic strategies in pancreatic neuroendocrine tumors (pNET)
  1532. Safety of GEMCITABINE in elderly patients .
  1533. Topical Silver Sulfadiazine for Prevention of Acute Dermatitis during Irradiation for Breast Cancer
  1534. Epigenetics silencing of the Tumor Suppressor Protein 14-3-3 sigma by methylation in Sporadic Breast Cancer.
  1535. A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF HEDGEHOG (HH) PATHWAY INHIBITOR GDC-0449 AS MAINTENANCE THERAPY IN PATIENTS WITH OVARIAN CANCER IN 2ND OR 3RD COMPLETE REMISSION (CR)
  1536. Cetuximab and 1st-line chemotherapy in elderly and younger patients with metastatic colorectal cancer (MCRC): a pooled analysis of the CRYSTAL and OPUS studies
  1537. Evaluation of prognostic value of HER2 and Vascular Endothelial Growth Factor (VEGF) expression for predicting early failure in patients with operable breast cancer
  1538. Concurrent gemcitabine and radiation in fungating skin tumors: Single Institution Results
  1539. Impact of Epistaxis on the Use of Fentanyl Pectin Nasal Spray to Treat Breakthrough Cancer Pain
  1540. First interim results of the Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study
  1541. Intra-arterial chemotherapy in complex treatment of cervix cancer stage II b
  1542. A Cost-Consequence Model for Octreotide LAR as Treatment for Metastatic Midgut NET
  1543. Time Elapsed between symptom onset, medical consultation, diagnosis and treatment in patient with advanced Non-Small-Cell Lung Cancer.
  1544. Phase 2 Randomized Discontinuation Trial (RDT) of Tivozanib in Patients With Renal Cell Carcinoma (RCC): Results in Patients Randomized to Tivozanib vs. Placebo
  1545. FUFIRI or mIROX for first-line treatment in metastatic colorectal cancer (mCRC) and secondary resection of liver metastasis: A post-hoc analysis of tumor response and overall survival in the FIRE-trial
  1546. Preclinical and Clinical Anti-Angiogenic Activity of BMS-690514
  1547. Her2 status in metastatic GI junction in intent to treat patients in Finistere since the TOGA publication
  1548. Analysis of advance directives among terminal cancer patients admitted to a palliative care unit: a single center’s experience
  1549. Pre-metastatic niche identification in node-negative breast cancer to assess metastasis risk. Pathological and clinical implications.
  1550. Pharmacogenomic profile of castration-resistant prostate cancer: the influence of AR +1733 G>A and SHBG +5790 G>A polymorphisms
  1551. Pregnancy and breast cancer
  1552. Expression of DNA repair genes as biomarkers of outcome in Epithelial Ovarian Cancer: a GEICO study.
  1553. Patient Preferences for Targeted Agents in Renal Cell Carcinoma (RCC): A Benefit Risk Conjoint Study
  1554. Prevalence of emotional distress, anxiety, and depression and their impacts on pain in terminally ill cancer patients
  1555. Lapatinib + capecitabine in advanced gastric cancer: an open-label phase II study of non-ErbB2-targeted disease
  1556. Comparison of median time to brain metastases development in triple negative BC and HER2 3+ BC
  1557. Complete response (CR) to nimotuzumab plus chemoradiation in locally advanced esophageal cancer: preliminary results of an ongoing randomized trial
  1558. A Systematic Review of Epidemiology, Treatment Pattern, Economic and Humanistic Studies in Advanced Neuroendocrine Tumors
  1559. Clinical outcome of advanced gastric cancer (GC) patients (pts) by human epidermal growth factor receptor 2 (HER2) status when treated before the trastuzumab era.
  1560. Sulphasalazine in the Prevention of Radiation-Induced Acute Proctitis in Patients with Prostate Cancer
  1561. MAGE-A3 gene expression frequency and demography data of stage IB-IIIA NSCLC patients from ongoing MAGRIT Phase III trial evaluating MAGE-A3 Antigen Specific Cancer Immunotherapeutic (ASCI) as adjuvant treatment
  1562. Bone Antiresorptive Agents in Patients With Metastatic Bone Disease: Pharmacokinetic and Pharmacodynamic Effects
  1563. Histology and outcomes of newly detected lung lesions in malignant melanoma (MM) patients
  1564. Treatment of lung cancer patients and concomitant use of drugs interacting with Cytochrome P450 isoenzymes
  1565. Pathological classification as a predictive factor in advanced Non-Small Cell Lung Cancer
  1566. A qualitative systematic review of the evidence base for non cross-resistance between steroidal and non-steroidal aromatase inhibitors (AIs) in metastatic breast cancer
  1567. Computerized physician order entry systems and chemotherapy (CT) prescription errors
  1568. Mixed histology lung cancer- better or worse than pure histology lung cancer?
  1569. School Health Program to Prevent Tobacco Use
  1570. Utility of progression-free survival (PFS) as a primary endpoint in clinical studies of advanced neuroendocrine tumors (NET)
  1571. Nonpegylated liposomal doxorubicin plus ifosfamide versus conventional doxorubicin plus ifosfamide in locally advanced or metastatic soft tissue sarcoma: interim analysis of a randomized phase II trial
  1572. Phase 3 RECORD-1 study of everolimus in metastatic renal cell carcinoma (mRCC): subgroup analysis of patients (pts) with 1 versus 2 prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI) therapies
  1573. Treatment of advanced non-small cell lung cancer (NSCLC) in patients (p) older than 70
  1574. Clinical trial of safety and pharmacologic evaluation of CIGB 300 in patients with uterine cervix carcinoma stage Ib-II. CERVIFARM-300
  1575. Impact of Mammaprint on the routine treatment decision making process in an unselected early breast cancer patient population in Belgium
  1576. Early breast cancer: prognosis related to Ki-67 expression.
  1577. Trends in Gastrointestinal Cancer Referrals in Acute Hospitals in London, UK
  1578. Trastuzumab as adjuvant therapy in HER2+ early breast cancer – cardiac safety analysis
  1579. Metastatic Renal Cell Carcinoma (mRCC): the Budget Impact for the Introduction of Everolimus (E) in the Cyprus Health Care System
  1580. Prognostic and predictive value of chromogranin A and neuron-specific enolase in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET) treated with everolimus
  1581. Outcomes for Metastatic Breast Cancer Patients Continuing on Bevacizumab Alone in Study E2100
  1582. Primary gliosarcoma: clinical experience from a regional cancer centre in north India
  1583. Analysis of overall survival among patients with metastatic colorectal cancer, with and without undergoing elective colectomy
  1584. Letrozole or Anastrozole for the Treatment of Hormone Positive Breast Cancer: A Clinical Comparison using Indirect Statistical Techniques
  1585. Adjuvant chemotherapy for resected biliary tract cancer: a retrospective analysis.
  1586. Phase II study of docetaxel and doxorubicin combination as neoadjuvant chemotherapy in operable breast cancer patients
  1587. Role of chemo-radiotherapy alone in the management of unfit patients with non-metastatic locally advanced squamous-cell carcinoma of the oesophagus
  1588. SPARC microenvironment signature (SMS) in patients treated with nab-paclitaxel (nab-P)/carboplatin (C)/bevacizumab(B) for triple negative metastatic breast cancer (TNMBC)
  1589. mRNA expression of VEGF family members has prognostic significance in high-risk early breast cancer patients participating in a prospective randomized study of the Hellenic Cooperative Oncology Group (HeCOG)
  1590. A clinico-pathological analysis of Breast Cancer patients with a family history
  1591. Pleurodesis (P) outcome in a series of metastatic cancer patients(pts) with symtomatic malignant pleural effusion (MPE)
  1592. Single Agent Gemcitabine in Palliative Management for the Malignant Pleural Effusion: A Phase II Study
  1593. A RNA Gene Signature For Screening OF Colorectal Cancer from Whole Blood With High Sensitivity And A Specificity Close To That OF Colonoscopy
  1594. Phase II study of oxaliplatin as third-line chemotherapy in patients with metastatic colorectal cancer
  1595. Activity of Sunitinib malate in non-clear cell kidney cancer patients: a single institution experience
  1596. Oral carcinoma after stem cell transplantation - a single centre experience
  1597. Oropharyngeal mucositis prophylaxis in combined radioimmunochemotherapy.
  1598. 2-year tolerance of adjuvant trastuzumab for early breast cancer occurring in elderly: A companion study of the GERICO-06 phase II trial
  1599. The Use of Complementary and Alternative Therapies in Cancer Patients of Southeastern Region of Turkey
  1600. Everolimus plus erlotinib versus erlotinib alone in previously treated patients with advanced non-small-cell lung cancer (NSCLC)
  1601. Preclinical and Clinical Activity of BMS-690514 in the Treatment of Non-small Cell Lung Cancer (NSCLC)
  1602. An Adjusted Indirect Comparison of Everolimus and Sorafenib Therapy in Sunitinib-Refractory mRCC Patients Using a Robust Matching Technique
  1603. Poorly differentiated neuroendocrine tumors (PD-NET): does Ki67 index correlate with response to chemotherapy?
  1604. Squamous cell carcinoma (scc) of the oesophagus: Induction cisplatin-paclitaxel-5fu (PTF) before definitive local therapy for locally advanced disease.
  1605. Chemoradiotherapy with 5-FU versus capecitabine on rectal cancer downstaging
  1606. A phase 2 study of safety and efficacy of temsirolimus (CCI-779) administered as a single agent in East Asian patients with advanced renal cell carcinoma
  1607. Validation of six different prognostic scores for advanced renal cell carcinoma
  1608. Experience of chemotherapy with modified FOLFOX as first-line in elderly Bangladeshi patients population with advanced gastric cancer
  1609. Feasibility of surgery followed by chemoradiotherapy in gastric cancer. phase II trial
  1610. Randomized, Placebo-controlled, Phase 3 Study of Everolimus in Patients with Metastatic Renal Cell Carcinoma (mRCC): Subgroup Analysis of Patients Intolerant of Prior Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFR-TKI) Therapy
  1611. Vinorelbine, ifosfamide and prednisolone as a salvage regimen in relapsed Hodgkin's Lymphoma
  1612. The Role of Clinical Pharmacy in minimize the medication errors
  1613. Multicenter Phase II study of sunitinib in patients with transitional cell carcinoma of the urothelium (TCCU) who failed or progressed after first line chemotherapy (CT) for locally advanced or metastatic disease. Preliminary results.
  1614. PHASE 1/2 STUDY OF GSK2118436, A SELECTIVE INHIBITOR OF V600 MUTANT (MUT) BRAF KINASE: EVIDENCE OF ACTIVITY IN MELANOMA BRAIN METASTASES (METS)
  1615. Cancer Waiting Times: Assesment Of One Month Wait Target From Diagnosis To Treatment Of All Cancers in England
  1616. Localization, expression and impact on outcome of CXCR4 expression in resected early stage Non Small Cell Lung Cancer
  1617. Darbepoetin Alfa versus Epoetin Alfa for Treatment of Chemotherapy-Induced Anemia: A Health Economic Evaluation
  1618. Level of HER2/neu gene (HER2) amplification in primary and metastatic sites in HER2-positive metastatic breast cancer and response to trastuzumab(T)-based therapy
  1619. Neutropenia And Gender Differencies At Liver-Only Metastatic Colorectal Cancer Patients Treated With Oxaliplatin-Based Neoadjuvant Chemotherapy Plus Bevacizumab: Is There Any Impact On Resection Rate?
  1620. Chemotherapy in Elderly Patients with Hormone Resistant Metastatic Prostate Cancer
  1621. Does obesity hamper response to trastuzumab (T) in post-menopausal patients (pts) with metastatic breast cancer (MBC)?
  1622. MGMT promotor methylation status and Ki-67 in correlation to survival and response to treatment with temozolamide and radiotherapy in newly diagnosed glioblastoma patients.
  1623. Clinical Profile and Patterns of Progression of Patients (P) with Advanced Non Small Cell Lung Cancer (NSCLC) Treated with Firs-Line Bevacizumab based-therapy: Preliminary results of the AVVA Study
  1624. Tonsil primary non hodghkin lymphoma : report of retrospective study
  1625. Deep Electro-Hyperthermia with or without Thermo-Active Drugs : our experience in patients with advanced Hepatic Cell Carcinoma (HCC)
  1626. Incidence and management of hepatic toxicity in pazopanib-treated patients
  1627. Cardiovascular AE, Hypertension and Antihypertensive Therapy During Sunitinib-Treatment in Patients with Metastatic Renal Cell Carcinoma (mRCC) - A Retrospective Analysis of 72 Patients -
  1628. Merkel cell carcinoma (MCC) – A Retrospective Analysis
  1629. Cyclin dependent kinase 4 as a therapeutic target for metastatic melanoma.
  1630. Implementation of Palliative Care Educational Courses in the Curricula of Medical Schools – The First Georgian Experience
  1631. Outcome Of Brain Metastases From Colorectal Cancer; A Single Institute Experience
  1632. A Phase 1 Study of Neratinib (HKI-272) in Combination with Paclitaxel in Japanese Patients with Solid Tumors
  1633. A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF HEDGEHOG PATHWAY INHIBITOR (HPI) GDC-0449 IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC)
  1634. An international pooled analysis identifying predictive factors of serious side effects and DLTs during cycle 1 in patients included in Phase I trials.
  1635. An International Expanded Access Program (EAP) of Everolimus in Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Are Intolerant of or Have Progressed After Prior Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy
  1636. A First in Class AEMD to Combat Cancer
  1637. Oral Chemotherapy To Optimize Care of Metastatic Breast Cancer (MBC) Patients: Considering Woman Preference And Quality Of Life (QoL).
  1638. RANDOMIZED, DOUBLE-BLIND PHASE III STUDY OF PAZOPANIB IN PATIENTS WITH ADVANCED/METASTATIC RENAL CELL CARCINOMA (MRCC): FINAL OVERALL SURVIVAL (OS) RESULTS
  1639. Phase II study of bevacizumab in combination with cisplatin and docetaxel as first-line treatment of patients (p) with metastatic non-squamous non-small cell lung cancer (NSCLC): Final report.
  1640. Multicenter randomized Phase II trial of adding Bemiparin to Chemo-Radiotheray in Small Cell Lung Cancer with limited disease
  1641. Cetuximab in combination with bendamustine as an alternative therapeutic option for recurrent head and neck cancer
  1642. Extraskeletal Ewing’s sarcoma (EES) in adults
  1643. A phase 2 study of the HER2 antibody-drug conjugate trastuzumab-DM1 (T-DM1) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab, lapatinib, and chemotherapy
  1644. CYP3A4*1B (rs2740574) gene polymorphism has prognostic value in ovarian cancer
  1645. Increased patient medication safety in advanced palliative home care through the inclusion of dispensing pharmacists: A development project
  1646. A novel approach using the telomerase-selective adenoviral marker for detection of circulation tumor cells in breast cancers
  1647. The outcome of patients who fail sunitinib and do not have access to sunitinib therapy.
  1648. Comparative cost analysis for Docetaxel, Cisplatin and 5-Fluorouracil (TPF) and Cisplatin and 5-Fluorouracil (PF) for head and neck cancer patients.
  1649. Advanced Neuroendocrine Tumors: A Structured Review of the Quality of Life Literature
  1650. A retrospective analysis of gallbladder cancer patients referred to the National Cancer Institute in Mexico between 2004-2009
  1651. Trough PK concentration, age of patient, and baseline ALT are important factors in predicting ALT elevations in pazopanib treated mRCC patients
  1652. Sequential Vinorelbine (VNR)/Capecitabine (CAP) Combination Followed By Metronomic CAP As First Line Treatment in HER2-Negative Metastatic Breast Cancer (MBC): Prospective Evaluation Of Activity, Safety and Quality Of Life.
  1653. Cost-effectiveness of treating metastatic renal cell carcinoma (mRCC) patients whose disease failed on VEGF-TKI therapies with everolimus compared to treating with best supportive care (BSC) alone: A Canadian societal perspective
  1654. male breast cancer
  1655. Economic Impact of OncotypeDx Assay in Axillary Node Negative Breast Cancer, (AxN-BC) with Positive Hormone Receptor (rec+)and Normal HER-2 (HER2-).
  1656. Do patients on molecular targeted therapy suffer from sexual disorders?
  1657. Prognostic Value of a Cell Cycle Expression Profile Score Among Men With Conservatively Treated Localized Prostate Cancer.
  1658. Development of a new objective prognostic score for cancer patients treated in phase I trials
  1659. Engineering functions in cell transduction domains: novel anticancer agents
  1660. Glutathione S-transferase Pi (GSTPi) for prediction of chemotherapy response and survival in stage IV colorectal cancer
  1661. Peri Operative Morbidity of Radical Cystectomy for Bladder Cancer- Impact of Neo adjuvant Therapy
  1662. Phase II study of fixed dose-rate infusion of gemcitabine and UFT combination chemotherapy in patients with advanced bile duct cancer: Daegu Gyeoungbuk Oncology Group
  1663. MAGE-C2/CT10 Protein Expression is an Independent Predictor of Recurrence in Prostate Cancer.
  1664. First baseline results of a Pan-European Phase IV open-label multicentre study of the titration of fentanyl buccal tablets (FBT) in patients with breakthrough cancer pain (BTcP)
  1665. Prediction of chemotherapy toxicity by the Groningen Frailty Index (GFI) and the Comprehensive Geriatric Assessment (CGA) in elderly cancer patients (pts): an interim analysis
  1666. Eribulin mesylate (E7389) vs treatment of physician’s choice (TPC) in patients (pts) with metastatic breast cancer (MBC): subgroup analyses from the EMBRACE study
  1667. A novel colorectal cancer susceptibility SNP in the EIF3H promoter influences patient survival and response to treatment.
  1668. Locally advanced pancreatic cancer
  1669. Introduction
  1670. Reducing mortality — prevention and treatment
  1671. Cardioncology - An alliance for prevention and treatment
  1672. Diabetes and cancers
  1673. The burden of chronic respiratory diseases in Europe
  1674. Conclusions
  1675. Phase I study of the tumor-targeting human L19TNF monoclonal antibody-cytokine fusion protein in patients with advanced solid tumors
  1676. GLOBOCAN 2008: The worldwide burden of cancer
  1677. RANDOMIZED MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED PHASE II STUDY EVALUATING METMAB, AN ANTIBODY TO MET RECEPTOR, IN COMBINATION WITH ERLOTINIB, IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER
  1678. Hamilton Fairley Award Lecture - Colorectal cancer: A multidisciplinary disease revealing significant progress
  1679. FINAL EFFICACY AND SAFETY RESULTS OF A RANDOMIZED PHASE II STUDY OF THE PARP INHIBITOR INIPARIB (BSI-201) IN COMBINATION WITH GEMCITABINE/CARBOPLATIN (G/C) IN METASTATIC TRIPLE NEGATIVE BREAST CANCER (TNBC)
  1680. Locally advanced pancreatic cancer
  1681. What can the molecular pathologist offer for optimal decision-making?
  1682. Invited Discussant, Abstracts 1234O and 1235O
  1683. Invited Discussant, Abstracts 1181O and 1236O
  1684. Invited Discussant, LBA13 and LBA14
  1685. Invited Discussant, Abstract 363O and LBA15
  1686. Invited Discussant, Abstracts 800O and 801O
  1687. Invited Discussant, Abstract 802O and 73O
  1688. Invited Discussant, Abstracts 77PD-79PD
  1689. Invited Discussant, Abstracts 1343O and 1344O
  1690. Invited Discussant, Abstracts 1345O, 1346O and 1347O
  1691. Invited Discussant, Abstracts 80PD-83PD
  1692. General Discussion
  1693. Invited Discussant, Abstracts 74O, 75O and 76O
  1694. Invited Discussant, LBA Abstracts
  1695. Invited Discussant, Abstracts 156O and 157O
  1696. Invited Discussant, Abstracts 158O and 159O
  1697. Invited Discussant, Abstracts 213O and 214O
  1698. Invited Discussant, LBA10 and Abstract 215O
  1699. Invited Discussant, Abstracts 275O and 276O
  1700. Invited Discussant, Abstract 277O
  1701. Invited Discussant, Abstracts 494O and 495O
  1702. Invited Discussant, Abstracts 496O and 497O
  1703. Invited Discussant, LBA22 and Abstracts 867O, 868O
  1704. Invited Discussant, LBA23 and Abstract 869O
  1705. Invited Discussant, Abstract 970O
  1706. Invited Discussant, LBA24, Abstracts 971O, 972O and LBA25
  1707. Invited Discussant, LBA26 and Abstract 1003O
  1708. Invited Discussant, Abstract 1004O
  1709. Invited Discussants, Abstract 160PD-164PD
  1710. Invited Discussants, Abstracts 165PD-169PD
  1711. Invited Discussant, Abstracts 1132O, 1133O and 1134O
  1712. Invited Discussant, Abstract 1135O
  1713. General Discussion
  1714. Invited Discussant, Abstracts 170PD-173PD
  1715. Invited Discussant, Abstracts 174PD-177PD
  1716. General Discussion
  1717. Invited Discussant, Abstract 1324O
  1718. Invited Discussant, Abstract 1325O and LBA27
  1719. Invited Discussant, Abstracts 216PD-220PD
  1720. Invited Discussant, Abstracts 221PD-223PD
  1721. General Discussion
  1722. Invited Discussant, Abstracts 278PD-282PD
  1723. Invited Discussant, Abstracts 283PD-286PD
  1724. General Discussion
  1725. Invited Discussant, LBA19 and Abstract 580O
  1726. Invited Discussant, LBA20 and LBA21
  1727. Invited Discussant, Abstracts 364PD-367PD
  1728. Invited Discussant, Abstracts 368PD-370PD
  1729. Invited Discussant, Abstracts 371PD-375PD
  1730. General Discussion
  1731. Invited Discussant, Abstracts 498PD-500PD
  1732. Invited Discussant, Abstracts 501PD-503PD
  1733. General Discussion
  1734. Invited Discussant, Abstracts 581PD-583PD
  1735. Invited Discussant. Abstracts 584PD-586PD
  1736. General Discussion
  1737. Invited Discussant, Abstracts 587PD-588PD
  1738. Invited Discussant, Abstracts 709PD-710PD
  1739. Invited Discussant, Abstracts 711PD-712PD
  1740. General Discussion
  1741. Invited Discussant, Abstracts 870PD-874PD
  1742. Invited Discussant, Abstracts 875PD-878PD
  1743. General Discussant
  1744. Invited Discussant, Abstracts 973PD-976PD
  1745. Invited Discussant, Abstracts 977PD-979PD
  1746. General Discussion
  1747. Invited Discussant, Abstracts 1006PD-1008PD
  1748. Invited Discussant, Abstracts 1009PD-1011PD
  1749. General Discussion
  1750. Invited Discussant, Abstracts 1085PD-1086PD
  1751. Invited Discussant, Abstracts 1087PD-1093PD
  1752. General Discussion
  1753. Invited Discussant, Abstracts 1136PD-1138PD
  1754. Invited Discussant, Abstracts 1139PD-1141PD
  1755. Invited Discussant, Abstracts 1142PD-1144PD
  1756. General Discussion
  1757. Invited Discussant, Abstracts 1199PD-1200PD-1182PD-1237PD
  1758. Invited Discussant, Abstracts 1238PD-1239PD-1183PD
  1759. General Discussion
  1760. Invited Discussant, Abstracts 567PD-570PD-575PD-569PD
  1761. Invited Discussant, Asbtracts 566PD, 568PD, 571PD, 572PD, 573PD
  1762. General Discussion
  1763. Coordination of cancer research through the FP7 HEALTH programme
  1764. Welcome and Introduction
  1765. Cancer and the immune system
  1766. Challenges of immunotherapy in advanced melanoma
  1767. Is immunotherapy going to change the treatment paradigm in advanced melanoma?
  1768. Panel Discussion
  1769. Introduction
  1770. Anthracyclines: an open field for research in 2010
  1771. Novel approach in the treatment of HER2-positive breast cancer patients
  1772. “Mysight”: Breast cancer treatment in clinical practice
  1773. Optimizing anthracycline use in oncology
  1774. Welcome and introduction
  1775. Rare, difficult and controversial: epidemiology and clinical practice in mesothelioma
  1776. Mesothelioma and new research on thymidylate synthase inhibitors and platinum compounds
  1777. Sticking to the blueprint: growth factor support in chemotherapy
  1778. Conclusions and discussion
  1779. Welcome and Introduction: Unmet medical needs and requirement for new treatment options for patients with relapsed ovarian and advanced prostate cancer
  1780. Are new treatment possibilities changing the standard of care in relapsed ovarian cancer?
  1781. Panel discussion: State of the art in relapsed ovarian cancer
  1782. A new paradigm in advanced prostate cancer: from hormone-refractory to castrate-resistant prostate cancer
  1783. Overcoming resistance to hormonal treatment with novel androgen biosynthesis inhibitors
  1784. Non-endocrine targets and new drugs for castrate-resistant prostate cancer
  1785. Panel discussion: Current status and future possibilities for patients with advanced prostate cancer
  1786. concluding remarks
  1787. Opening remarks
  1788. Changing paradigms in SCCHN* treatment demand effective management of toxicities (*SCCHN, squamous cell carcinoma of the head and neck)
  1789. Panitumumab with cisplatin and 5-FU as 1st-line treatment of recurrent or metastatic SCCHN*: the phase III SPECTRUM study (*SCCHN, squamous cell carcinoma of the head and neck)
  1790. Panitumumab in the management of colorectal cancer
  1791. Future perspectives: Amgen’s investigational compounds in gastrointestinal cancer
  1792. Panel discussion
  1793. Closing remarks
  1794. Chairman’s welcome and introduction
  1795. Everyday challenges in treating patients with EGFR mutation-positive tumours
  1796. How did EGFR mutation testing become routine in Japan?
  1797. Panel discussion
  1798. Closing remarks
  1799. Chairman’s welcome and introduction
  1800. ATAC – 10 years on…
  1801. Treatment options in advanced breast cancer – optimising efficacy with fulvestrant 500mg
  1802. CONFIRM: Translating the data into clinical practice
  1803. Audience questions
  1804. Closing remarks
  1805. Welcome
  1806. Evolution of a targeted therapy in cancer: the past, present, and future
  1807. Treatment options in renal cell carcinoma: a growing body of evidence toward improved outcomes
  1808. Broadening horizons in the treatment of hepatocellular carcinoma
  1809. Integrating the standard of care in HCC in the clinical practice
  1810. Emerging treatment options in differentiated thyroid cancer
  1811. The role of targeted therapies in HER2 negative metastatic breast cancer
  1812. The shifting paradigm in the treatment of NSCLC: from combination therapy to personalized medicine
  1813. Questions and answers
  1814. Concluding remarks
  1815. Being There: Goals and Evidence in Current MBC Treatment
  1816. Microtubules in Anticancer Therapies: Mechanisms, Dynamics and Effects
  1817. Results and Tolerability With a Novel Non-taxane Microtubule Dynamics Inhibitor
  1818. EMBRACE: Option for Improved Survival with Monotherapy in Late-stage MBC
  1819. Real World Experience with Monotherapy for MBC
  1820. Looking to the Future of Late-stage Therapy of MBC: Innovation and Hope
  1821. Faculty Discussion
  1822. Welcome and introduction
  1823. Selecting patients for treatment in advanced NSCLC: Microscopic vs Molecular
  1824. Microscopic
  1825. Final remarks
  1826. Prioritising treatment strategies in advanced NSCLC: First-line vs Maintenance
  1827. First-line
  1828. Final remarks
  1829. Closing remarks
  1830. Welcome and introduction
  1831. Optimizing the treatment in locally advanced SCCHN
  1832. Integrating ERBITUX into routine clinical practice in LA SCCHN— a real world case study
  1833. EXTREME – a new treatment standard for 1st-line r/m SCCHN
  1834. Integrating ERBITUX into routine clinical practice in 1st L R/M SCCHN — a real world case study
  1835. Closing remarks
  1836. Welcome and introduction
  1837. Prolonging survival through a personalized approach in mCRC
  1838. Response rate and tumor shrinkage in the treatment of mCRC
  1839. Perspectives on resection in mCRC
  1840. Summary and close
  1841. Welcome and Introduction
  1842. The Rationale for Histone Deacetylase Inhibitors in Solid Tumors
  1843. Patient Selection for Adjuvant Therapy in High-Risk Malignant Melanoma
  1844. mTOR Inhibitors Single Agent & Unique Combinations
  1845. Evidence-Based Management of CINV: Where are we today?
  1846. Panel Discussion (Baas P., Blay J., Gralla R., Hauschild A.)
  1847. Welcome and Opening Remarks
  1848. Endocrine therapy approaches for postmenopausal hormone-responsive breast cancer: Maximizing the benefit
  1849. Potential anticancer properties of bisphosphonates: Rationale
  1850. Treatment considerations in breast cancer: Beyond endocrine therapy
  1851. Promising agents in ER+ and HER2+ breast cancer: mTOR and beyond
  1852. Panel discussion: Managing breast cancer—treating the patient, not the disease
  1853. Welcome and Opening Remarks
  1854. Case Study 1: Renal Cell Carcinoma—Strategies for Patient Management Across the Disease Continuum: TKIs and Beyond
  1855. Question-and-Answer Session
  1856. Case Study 2: Prostate Cancer—Caring for the Patient From Initial Diagnosis Through End-stage Disease
  1857. Future Directions With Bone-Targeted Therapies in GU Malignancies
  1858. Question-and-Answer Session
  1859. Concluding Remarks
  1860. Welcome, introduction, and demographics
  1861. Clinical opinion poll question
  1862. Understanding the biology of triple‐negative breast cancer (TNBC)
  1863. Panel Commentary
  1864. Clinical opinion poll question
  1865. Triple‐negative breast cancer: What we know and what we don’t know
  1866. Panel Commentary
  1867. Clinical opinion poll question
  1868. PARP inhibition: Why it works in TNBC
  1869. Panel Commentary
  1870. Take home messages and future directions
  1871. Presentation: Transforming the treatment landscape: angiogenesis inhibition in cancer
  1872. Controlling tumour growth through angiogenesis inhibition
  1873. Patient-driven treatment strategies in CRC
  1874. Optimising patient outcomes in mBC with anti-angiogenic therapy
  1875. Anti-VEGF therapy: innovating NSCLC treatment
  1876. Role of angiogenesis in GBM
  1877. Clinical data update: anti-angiogenesis in front-line ovarian cancer
  1878. Meeting close
  1879. Welcome and introduction: Current and future challenges in the treatment of advanced lung cancer
  1880. Current and future biomarkers in NSCLC: making innovation a reality
  1881. Understanding the benefits of anti-VEGF therapy: why, when and who?
  1882. Optimising treatment success with maintenance therapy in NSCLC
  1883. Summary and close
  1884. Bioenergetics of metabolism in cancer
  1885. Targeting metabolic transformation for cancer therapy
  1886. Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role for carnitine system
  1887. Welcome and introduction
  1888. Iron deficiency and anaemia – frequent comorbidities in cancer patients
  1889. Iron – availability counts, not just storage
  1890. I.V. iron – from supplementary treatment to monotherapy
  1891. Expanding the role of iron in oncology
  1892. Outcomes and conclusions
  1893. Welcome and introduction
  1894. Welcome and introduction
  1895. How guidelines influence the approach in Europe to the treatment of advanced RCC
  1896. Making treatment decisions in clinical practice
  1897. Q&A
  1898. Achieving a continuum of care: Overcoming resistance through sequential treatment
  1899. An evolving landscape: Current worldwide trials
  1900. Q&A
  1901. Summary and close
  1902. Introduction
  1903. Metastatic breast cancer: Balancing quality of life and prolongation of survival
  1904. Panel discussion/Questions & Answers
  1905. How to assess post-menopausal status in breast cancer patients to optimize treatment?
  1906. Panel discussion/Questions & Answers
  1907. Elderly women with breast cancer: Can they handle more than they get?
  1908. Panel discussion/Questions & Answers
  1909. Summary and conclusions
  1910. The central role of the RANK Ligand pathway in cancer treatment induced bone loss
  1911. RANK Ligand inhibition – improving care in men with advanced prostate cancer
  1912. Challenging the current standard for prevention of bone complications in the advanced cancer setting
  1913. Working towards prevention of bone metastases with innovative adjuvant therapies
  1914. Interactive session and discussion
  1915. Molecular
  1916. Maintenance therapy
  1917. Close of Part 1 and audience exchange
  1918. Welcome to Milan and 'Beyond docetaxel - New treatment options in mHRPC'
  1919. Overcoming taxane resistance – New solution for an old problem
  1920. Management of mHRPC patients previously treated with docetaxel – Evidence of survival benefits
  1921. New treatment options for mHRPC patients: When and whom to consider – A case study
  1922. Summary of key findings
  1923. Chair\'s introduction and welcome
  1924. Plk1 inhibition: pioneering novel targets
  1925. Novel anti-angiogenic agents in NSCLC: a multi-target approach
  1926. Exploring the role of anti-angiogenic agents in ovarian cancer
  1927. Q&A
  1928. Chair\'s introduction and welcome
  1929. Are EGFR inhibitors living up to their promise in NSCLC?
  1930. Biomarkers in NSCLC: Are we there yet?
  1931. Refreshing our perspective: inhibiting HER signalling in breast cancer
  1932. Renewed hope in head and neck cancer: targeting EGFR
  1933. Q&A
  1934. Discussant Abstracts 566PD-568PD-571PD-572PD-573PD
  1935. Discussant Abstracts 567PD, 569PD, 570PD, 574PD, 575PD
  1936. Hematological malignancies
  1937. Gastrointestinal tumors
  1938. Head and neck cancer
  1939. Colorectal cancer
  1940. Supportive & palliative care
  1941. Breast cancer, early
  1942. Breast cancer, advanced
  1943. Sarcoma
  1944. Melanoma
  1945. Basic Science, biomarkers and TR
  1946. Developmental therapeutics
  1947. Gynecological cancer
  1948. Genitourinary tumors
  1949. Chest tumors
  1950. Congress closing remarks
  1951. PHASE II STUDY OF PAZOPANIB MONOTHERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY UROTHELIAL CANCER (INT70/09, NCT01031875)
  1952. Invited Discussant, LBA1 and LBA2
  1953. Invited Discussant, Abstract 274O and LBA3
  1954. Invited Discussant, LBA4
  1955. Invited Discussant, LBA5
  1956. Invited Discussant, LBA6
  1957. Invited Discussant, LBA7
  1958. Invited Discussant, LBA8 and LBA9
  1959. Invited Discussant, LBA11 and LBA12
  1960. Invited Discussant, LBA16
  1961. Invited Discussant, LBA17 and LBA18
  1962. Introduction: Quality fatality, necessity or opportunity?
  1963. The OECI accreditation programme
  1964. ESMO designated centres of integrated oncology and palliative care
  1965. Developing a designation system for cancer centres
  1966. Assessment frameworks for cancer centres: novel methodologies
  1967. Q&A and conclusions
  1968. Welcome and Introduction
  1969. Case #1—Targeted therapy for HER2-overexpressing metastatic breast cancer
  1970. Case #2 – Strategies for improving outcomes in HER2-negative breast cancer
  1971. Faculty panel discussion
  1972. Case #3 – Risk assessment and treatment planning in early breast cancer: How can we determine optimal therapeutic strategies?
  1973. Faculty panel discussion
  1974. Concluding remarks and summary of key take home messages
  1975. Faculty panel discussion
  1976. Coffee break
  1977. Break
  1978. Welcome and Introduction
  1979. Case 1: A patient with an intermediate risk GIST
  1980. Point – counter point discussion: Should all intermediate risk patients be treated with adjuvant therapy?
  1981. Case 2: A patient with a primary GIST with an exon 9 mutation
  1982. Point – counter point discussion: What is the relevance of imatinib dose in the adjuvant setting?
  1983. Case 3: A patient with a high risk GIST on adjuvant therapy
  1984. Point – counter point discussion: What duration of adjuvant therapy?
  1985. Closing remarks
  1986. Panel discussion
  1987. Current and future treatment options in renal cell carcinoma
  1988. Triple-negative breast cancer: What we know and what we don\'t know
  1989. PARP inhibition: Why it works in TNBC
  1990. Any limits to the use of I.V. iron in clinical routine?
  1991. Welcome and introduction
  1992. Opioid Availability and Use in Cancer Patients within Europe
  1993. Managing the Side Effectgs of Opioids
  1994. Methylnaltrexone: A Targete Treatment for Opioid-Induced Constipation in the Palliative Care Setting
  1995. Questions and Aswers
  1996. Welcome and Introduction
  1997. State-of-the-Art Review of NET in 2010
  1998. State-of-the-Art Review of NET in 2010 Q/A Session
  1999. Current Challenges in the Management of Advanced NET: The Experts’ Opinion
  2000. Current Challenges in the Management of Advanced NET: The Experts’ Opinion Q/A Session
  2001. Practice Changing Clinical Trials in NET
  2002. Practice Changing Clinical Trials in NET Q/A Session
  2003. Closing Remarks
  2004. Pre-symposium refreshments
  2005. Development of pazopanib for mRCC
  2006. Clinical evidence for pazopanib in mRCC
  2007. Data in the spotlight: Interactive debate
  2008. Challenges
  2009. Defence
  2010. Selectivity of TKIs - does it matter? Challenges and debates on the issues around selecting the appropriate TKI for patients
  2011. Which TKI? Interactive debate
  2012. Challenges
  2013. Defence
  2014. Progress in overcoming drug resistance in treatment of mRCC
  2015. Integrating pazopanib into the treatment paradigm of mRCC
  2016. Case 1: Managing a patient with mRCC - new treatment options?
  2017. Case 2: Pazopanib in real-life clinical practice
  2018. Closing remarks and questions
  2019. Experts in the fields of anaemia management and iron deficiency give key evidence-based presentations, followed by focused panel debate and interactive discussions. The faculty:
  2020. Introduction
  2021. Revision and management of patients with skin problems for radiotherapy
  2022. Management fo alopecia problems for Qol
  2023. The rehabiliative nursing funciton for urinary incontinence. A challenge for Best Qol
  2024. Therapeutic relation with the patient

Search within Meeting Abstracts

 
 

 

 
 
 
 
 
 

Most Viewed Meeting Abstracts